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Myocardial infarction (MI) affects nearly 600,000 individuals each year, and the resulting 
damage initiates a pathophysiological progression towards congestive heart failure (CHF).  A 
shortage of donor organs precludes heart transplantation as a practical solution, and neither surgical 
intervention nor stem cell therapy have yielded consistent and sufficiently positive results in clinical 
investigation.  
To prevent CHF, prospective therapies must target the cause of the maladaptive cardiac 
remodeling which precedes it—the nonfunctional, dyskinetic infarct scar—and aim to replace it 
with functional cardiac muscle. Tissue engineering holds promise for the development of novel 
therapies to either halt or reverse post-MI cardiac remodeling.  However, early efforts to implant 
thick (> 100 µm), functional, tissue-engineered grafts have failed in animal models because such 
grafts lack the vascularization, among other features, necessary for long term survival.  Therefore, 
the primary goal of this research was to develop a tissue-engineering approach to fulfill the need 
for thick, fully vascularized, and functional myocardial grafts to replace infarct scar tissue and 
prevent or reverse development of CHF in affected patients.  
First, myocardial flap scaffolds based on decellularized (DCELLed) porcine left-
ventricular myocardium and its associated coronary arteries and veins were generated and 
characterized.  All scaffolds displayed a fully intact and patent vasculature to the level of capillaries, 
were devoid of cellular proteins, contained only residual DNA, retained collagen, elastin, and basal 
laminar components, exhibited excellent mechanical properties, and were compatible towards 
seeded cells.  
To evaluate the host response to the scaffold material in a xenogeneic scenario, scaffold 
samples were implanted subdermally in rats.  Long-term, macrophages at the implant site were 
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observed to shift in polarization from an inflammatory to a more constructive, remodeling 
phenotype. 
In a subsequent series of studies, these scaffolds were seeded with human adipose derived 
stem cells (hADSC) and exposed to stimuli reflective of the cardiac environment using a custom-
designed platform.  Seeded constructs were subjected to various combinations of mechanical, 
electrical, and pharmacological stimuli with the objective of directing the differentiation of hADSC 
into a cardiomyocyte phenotype en route to resembling functional myocardial tissue. 
 Finally, the feasibility of infarct scar surgical replacement with myocardial scaffold-based 
grafts was evaluated in a porcine model.  A surgical anastomosis of the scaffold’s vessels to the 
host’s vasculature demonstrated complete perfusion of the scaffold.  Hemostasis was achieved with 
no major bleeding events, and no complications were encountered.  
It is expected that this research will have a positive impact upon efforts to treat a growing 
population of patients suffering from complications of MI.  It will not only enable clinicians to 
prevent or reverse the progression towards CHF—saving lives and improving the quality of life for 













The author would like to acknowledge the incredible support and guidance he 
received from his advisors, Drs. Agneta and Dan Simionescu.  Their mentorship has shaped 
him both as a scientist and a person.  For their time and indispensable advice, he would 
like to thank committee members Christopher C. Wright, M.D., of the Greenville Health 
System, Greenville, SC; Richard P. Visconti, Ph.D., of the Medical University of South 
Carolina, Charleston, SC; and Martine LaBerge, Ph.D., of Clemson University, Clemson, 
SC.  He is grateful for the friendship and assistance of all Biocompatibility and Tissue 
Regeneration Laboratories (BTRL) members, past and present, including: Jeremy Mercuri, 
Ph.D, George Fercana, Ph.D., James Chow, Ph.D., Lee Sierad, Ph.D, Richard Pascal, Grace 
Dion, Allison Kennamer, Theresa Hafner, Katy Jaeggli, Natasha Topoluk, Chris DeBorde, 
and Alex Bina.  He would like to extend a special thanks to all those who contributed 
directly to this project: Joshua Biggs, Robert Marti, Laura McCallum, Katelyn Rye, Mike 
Jaeggli, and Barry C. Starcher, Ph.D.  Finally, the author would like to thank the Clemson 
University Department of Bioengineering and its staff, including: Maria Torres, Leigh 
Humphries, Sherri Morrison, Maranda Arnold, Michelle Kirby, Mellissa McCullough, and 
Tammy Rothell.  Funding for this research was furnished by the National Institutes of 
Health through several grants: R21EB009835 and 2P20GM103444-06 (to AS) and R01 











TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
DEDICATION ................................................................................................................ iv 
 
ACKNOWLEDGMENTS ............................................................................................... v 
 
LIST OF TABLES ......................................................................................................... xii 
 
LIST OF FIGURES ...................................................................................................... xiii 
 
CHAPTER ONE: REVIEW OF LITERATURE ............................................................. 1 
 
   1.1 Introduction and Background ............................................................ 1 
   1.1.1 Etiology and Pathology................................................................... 1 
   1.2 Treatment ........................................................................................... 5 
   1.2.1 Clinical Therapeutic Options .......................................................... 5 
   1.2.2 Experimental Clinical Techniques ................................................ 10 
   1.2.3 Rationale for Tissue Engineering ................................................. 12 
   1.3 Design Requirements for Engineered Heart Tissue ......................... 13 
   1.4 Current Strategies for Producing Engineered Heart Tissue ............. 15 
   1.4.1 Synthetic Biomaterials .................................................................. 16 
   1.4.2 Natural Biomaterials .................................................................... 18 
   1.4.3 Combination Biomaterials ............................................................ 21 
   1.4.4 “Scaffold-Free” Cell Sheet Engineering ...................................... 22  
   1.5 Limitations, Challenges, and Barriers in 
    Myocardial Tissue Engineering ....................................................... 23 
   1.5.1 Effects of Scaffold on Engineered Heart 
    Tissue Viability and Function .......................................................... 23 
   1.5.2 Vascularization and Growth Promoting Factors ......................... 26 
   1.5.3 Cell Sourcing and Expansion........................................................ 27 
   1.5.4 Bioreactors for Seeding and Preconditioning .............................. 28 
   1.5.5 Applications of Cardiomyocyte and 
    Myocardial Extracellular Matrix Mechanics .................................. 30 
   1.5.5.1 The Cardiomyocyte Cytoskeleton .............................................. 32 
   1.5.5.2 Cytoskeletal-Extracellular Matrix Linkages .............................. 33 
   1.5.5.3 Cell-Cell Linkages ..................................................................... 34 
vii 
 
Table of Contents (Continued)                                                                                       Page 
   
   1.5.5.4 Using Models to Define Effective 
    Mechanical Stimuli in Cell Differentiation ...................................... 35 
   1.5.6 Surgical Considerations................................................................ 38 
   1.5.7 Myocardial Tissue Engineering in the Diseased Patient .............. 40 
   1.6 Summary and Conclusions .............................................................. 42 
   1.7 References ........................................................................................ 43 
 
CHAPTER TWO: PROJECT MOTIVATION, SPECIFIC AIMS, AND  
 SIGNIFICANCE ................................................................................................ 53 
 
   2.1 Introduction and Clinical Relevance ................................................ 53 
   2.2 Current Standards of Care and Limitations ..................................... 54 
   2.3 Specific Aims ................................................................................... 56 
   2.4 Project Significance ......................................................................... 60 
   2.5 References ........................................................................................ 60 
 
CHAPTER THREE: DEVELOPMENT AND CHARACTERIZATION OF AN 
ACELLULAR MYOCARDIAL SCAFFOLD ENRICHED WITH PATENT 
VASCULAR NETWORKS AND BIOCOMPATIBLE CELL NICHES ......... 63 
 
   3.1 Introduction ...................................................................................... 63 
   3.2 Methods and Materials ..................................................................... 65 
   3.2.1 Decellularization of Porcine Myocardium ................................... 65 
   3.2.2 Histology and Immunohistochemistry........................................... 68 
   3.2.3 DNA, Collagen and Elastin Quantification .................................. 69 
   3.2.4 Mechanical Properties .................................................................. 69 
   3.2.5 Evaluation of Scaffold Vasculature .............................................. 70 
   3.2.6 Cell Seeding and Analysis ............................................................. 71 
   3.2.6 Cell Seeding and Analysis ............................................................. 72 
   3.3 Results .............................................................................................. 72 
   3.3.1 Removal of Cellular Components ................................................. 72 
   3.3.2 Preservation of Matrix Architecture and Mechanical Integrity ... 76 
   3.3.3 Preservation of ECM Proteins and Basal Lamina ....................... 79 
   3.3.4 Preservation of Vascular Integrity and Patency ........................... 81 
   3.3.5 Cytocompatibility .......................................................................... 83 
   3.4 Discussion ........................................................................................ 84 
   3.4.1 Evaluation of Decellularization Efficiency ................................... 84 
   3.4.2 Removal of Cellular Material ....................................................... 85 
   3.4.3 Preservation of Basal Lamina Components ................................. 87 
   3.4.4 Preservation of Collagen and Elastin ........................................... 88 




Table of Contents (Continued)                                                                                       Page 
 
   3.4.6 Vascular Integrity and Patency .................................................... 90  
   3.4.7 Cytocompatibility and Cardiomyocyte Cell Seeding .................... 90 
   3.4.8 Analysis of Optimal Decellularization .......................................... 91 
   3.5 Conclusions ...................................................................................... 92 
   3.6 Updates to These Methods ............................................................... 93 
   3.7 References ........................................................................................ 94 
 
CHAPTER FOUR: EVALUATION OF THE HOST RESPONSE TO IMPLANTED 
MYOCARDIAL SCAFFOLDS  ........................................................................ 97 
    
   4.1 Introduction ...................................................................................... 97 
   4.2 Biocompatibility Study 1 ................................................................. 98 
   4.2.1 Methods ......................................................................................... 98 
   4.2.1.1 In Vitro Cytotoxicity Assessment ............................................... 98 
   4.2.1.2 Scaffold Sample Preparation for Implantation .......................... 99 
   4.2.1.3 Subdermal Implantation Procedure ........................................... 99 
   4.2.1.4 Explantation and Histological Evaluation............................... 100 
   4.2.2 Results ......................................................................................... 100 
   4.2.2.1 In Vitro Cytotoxicity Assessment ............................................. 100 
   4.2.2.2 Explantation and Histological Evaluation............................... 102 
   4.2.3 Discussion ................................................................................... 104 
   4.3 Aims for Biocompatibility Study 2 ................................................ 107 
   4.4 Biocompatibility Study 2 ............................................................... 110 
   4.4.1 Methods....................................................................................... 110 
   4.4.1.1 Quality Control Characterization of Scaffolds: DNA 
   Quantification, SDS Quantification, and 
   alpha-1,3-galactose Screening ............................................................ 110 
   4.4.1.1.1 DNA Quantification .............................................................. 110 
   4.4.1.1.2 SDS Quantification ............................................................... 110 
   4.4.1.1.3 Screening for alpha-1, 3-galactose ....................................... 111 
   4.4.1.2 Scaffold Preparation and PGG fixation .................................. 112 
   4.4.1.3 Subdermal Implantation in Rats .............................................. 112 
   4.4.1.4 Explantation and Semi-quantitative Histological Analysis ..... 113 
   4.4.1.5 Statistical Analysis ................................................................... 114 
   4.4.2 Results ......................................................................................... 114 
   4.4.2.1 DNA Quantification ................................................................. 114 
   4.4.2.2 SDS Quantification .................................................................. 115 
   4.4.2.3 Screening for alpha-1, 3-galactose .......................................... 117 
   4.4.2.4 Semi-quantitative histological analysis of cellularity, foriegn 
    body giant cell proliferation, vascularity, and collagen content ... 119  
   4.4.2.5 Cell infiltration......................................................................... 120 
   4.4.2.6 Vascularity ............................................................................... 120 
ix 
 
Table of Contents (Continued)                                                                                       Page 
    
   4.4.2.7 FBGC count ............................................................................. 122 
   4.4.2.8 Collagen Content ..................................................................... 122 
   4.4.2.9 Semi-quantitative histological analysis of 
    macrophage polarization ............................................................... 125 
   4.4.3 Discussion ................................................................................... 129 
   4.4.3.1 General Observations .............................................................. 129 
   4.4.3.2 Macrophage Polarization ........................................................ 132 
   4.4.4 Conclusions ................................................................................. 135 
   4.5 References ...................................................................................... 136 
    
CHAPTER FIVE: DEVELOPMENT OF A PLATFORM FOR IDENTIFYING 
DRIVING FACTORS IN THE DIFFERENTIATION OF STEM CELLS 
TOWARD A CARDIOMYOCYTE PHENOTYPE ........................................ 139 
 
   5.1 Introduction .................................................................................... 139 
   5.2 Pilot Study: Differentiation of hADSC Cultured Statically 
    on Decellularized Myocardial Scaffolds ........................................ 142 
   5.2.1 Introduction ................................................................................. 142 
   5.2.2 Methods....................................................................................... 143 
   5.2.2.1 Scaffold preparation, cell seeding, 
    AZT stimulation, and cell culture................................................... 143 
   5.2.2.2 Isolation of mRNA and protein ................................................ 144 
   5.2.2.3 Histology, immunofluorescence, and IHC staining ................. 144 
   5.2.2.4 Western blotting ....................................................................... 145 
   5.2.2.5 Quantitative reverse transcription-polymerase 
    chain reaction (qRT-PCR) ............................................................. 146 
   5.2.2.6 Enzyme-linked immunosorbent assay (ELISA) ........................ 146 
   5.2.3 Results ......................................................................................... 146 
   5.2.3.1 Histology, immunofluorescence, and IHC staining ................. 146 
   5.2.3.2 Western blotting ....................................................................... 149 
   5.2.3.3 qRT-PCR .................................................................................. 150 
   5.2.3.4 Enzyme-linked immunosorbent assay (ELISA) ........................ 153 
   5.2.4 Discussion ................................................................................... 154 
   5.2.5 Conclusion .................................................................................. 158 
   5.3 hADSC Differentiation with Flexcell System ............................... 158 
   5.3.1 Introduction ................................................................................. 158 
   5.3.2 Methods....................................................................................... 160 
   5.3.2.1 System Design .......................................................................... 160  
   5.3.2.2 Modified Flexcell Well Plate Design ....................................... 167 
   5.3.2.3 Experimental Setup .................................................................. 170 
   5.3.2.4 Preparation of Scaffolds .......................................................... 171 
   5.3.2.5 Cell Seeding and AZT stimulation ........................................... 172 
x 
 
Table of Contents (Continued)                                                                                       Page 
   
   5.3.2.6 Construct Attachment and Stimulation Parameters ................ 173 
   5.3.2.7 Isolation of mRNA and protein ................................................ 174 
   5.3.2.8 Histology, immunofluorescence, and IHC staining ................. 174 
   5.3.2.9 Live/Dead Assay....................................................................... 175 
   5.3.2.10 Calcium Staining Assay ......................................................... 175 
   5.3.3 Results ......................................................................................... 176 
   5.3.3.1 Isolation of mRNA and protein ................................................ 176 
   5.3.3.2 Live/Dead Assay....................................................................... 176 
   5.3.3.3 Calcium Staining Assay ........................................................... 177 
   5.3.3.4 Histology, immunofluorescence, and IHC ............................... 180 
   5.3.4 Discussion ................................................................................... 182 
   5.3.4.1 Histology, immunofluorescence, and IHC ............................... 183 
   5.3.4.2 Design Iterations and Challenges ............................................ 185 
   5.3.4.3 Cell Seeding Challenges .......................................................... 189 
   5.3.4.4 Perspectives on Dynamic Stimuli in 
    Cardiomyogenic Differentiation .................................................... 190 
   5.3.5 Conclusions ................................................................................. 192 
   5.3.6 References ................................................................................... 193 
 
CHAPTER SIX: FEASIBILITY STUDY OF MYOCARDIAL SCAFFOLD 
IMPLANTATION IN A PORCINE MODEL ................................................. 196 
 
   6.1 Introduction .................................................................................... 196 
   6.2 Pilot Study: In Vitro Test of Surgical Attachment......................... 201 
   6.2.1 Introduction ................................................................................. 201 
   6.2.2 Methods....................................................................................... 202 
   6.2.2.1 Porcine Heart Model ............................................................... 202 
   6.2.3 Results ......................................................................................... 205 
   6.2.3.1 Porcine Heart Model ............................................................... 205 
   6.2.3.2 Rabbit Heart Model ................................................................. 207 
   6.2.4 Discussion ................................................................................... 208 
   6.2.5 Conclusions ................................................................................. 208 
   6.3 Group 1: Acute Implantation Testing ............................................ 209 
   6.3.1 Methods....................................................................................... 209 
   6.3.1.1 Modification of Myocardial Scaffold with Vascular 
    Scaffolds for Anastomosis .............................................................. 209 
   6.3.1.1.1 Vascular Scaffold Preparation ............................................. 209 
   6.3.1.1.2 Cleaning and Preparation .................................................... 210 
   6.3.1.1.3 Tissue Decellularization and Sterilization ............................ 211 
   6.4 Group 2: Induction of Myocardial Infarct ..................................... 213 
   6.5 Group 3: Short-term Implantation Testing .................................... 214 
   6.5.1 Blood collection .......................................................................... 215 
xi 
 
Table of Contents (Continued)                                                                                       Page 
   
   6.5.2 Fat collection .............................................................................. 216 
   6.5.3 Post-operative Recovery and Monitoring ................................... 216 
   6.6 Results ............................................................................................ 217 
   6.6.1 Group 1 ....................................................................................... 217 
   6.6.2 Histological Assessment of Scaffold Perfusion ........................... 220 
   6.7 Discussion ...................................................................................... 223 
   6.8 Conclusions .................................................................................... 226 
   6.9 References ...................................................................................... 226 
 
CHAPTER SEVEN: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK ............................................................................................................. 228 
 
   7.1 Summary of Project Development ................................................. 228 
   7.2 Progress toward Achievement of Specific Aims ........................... 229 
   7.2.1 Aim 1 (Chapter 3) ....................................................................... 230 
   7.2.2 Aim 2 (Chapter 4) ....................................................................... 231 
   7.2.3 Aim 3 (Chapter 5) ....................................................................... 232 
   7.2.4 Aim 4 (Chapter 6) ....................................................................... 233 
   7.2.5 Perspectives on Progress Made and Comments on 
    Potential Continued Research ....................................................... 233 
   7.3 Recommendations for Future Work............................................... 234 
   7.3.1 Aim 2 ........................................................................................... 234 
   7.3.2 Aim 3 ........................................................................................... 235 
   7.3.2.1 In Vitro Conditioning of Cell-Seeded 
    Constructs in a Bioreactor ............................................................. 236 
   7.3.2.1.1 Bioreactor Design ................................................................. 236 
   7.3.2.1.2 Scaffold Preparation ............................................................. 239 
   7.3.2.1.3 Cell seeding, incorporation of constructs into 
    bioreactor, and conditioning ......................................................... 239 
   7.3.2.1.4 Cell Culture ........................................................................... 241 
   7.3.2.1.5 Characterization of conditioned constructs .......................... 241 
   7.3.2.1.6 Outcome Success Measures .................................................. 243 
   7.3.2.1.7 Challenges and Alternative Strategies .................................. 244 
   7.2.4 Aim 4 ........................................................................................... 245 
   7.4 References ...................................................................................... 246 
 
 
APPENDICES ............................................................................................................. 248 
 





LIST OF TABLES 
 
 
Table                                                                                                                               Page 
 
 1 Dimensions of Pores within Myocardial Scaffolds ..................................... 77 
 
 2 Immunohistochemical Staining of Basement Membrane 
   Proteins and Fibronectin ........................................................................ 78 
 
 3 Ratio of Collagen Weight Percentage to Elastin Weight  
   Percentage .............................................................................................. 81 
 
 4 Summary of Observations on the Effects of Various Chemical  




LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
 1.1 Schematic of the arterial stenosis and subsequent blockage 
   that causes acute myocardial infarction (MI)........................................... 2 
 
 1.2 Graphic illustration showing the points of anastomosis (attachment) of the 
   vascular graft in coronary artery bypass grafting surgery (CABG) ......... 7 
 
 1.3 Graphical representation of the various methods used to deliver 
   potentially therapeutic cells via cellular cardiomyoplasty ..................... 11 
 
 1.4 Various concepts in generating engineered heart tissue (EHT) ................... 15 
 
 1.5 A diagram of the potential influences the extracellular 
   matrix (ECM) can exert on cells ............................................................ 25 
 
 2.1 Overview of proposed translational approach and clinical scenario ........... 55 
 
 3.1 Decellularization of myocardium ................................................................ 67 
 
 3.2 Histology showing removal of cellular components ................................... 74 
 
 3.3 Histology showing preservation of collagen and elastin ............................. 75 
 
 3.4 Immunohistochemistry showing preservation of basement membrane in 
myocardial ECM .................................................................................... 77 
 
 3.5 Immunohistochemistry showing preservation of basement membrane in 
coronary arterial ECM ........................................................................... 78 
 
 3.6 Biochemical quantification of collagen and elastin content of 
   decellularized myocardial scaffolds ....................................................... 80 
 
 3.7 Vascularization of decellularized myocardial scaffolds .............................. 82 
 
 3.8 Cytocompatibility of decellularized myocardial scaffolds .......................... 84 
 
 3.9 Continuous-flow, perfusion-immersion system for decellularization ....... 248 
 
 3.10 Continuous-flow, perfusion-immersion system 
   for whole heart decellularization ......................................................... 250 
xiv 
 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 4.1 In vitro cytotoxicity assessment ................................................................. 101 
 
 4.2 Histological analysis of explanted scaffolds 
   from Biocompatibility Study 1 ............................................................ 103 
 
 4.3 Effects of PGG as assessed by histology 
   and cytokine array ................................................................................ 108 
 
 4.4 Screening of myocardial scaffolds for DNA content ................................. 115 
 
 4.5 Screening of myocardial scaffolds for SDS content .................................. 116 
 
 4.6 Screening of myocardial scaffolds for alpha-1, 3-galactose ...................... 118 
 
 4.7 Histological evaluation of explanted scaffolds 
   from Biocompatiblity Study 2 ............................................................. 119 
 
 4.8 Semi-quantitative analysis of histological images of explanted 
   scaffolds from Biocompatiblity Study 2 .............................................. 121 
 
 4.9 Semi-quantitative analysis of histological images of explanted 
   scaffolds from Biocompatiblity Study 2 .............................................. 123 
 
 4.10 Evaluation of explanted scaffolds from 
   Biocompatiblity Study 2 by immunofluorescence ............................... 124 
 
 4.11 Semi-quantitative analysis of immunofluorescence images of 
   explanted scaffolds from Biocompatiblity Study 2 ............................. 127 
 
 4.12 Semi-quantitative analysis of immunofluorescence images of 
   explanted scaffolds from Biocompatiblity Study 2 ............................. 128 
 
 5.1 Analysis of Differentiation of hADSC Cultured Statically 
   on Decellularized Myocardial Scaffolds by IHC and IF ..................... 148 
 
 5.2 Analysis of Differentiation of hADSC Cultured Statically 
   on Decellularized Myocardial Scaffolds by Western blotting ............. 150 
 
 5.3 Analysis of Differentiation of hADSC Cultured Statically 
   on Decellularized Myocardial Scaffolds by qRT-PCR ........................ 152 
xv 
 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 5.4 Analysis of Differentiation of hADSC Cultured Statically 
   on Decellularized Myocardial Scaffolds by ELISA ............................ 154 
 
 5.5 Design of Flexcell system .......................................................................... 163 
 
 5.6 Detailed operation of Flexcell system........................................................ 165 
 
 5.7 Design of Flexcell plates and well inserts.................................................. 169 
 
 5.8 Analysis of hADSC differentiation with Flexcell system.......................... 177 
 
 5.9 Analysis of hADSC differentiation with Flexcell system.......................... 179 
 
 5.10 Analysis of hADSC differentiation with Flexcell system.......................... 181 
 
 5.11 Modification of Flexcell system ................................................................ 188 
 
 6.1 Overview of an animal model to test clinical 
   implementation of myocardial grafts ................................................... 197 
 
 6.2 Overview of preliminary animal study to test 
   clinical implementation of myocardial grafts ...................................... 199 
 
 6.3 In vitro test of scaffold implantation method, Part 1 ................................. 204 
 
 6.4 In vitro test of scaffold implantation method, Part 2 ................................. 206 
 
 6.5 In vitro test of scaffold implantation method, Part 3 ................................. 204 
 
 6.6 Perfusion bioprocessor for decellularization of vascular scaffolds ........... 210 
 
 6.7 Acute implantation testing of myocardial scaffold in a porcine model ..... 219 
 
 6.8 Histological evaluation of acute implantation of myocardial scaffold ...... 222 
 
 7.1 Conceptual drawing of possible perfusion bioreactor ............................... 238
1 
 
CHAPTER ONE: REVIEW OF LITERATURE 
 
1.1 Introduction and Background: 
1.1.1 Etiology and Pathology: 
 Hypertensive, hypercholesterolemic individuals often develop coronary artery 
disease (CAD), which is characterized by atherosclerosis in one or both of the coronary 
arteries.  Atherosclerotic lesions in these arteries, especially the left anterior descending 
(LAD) coronary artery, are associated with a high risk for occurrence of adverse cardiac 
events, including unstable angina, acute MI, and sudden death from cardiac failure.[1]  
These lesions, or atheromatous plaques (atheromas), are suspected to develop according to 
the established inflammatory mechanisms of atherosclerosis, but typically do not grow 
large enough to achieve any appreciable stenosis of the vessel.  Rather, the mechanism 
responsible for triggering cardiac events is thrombosis or subsequent thromboembolism 
within the coronary arteries or their branching vessels.[1]   
 In the pathogenesis of MI, thrombus formation occurs following the rupture of the 
endothelium and fibrous cap which overlay the atheroma.  The atheroma’s lipid core is left 
exposed and free to contact and activate platelets, initiating blood clot formation.[1] The 
resulting thrombus occludes the coronary circulation either at the site of the lesion or 
embolizes to some distal point, and all cells nourished by the occluded vessel are subjected 
to severe ischemic insult if they are located distal to the blockage.  Hypoxia and lack of 
sufficient nutrient and waste exchange resulting from ischemia cause necrosis of the 
affected cells, and the injured area, or necrotic core, becomes inflamed.[2] 
2 
 
 Following the inflammatory response, the tissue is remodeled into a dynamic, but 
functionally inferior, scar composed of fibrous matrix proteins (i.e. collagen type I and III) 
and myofibroblasts (Figure 1.1).[3] This fibrotic response is heavily favored over any 
competing regenerative response (e.g. restoration of native structure and function of the 
tissue) because the former is a much more rapid process, and there is a strong impetus to 
repair (e.g. restore tissue integrity) injury in a vital organ such as the heart as quickly as 
possible.[4]  This remedy for the injury is analogous to sealing a hole in a ship’s hull with 
duct tape instead of welding a new piece of metal in place of the void—it is a haphazard 
attempt at repair.  
 
Figure 1.1: Schematic of the arterial stenosis and subsequent blockage that causes acute myocardial 
infarction (MI).  The area of affected tissue is also shown.  The cells in this area succumb to necrosis and the 
tissue is remodelled into a fibrous scar. 
In the first 2 days post-MI, activated macrophages contribute to increased 
expression of transforming growth factor-beta (TGF-β), which is thought to drive the 
phenotypic shift of interstitial cardiac fibroblasts into myofibroblasts.  These 
myofibroblasts, in conjunction with increased levels of angiotensin II and TGF-β, mediate 
transcription of collagen type I and III mRNAs at the site of the infarct.[3]   
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 The resulting fibrosis is not localized to the necrotic core or tissue immediately 
adjacent to it, but is frequently observed to affect sites remote to the infarct.  In an infarct 
of the left ventricular anterior wall, for example, areas of increased fibrillar collagen 
deposition can appear intraseptally, in the septal endocardium, in the right ventricle, and in 
the visceral pericardium.[3]  This effect is most likely an indirect result of the damage 
caused by the infarct and is mediated by physiologically-driven changes in cell 
morphology, and therefore, changes in the expression of fibrillar matrix proteins 
Following MI, the body will attempt to maintain homeostasis despite the infarct-
induced death of cardiomyocytes (CM) and accompanying loss of their energetic 
contribution to the stroke volume (volume of blood pumped during systole) of the left 
ventricle.  This means the collective demand of the body’s cells for blood will not deviate 
from pre-infarct levels, and, consequently, the remaining healthy myocardium must work 
harder to maintain the original cardiac output.[5]  As a result, the heart undergoes changes 
at both the cellular and organ level in order to normalize stroke volume.  
The noncontractile infarct scar is a weak point in the ventricular wall that acts as a 
stress concentration during ventricular systole.  Thus, ventricular pressure without 
counteracting force evolved from wall tension in that area causes stretching and thinning 
of the infarct and an increase in the radius of the chamber.  Pursuant to the Law of Laplace, 
which can be used to model the relationships between pressure, volume, and wall geometry 
in the left ventricle, an increase in radius helps to normalize wall tension and stroke volume 
initially.  With time, however, this increased radius diminishes the preload (and ejection 
fraction) the ventricle is able to generate, and other mechanisms of remodeling such as 
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increased CM contraction force and wall thinning are enlisted to help augment preload 
generation.   
Increased CM contraction force is managed through cellular hypertrophy.  Via 
mechanotransduction, CM experience chronically increased mechanical stresses and 
synthesize additional muscle filaments (actin, myosin, and titin) to handle the larger 
workload.  Since the ventricle increases in volume, the myocardium is under volume 
overload, and it has been established that volume overload produces eccentric CM 
hypertrophy.[6]  Specifically, CM add muscle filaments in series rather than in parallel (as 
in pressure overload scenarios) so that CM lengthen.  The aggregate of this lengthening is 
an increasing ventricular radius, which circles back to create the original problem of 
reduced preload.  
 Initially, this hypertrophic response is effective in maintaining cardiac output, but 
the long term effects are deleterious.    Since these cells are surrounded by an extracellular 
matrix (ECM) of collagen, there is an attendant increase in the synthesis of fibrous ECM 
components to support the hypertrophic cells.[7, 8]  This fibrosis leads to decreased 
compliance, poor diastolic filling, and chronic excessive wall stress.  There is also evidence 
that chronic hypertrophy involves shedding of integrins–the transmembrane proteins 
responsible for myocyte-ECM adhesion—into the adjacent ECM, potentially causing 
disordered mechanotransduction and diminsished transfer of myocyte contraction force to 
the ECM.[9]   Additionally, activation of matrix metalloproteases (MMP) under chronic 
volume overload can lead to degradation of the collagen network (the perimysium) and 
cause increased elasticity and muscle fiber slippage.[10]  A possible manifestation of this 
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slippage is the expansion of the ventricle and thinning of the ventricular wall, which leads 
to global enlargement of the heart, weakening of the ventricular walls, and dangerously 
reduced cardiac output.[11]  Together, these constitute the hallmark symptoms of dilated 
cardiomyopathy (DCM) and congestive heart failure (CHF), a fatal condition which can 
result in the years immediately following an MI, especially if the infarct is left untreated 
beyond reperfusion.[7, 12]   
 The hearts of patients with CHF consistently display such characteristic ventricular 
wall distension and aneurysmal dilation, which result in the development of widespread 
edema (including pulmonary edema) and severe exercise intolerance.  CHF is the final 
stage of a degenerative cascade of events which begins with MI and the scar tissue it 
produces.[7, 12]  Therapies which seek to halt progression toward CHF must necessarily 
target the prevention of infarct scar formation or its replacement with functional 
myocardium.   
 
1.2 Treatment: 
1.2.1 Clinical Therapeutic Options: 
 Orthotropic, or whole organ replacement, is currently the only curative therapy for 
myocardial damage, namely prevention of left ventricular dysfunction and remodeling, 
CHF or subsequent MI.[13, 14]  Transplantation is limited by a severe shortage of donor 
hearts, as fewer than 2,500 transplant procedures are performed annually, and over 3,000 
patients perennially remain on the waiting list.[15, 16]  The unmet need is not fully conveyed 
by these figures, however, if one considers the annual number of patients who suffer a first 
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MI (roughly 600,000).[17]  This would seem to suggest the existence of a vastly underserved 
population of patients who could benefit from transplantation, but are either ineligible, or 
deem it futile to request a place on the waiting list.   
 The inflammatory response following MI occurs rapidly.  It is estimated that 
necrosis of CM begins 20-30 minutes after the initial blockage of the coronary 
vasculature.[2] The current gold standard in clinical care post-MI is percutaneous coronary 
intervention (PCI), a transcatheter procedure wherein an angioplasty balloon is used to 
dilate the vessel lumen immediately adjacent to the site of thrombotic occlusion, thus 
restoring flow to the downstream tissues.[18]   One complication limiting the efficacy of 
PCI is ischemia-reperfusion injury, an inflammatory condition created by sudden reversal 
of a hypoxic state wherein microvascular endothelial cells become activated and produce 
reactive oxygen species.  Currently, chest pain centers and cardiac care units have set a 
benchmark door-to-balloon time (elapsed time between patient admission to completion of 
PCI) of 90 minutes in order to limit the extent of damage produced by MI.[19, 20]   While 
minimizing door-to-balloon time has shown a direct correlation with reduced infarct scar 
size, it is difficult to imagine achieving reperfusion of the ischemic tissue before CM 
necrosis sets in.  This means patients are inevitably faced with the development of an infarct 
scar and its complications unless response and transport times dramatically increase or an 
at-hand/pre-hospital admission treatment is developed.[21]     
 An alternative to PCI is CABG, a surgical procedure which involves using an 
autograft (either a length of the saphenous vein or mammary artery) to reroute blood flow 
around the thrombus (thus, bypassing it) that blocks the coronary circulation and restoring 
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blood supply to the ischemic myocardium (Figure 1.2).  CABG is used frequently in an 
interventionary capacity among patients with angina caused by coronary artery disease.  It 
can be indicated as a treatment for aborting and mitigating damaged caused by MI, but is 
associated with increased morbidity (i.e. stroke, brain dysfunction) as the immediacy of its 
performance following MI increases (although this correlation could be derived from 
general instability of the patient prior to surgery).[22, 23] The overall efficacy of CABG as 
assessed by long-term (10 year) mortality rate is favorable, with rates of only 26 – 32% 
reported in several clinical trial.[22-25]  PCI, including percutaneous translumenal coronary 
angioplasty (PTCA) performed with either balloons or stents is associated with slightly 
higher mortality rate, but presents a less invasive alternative with comparable relief of 
symptoms.[26, 27]   
 
Figure 1.2: Graphic illustration showing the points of anastomosis (attachment) of the vascular graft in 
coronary artery bypass grafting surgery (CABG). 
 The therapies discussed above are only marginally effective in limiting the size of 
the infarct scar, and focus solely on myocardial revascularization.  By the time these 
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treatments are implemented, they are not completely preventive in regards to scar 
formation and thus do not avert the greatest threat that MI presents to patients – the 
pathological progression towards CHF.  These shortcomings in treatment of MI-induced 
damage have prompted the development of surgical EHThniques aimed at restoring 
ventricular function subsequent to remodeling and onset of DCM.   
 The first such attempt was the ill-fated construction of a muscular sling using the 
latissimus dorsi muscle in hopes that its contraction would augment that of the 
dysfunctional left ventricle in heart failure patients.[28]  Another approach hypothesized that 
reducing the size of dilated LV would somewhat restore cardiac efficiency by increasing 
ejection fraction and stroke volume.  This is known by several names: endoventricular 
circular patch plasty (EVCPP), surgical ventricular reconstruction, or the Dor procedure 
(after the surgeon who pioneered the EHThnique).[29]  The procedure entails incising the 
aneurysmal area, which is coincident with the area of the infarct scar, and threading a purse-
string suture at the peri-infarct border along the endocardial wall.  The circular suture 
pattern is then tightened, effectively reigning in the aneurysm and reducing the chamber 
diameter.[29]  EVCPP is typically performed simultaneously with CABG, and a recent 
clinical trial was conducted to elucidate the added benefit, if any, of performing EVCPP 
with CABG.  Upon completion of the Surgical Treatment for Ischemic Heart Failure 
(STITCH) trial, Jones et al. concluded that EVCPP did significantly reduce end-systolic 
volume, but this effect was not associated with a decrease in the frequency of post-
operative hospitalization or death from cardiac causes (the primary endpoint of the trial) 
9 
 
when compared to CABG performed alone.[30]  These results suggest that EVCPP is 
ineffective as a treatment for DCM and in forestalling development of CHF. 
 A final approach to treatment of MI complications, specifically CHF, is the use of 
left-ventricular assist devices (LVAD).  LVADs are implantable medical devices which 
mechanically pump blood from the left ventricle into the aorta, essentially replacing the 
muscular function of the ventricle with an artificial pump.  Originally developed as a 
bridge-to-transplant therapy for end-stage heart failure patients on the transplant waiting 
list, they were ultimately explored as a destination therapy for transplant-ineligible heart 
failure patients.[31]  The Randomized Evaluation of Mechanical Assistance for the 
Treatment of Congestive Heart Failure (REMATCH) trial of 2001 placed 129 end-stage 
(New York Heart Association class IV) heart failure patients into either an optimum 
medical management group or an LVAD-treated group.  Results demonstrated a 48% 
decrease in mortality among the LVAD-group when compared with the medical 
management group.  One and two year survival rates were 52% and 23%, respectively, in 
the device group.[31]  Despite this high mortality rate, it must be noted that these patients 
were in an advanced stage of deterioration, and if the devices could drastically increase 
survival at such a point, their beneficial effects might be significantly enhanced if 
implanted in patients with less advanced heart failure.  The potential of LVADs is 
tempered by concerns of hemocompatibility, infection, and durability, and both the 
cumbersome nature of the devices and daily attention required for their operation still 




1.2.2 Experimental Clinical Techniques: 
 When it is understood that the key to limiting the impact of MI lies in restoring the 
lost functionality of necrotic myocardium, the goal then becomes to replace the resultant 
fibrous infarct scar with functional tissue.   
 The marriage of advancements in the fields of stem cell biology and percutaneous 
(catheter-based) device engineering have made it possible to imagine that pluri- or 
multipotent stem cells could be transplanted into infarcted myocardium in order to facilitate 
a regenerative response within the scar tissue.  This approach, termed cellular 
cardiomyoplasty, uses in situ injection of autologous and potentially therapeutic cells 
through intracoronary or endoventricular catheter introduction (Figure 1.3).[33]  A litany of 
stem and progenitor cells have been proposed for use with this method, including skeletal 
myoblasts, bone marrow stem cells, peripheral blood stem cells, vascular endothelial cells, 
mesenchymal stem cells (MSC), adipose-derived stem cells (ADSC), umbilical cord cells, 
induced pluripotent stem cells (IPSCs), endothelial progenitor cells, cardiac stem cells, and 
embryonic stem cells (ESC).[34, 35]  For a more in-depth discussion and analysis of studies 
and clinical trials involving cellular cardiomyoplasty performed using these various cell 
types, the reader is referred to several comprehensive reviews of the subject.[35-38]  The 
therapeutic goals and potential effects associated with this method, as outlined by 
Chachques, et al. are to reduce the size of infarct scars, improve myocardial viability, limit 
global ventricular dilation, improve ventricular wall compliance and diastolic function, and 




Figure 1.3: Graphical representation of the various methods used to deliver potentially therapeutic cells via 
cellular cardiomyoplasty.  Intramyocardial, transendocardial, intravenous, and intracoronary routes of 
administration are shown. 
 Despite indications of success in several clinical trials,[35] controversy lingers over 
the precise mechanisms of action, most appropriate cell sources, and timing of cell 
transplantation following MI.  Furthermore, apparent limitations with transplanted cells, 
such as cell “regurgitation” from the injection site, poor cell engraftment and integration 
with host tissue, extensive apoptosis, and absent or limited differentiation into desired cell 
types, must be addressed.[14, 34, 39, 40]  One critical factor in the success of in situ cellular 
cardiomyoplasty is the inhospitable microenvironment into which these cells are 
implanted.  Depending upon the timing of the procedure, the cells are either thrust into a 
strong, local inflammatory response capable of inducing apoptosis (early post-MI) or into 
a poorly vascularized and dense matrix of collagen (late post-MI).  It would be perhaps 
overly optimistic to expect a high rate of cell attachment and viability in these 
environments, much less proper signaling, integration, or differentiation.[39]  Intracoronary 
or intramyocardial injection of stem cells is thus clearly limited by the lack of a stable cell 
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delivery method, and so in situ cellular cardiomyoplasty, at least at the moment, does not 
“stick” 
 
1.2.3 Rationale for Tissue Engineering: 
 Just as it has in many pathologies where organ transplant is considered the gold 
standard in clinical practice, tissue engineering has gained popularity as a potential therapy 
for regenerating functional myocardium.  The strategy of combining cells, engineered 
matrices (or scaffolds), and growth factors in order to produce an implantable graft presents 
clinicians with a much needed alternative to using donor organs or autografts in the 
treatment of such conditions, mainly to better serve demand for organ or tissue 
replacement.  
 Tissue engineering is a relatively young field, and myocardial tissue engineering is 
younger still.  As such, implantation studies of EHT are limited.  The first ever clinical trial 
(MAGNUM-trial) involving an EHT construct was begun in 2003, and used autologous 
bone marrow cells (BMC) seeded onto a 3-D collagen type I scaffold.[41]  The construct 
was implanted over the epicardial surface of the post-infarct scar in a group of 10 patients 
while they were undergoing CABG.  Follow-up at 10 months indicated prevention of 
cardiac remodeling and thickening of the scar (via cell ingrowth) with functional, healthy 
tissue.  There were no indications of immune or inflammatory reactions, no arrhythmias, 
and the EHT appeared to integrate well with the host tissue.[41]   
 It is important to note that this particular EHT construct was not intended to be 
functional, meaning it was neither contractile nor vascularized.[42]  Its mechanism of action 
13 
 
was one of providing “passive” support, and the collagen matrix most likely acted as a 
stable microenvironment from which the BMC could secrete paracrine signals to the 
healthy cells in the peri-infarct tissue.  Regardless of the mechanism at work in this graft, 
its success demonstrates the need for a scaffold in which to house transplanted cells and 
offers a possible explanation for the shortcomings of cellular cardiomyoplasty.  In addition, 
it highlights the need for tissue engineering approaches in order to successfully replace 
infarct scar and regenerate functional myocardium. 
 
1.3 Design Requirements for Engineered Heart Tissue: 
Desired characteristics of an engineered heart tissue (EHT) grafts are the 
attenuation of ventricular wall remodeling or dilation, development of systolic force, 
possession of sufficient compliance to withstand diastolic loading, electrical coupling of 
the CM in the graft with those of the host, and the avoidance of arrhythmias, inflammation, 
encapsulation, or calcification.[39, 42, 43]   
 If biomimicry, “remuscularization” (or restored functionality), and full replacement 
of a transmural (spanning the full thickness of the ventricular wall) infarct scar are assumed 
to be the goals of a particular EHT strategy, an attempt must be made to reproduce 
characteristics of the native myocardium as closely as possible.  In addition, the full or 
partial resection of the infarct scar may be necessary for full integration and improvement 
in function of infarcted hearts.[42, 44]  
 The average thickness of the ventricular wall is 1.5 cm, and the cell density of native 
myocardium is estimated at 2 x 108 cells/cm3.[45]  In the ventricles, this figure encompasses 
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4 predominant cell types, each with their own specific function, and organized in such a 
way as to provide the optimum function of the tissue.[39, 45]  These cell types (CM, cardiac 
fibroblasts (CF), vascular smooth muscle cells (VSMC), and endothelial cells (EC)) appear 
in defined and consistent ratios within healthy myocardium.[46]  In addition, the 
myocardium is very metabolically demanding, and is thus highly vascularized with an 
estimated capillary density of 2,500 capillaries/mm2.[47]  This latter point illustrates the 
need for an EHT graft which is highly vascularized, as the function and survival of a graft 
with poor blood supply could be limited. 
 The ECM of the myocardium is also of great importance, as it largely influences 
the orientation of the cells, the extent of their electrical coupling, and the mechanical 
properties of the tissue.[46]  Developing a scaffold with both porosity and mechanical 
properties comparable to native ECM is a significant challenge.   
 An aspect often overlooked in tissue engineering efforts, the method of surgical 
implantation used in delivering EHT grafts, could be a major determinant of both their 
success and feasibility.  The current trend in implant delivery is toward trans-catheter 
EHThniques, which are minimally invasive and thus reduce the risk of surgical 
complications.[48]  Since these advantages appeal to surgeons, the question then becomes 
one of how to design an EHT graft which is compatible with trans-catheter delivery.   
 Each of these design considerations impose their own particular range of caveats 
and limitations upon the potential success of a given approach to generating EHT.  These 




1.4 Current Strategies for Producing Engineered Heart Tissue: 
Despite its short lifetime, tissue engineering and the application of its principles to 
the treatment of post-MI damage and CHF have generated great interest.  An assortment 
of innovative tissue engineering strategies have been developed by a wide range of research 
groups.[39, 40, 42, 43]  These strategies include (a) the classical approach of using a synthetic 
biomaterial to generate a scaffold which is then functionalized via repopulation with 
appropriate cell types; (b) the same approach used above, with the exception that the 
synthetic biomaterial is substituted for natural materials in creating the scaffold; (c) again, 
the same approach as above, but using a combination synthetic and natural biomaterial 
scaffold instead; (d) and an approach of constructing “scaffold free” cell sheets, or stacked 
monolayers of cells (Figure 1.4). 
 
Figure 1.4: Various concepts in generating engineered heart tissue (EHT): (I) natural or synthetic material 
for cell repopulation; (II) cells seeded on soluble collagen and extracellular matrix (ECM) proteins; (III) 





1.4.1 Synthetic Biomaterials: 
 Synthetic biomatrices have been created using polymers with established properties 
of biocompatibility and biodegradability, such as polylactic acid (PLA), poylglycolic acid 
(PGA), and formulations of their copolymer, polylactic-co-glycolic acid (PLGA).[39, 42, 43]  
In addition, other elastomeric polymers, including polycaprolactone (PCL), poly(glycerol-
sebacate) (PGS), poly(trimethylene carbonate-co-lactide) (PTMCLA), and polyurethane 
(PU), have been employed to fabricate scaffolds for EHT.[39]  
 A variety of different materials processing approaches have been implemented to 
create scaffolds with defined structures similar to the native ECM.  This control over the 
geometrical and chemical characteristics of scaffolds is an advantage inherent to the use of 
synthetic materials.  Scaffolds with defined porosity, alignment, and surface chemistry can 
be generated through such methods as salt (particulate) leaching, laser sintering, and 
electrospinning.[39, 43, 49]   
 Lesman et al. seeded highly porous PLA/PLGA grafts generated via particulate 
leaching with a combination of human embryonic stem cell-derived CM, human umbilical 
vein EC, and human embryonic fibroblasts which were subsequently implanted into a nude 
rat model for 2 weeks.  The grafts appeared to successfully attach to the recipient 
myocardium and showed evidence of neovasculature formation.  Some grafts, however, 
were encapsulated by fibrous tissue, indicating poor integration with the host tissue.[49]   
 In another study, Ke et al. implanted a PGA patch seeded with undifferentiated 
mouse ESC into a rat model of MI.  After evaluation of cardiac function at 8 weeks 
following implantation, nearly twice the number of animals in the group which received 
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the graft survived in comparison with the sham control group.[50]  Similarly, BMC-seeded 
PCL patches were applied to the infarcted hearts of rats, and the authors reported a 
reduction in left ventricular remodeling, preservation of left ventricular systolic function, 
and deEHTtion of myosin heavy chain proteins.[51]  The latter seem to indicate possible 
transdifferentiation of BMC into cardiac cell types.  Lack of ability to induce the 
differentiation of stem cells grown on polymer grafts has been cited in the criticism of such 
grafts.[42] 
 Owing to its elastomeric characteristics, PGS has been investigated as potential 
scaffolding by several groups.[5, 52-54]  Its versatility and ability to be machined into precise, 
repeatable accordion like structures provided it with anisotropic mechanical properties 
similar to those of the right ventricular myocardium.[55]  It was reported to induce cell 
alignment[54, 55] and to support the viability and vascularization of a cell-seeded scaffold 
when implanted in a rat infarct model [52].  When it was compared via an implantation 
study to scaffolds composed of either poly(ethylene terephthalate)/dimer fatty acid (PED) 
and PED reinforced with titanium oxide (PED-TiO2), the PGS scaffold adhered to the host 
myocardium while undergoing degradation.  The PED did not remain attached to the host 
tissue, and the PED-TiO2 contributed to increased chamber dilation and infarct scar size.
[5]  
Thus, the application of PGS and similar thermoplastic elastomers cast doubt on the 
contention that synthetic materials cannot adequately reproduce the physiological 





1.4.2 Natural Biomaterials: 
 The use of naturally occurring materials to generate scaffolds for EHT has involved 
collagen, collagen gels (e.g. Matrigel), GAGs, fibrin, hyaluronic acid, and alginate.[39]  
Collagen is the most widely used natural material in efforts to produce EHT, and can be 
found in dry sheet, gel, or preserved in its native form as the predominant component of 
the cardiac ECM.[7, 8, 39, 43]  Ergo, this section will focus predominantly on material 
formulations which employ collagen as the main component.  For a discussion of the other 
materials mentioned above, the interested reader is directed to an extensive review of 
materials, both natural and synthetic, with potential applications to myocardial tissue 
engineering.[56]   
  The work of Zimmermann et al. over the last decade has focused on development 
of an EHT construct using neonatal CM and an extracellular matrix consisting of collagen 
type I and Matrigel.  Implantation of this construct in an infarcted rat model has shown that 
it is able to electrically couple with the host myocardium, contract for up to 8 weeks in 
vivo, contribute to newly formed myocardium,  and that it is associated with wall 
thickening in the infarcted area.[57, 58]  One disadvantage to this approach is the use of 
Matrigel, the safety of which is questionable since it is composed of ECM extracted from 
mouse tumors.[59]  The group addressed this issue with the claim that they had developed 
both serum-free and Matrigel-free EHT constructs.[59]   
 Additional studies have confirmed beneficial results such as graft-host myocyte 
electrical coupling, neovascularization or angiogenesis, and increased ventricular wall 
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thickness in EHT grafts generated using collagen along with either neonatal rat CM, mouse 
ESC, or bone marrow-derived MSC.[60-62]   
 A particularly unique method of generating a collagenous scaffold is that of 
decellularization (DCELL), or the removal of all cell constituents and cell membrane 
components which could be potentially immunogenic if implanted as an allo- or xenograft.  
DCELL can employ one or both of two mechanisms, chemical and physical agitation, to 
render a donor tissue completely free of epitopes which might trigger an immune response 
from a graft recipient.[56]  Following DCELL, the remaining tissue is composed of structural 
ECM proteins (i.e. collagens, elastin, and GAGs). These proteins elicit little to no immune 
response upon implantation due to the extensive evolutionary conservation of the genes 
which code for them.[56]  Notwithstanding the tremendous advantages offered by a scaffold 
with physiologically accurate concentrations, distibutions, and organization of natural 
ECM proteins, the option to create it from readily available xenogeneic tissue sources only 
enhances the appeal of this method.[63, 64]  Perhaps the most attractive feature of DCELL, 
however, is the ability to preserve whole, intact vascular networks along with the native 
ECM.  This provides the means to perfuse the scaffold with media, and could even enable 
direct surgical attachment of such a perfused graft to the host vasculature upon 
implantation.[63, 64]   
 This method has been applied to tissue engineering efforts in regeneration or 
replacement of the kidneys, esophagus, heart valves, urethra, bladder, skeletal muscle, 
peripheral nerves, and, most recently, the myocardium.[63, 65-72]  Effective DCELL 
procedures should not be so harsh that they nonspecifically degrade everything within the 
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treated tissue.  Rather, they must strive to remove all unwanted components, while leaving 
the desired components unaltered in both conformation and quantity.  For example, some 
DCELL methods have used the action of enzymes to speed the process by catalyzing 
protein cleavage.[73, 74]  One such enzyme is the protease, trypsin, which readily degrades 
elastin and fibrillin via cleavage of peptide bonds following positively charged amino acid 
residues.[7, 75] 
 This type of nonspecific action can destroy components of the native ECM which 
are actually important to maintain, especially if a subsequent attempt to repopulate a 
DCELLed scaffold is to be carried out successfully.  Such components include basal 
laminar proteins and proteoglycans to which seeded cells would bind (e.g. collagen type 
IV and laminin).[7, 76]  Evaluation of several DCELL methods has shown they are effective 
in accomplishing this goal, and seeded cells both adhere to and proliferate on the resulting 
scaffolds.[63, 77]  These studies provide proof of principle for the DCELL approach, and 
their authors also suggest it can be used as a technique for whole organ replacement.[63, 72, 
77]  However, due to the finite number of requisite cells which can be generated via in vitro 
culture and differentiation of autologous stem cells, efforts to repopulate an entire 
DCELLed organ (e.g. the heart) at the appropriate cell density are over-ambitious and 
unlikely to succeed.[78]  This approach becomes more feasible when applied to the 






1.4.3 Combination Biomaterials: 
 A few groups have sought to produce scaffolds which are composites of both 
synthetic and natural materials in an attempt to pool their respective advantages.  Stankus 
et al. created electrospun scaffolds composed of type I collagen and poly(ester 
urethane)urea, which they reported to improve cell adhesion despite having deficient 
mechanical properties.[79]  In a similar approach, neonatal CM seeded on collagen type I-
coated, electrospun PCL nanofibers exhibited enhanced attachment.  The cells integrated 
into a nanofibrous mesh which could be stretched to provide a passive load and allow the 
beating cells to contract at natural frequency.  This represents an advantageous method for 
mimicking the ECM and for providing mechanical stimuli.[80]  Another group investigated 
the in vitro performance of a dilinoleic acid (fatty acid dimer)-conjugated poly(ethylene 
terephthalate) elastomer with mouse and human ESC-derived CM.  They reported 
favorable results but have not generated any in vivo data up to this point.[81] 
 In yet another variation of this approach, Krupnick et al. delivered BMC to the 
infarct scars of rat hearts after seeding the cells onto a non-woven PLA mesh reinforced 
with poly(tetrafluoroethylene) (PTFE).  The mesh was coated with the cells, which were 
suspended in a mixture of Matrigel and collagen type I and IV before the addition of 
collagenase and subsequent implantation.  The grafts appeared to integrate well with the 
host tissue, displaying no signs of arrhythmogenesis or inflammation and demonstrating 





1.4.4 “Scaffold-Free” Cell Sheet Engineering:   
 This method for generating EHT was first conceived by Yamada et al. following 
their development of temperature-responsive culture dishes composed of poly(N-
isoproplyacrylamide) (PIPAAm).  These unique culture surfaces alternate between being 
hydrophobic and hydrophilic within a small range of temperatures (i.e. they are 
hydrophobic at optimum culture conditions (37°C) and hydrophilic at room temperature (< 
32°C)).[80]  The researchers realized this afforded them the capability to grow entire 
monolayers of cells and then readily detach them simply by altering the ambient 
temperature of their PIPAAm culture vessels.[83]  A critical advantage provided by this 
method was the elimination of the need for proteases to detach cells from culture vessels, 
thus sparing the cell-synthesized ECM from any alteration or degradation. 
 Okano et al. then expanded on this approach, growing monolayers of neonatal rat 
CM and stacking them on each other to generate constructs of spontaneously aggregating 
and beating CM in vitro.[39]  The thickness of these constructs was limited to 3-6 layers, or 
a thickness of about 100 µm, as a consequence of their lack of vascularization.[63]  In an 
attempt to overcome this problem, they devised a “polysurgery approach” wherein these 
cell sheet stacks were successively implanted on top of one another through the 
performance of recurrent surgical procedures.  Each individual thin stack became 
vascularized prior to implantation of the next thin stack, producing a thicker tissue 
construct.[83, 84]   
 Other cell types besides CM have been employed with this method.  In particular, 
cell sheets consisting of undifferentiated ADSC were implanted into a sub-acute rat model 
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of infarct.  Upon explantation, these constructs contained differentiated CM and newly 
formed blood vessels.  They also appeared to limit the extent of ventricular wall 
distension.[85]  The major disadvantage of this approach is the limited ability to induce 
vascularization within the constructs in vitro.  Lack of blood supply restricts the thickness 
of the constructs to the maximal diffusion range of oxygen and other nutrients within tissue, 
a distance estimated to be about 200 µm.[63]  Consequently, limited thickness translates to 
extremely low mechanical properties and the creation of constructs which are not easy to 
handle or implant without fear of ripping them apart.[39, 42] 
 These disadvantages were addressed by first attempting to reinforce the constructs 
with layers of collagen gel.  This resulted in improved cardiac function and integration with 
the host myocardium, but it must be noted that collagen gel is not ideal for this application 
since it has a lower modulus and greater compliance than other forms of collagen.[39, 86]  In 
a more direct approach to the problem, Murry et al. employed coculture of CM, fibroblasts, 
and EC to generate prevascularized cardiac patches which could actively contract and 
electrically pace.  More importantly, the prevascularized patches demonstrated 10-fold 
greater cell engraftment upon implantation than did patches comprised of CM alone.[87] 
 
1.5 Limitations, Challenges, and Barriers in Myocardial Tissue Engineering: 
1.5.1 Effects of Scaffold on Engineered Heart Tissue Viability and Function:  
 A major determinant of success in producing EHT is the ability to seed appropriate 
cell types onto a scaffold and subsequently maintain their viability, promote their 
integration with host tissue, and, ideally, induce their proliferation.  To that end, the logical 
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place to begin improving EHT design efforts lies in optimizing the scaffold for cell 
attachment.[7, 46, 56]  Matching the characteristics of native ECM, rather than native tissue, 
is the desired outcome in those EHT strategies which attempt to repopulate a scaffold with 
relevant cell types.  The rationale for this is that cells will respond favorably (i.e. attach 
and assume normal morphology) to a scaffold which bares similarities to the structure 
which they naturally bind–the ECM.[7] 
 Mimicking the ECM requires that native proteins and ground substance, or 
elements which mimic both their structure and surface chemistry/bioactivity, are present 
within the scaffold.  Reproducing native ECM structure (i.e. porosity, composition, and 
interconnection of the individual constituents) is of great importance, since it will align the 
mechanical properties of the scaffold with those of the physiological ECM.[7, 46, 56]  Given 
that the ECM’s role in relaying external mechanical stimuli to cells has been well 
established, creating a scaffold with similar mechanical properties ensures that seeded cells 
are relayed the same mechanical signals as they would be if they were residing within 
healthy myocardium.  Via the process of mechano-transduction, these mechanical signals 
are translated into chemical signals which mediate intracellular pathways, and are capable 
of producing changes in levels of gene expression.[46, 56]  Collectively, this process has an 
immense impact upon cell fate (i.e. differentiation and morphology) and survival[88] 
(Figure 1.5).   Furthermore, recent findings have suggested that the ECM is significantly 
involved with conduction of the electrical signals responsible for synchronous contraction 





Figure 1.5: A diagram of the potential influences the extracellular matrix (ECM) can exert on cells.  
Interaction of cells with the ECM can induce apoptosis, migration, and/or differentiation.  Matrix 
characteristics such as porosity, archiEHTture, compliance, and sufrace chemistry mediate these influences. 
 Having outlined the cell-ECM relationship, some regard must be given to the 
connections that make the cell-ECM interface possible.   In the myocardium, CM attach to 
the ECM through integrins and a specific protein complex, which bind laminin and 
perlecan (constituents of the basal lamina), respectively.[91]  Thus, when attempting to 
create a scaffold which is conducive to cell attachment, it is necessary to consider 
incorporating these macromolecules, or functional substitutes thereof, within the material.  
Results from a recent study, however, indicate that functional analogs of ECM proteins, 
such as RGD, performed poorly in inducing CM attachment when compared to the holo-
protein (i.e. laminin or collagen type I).[92]   
 The difficulty of the scaffold creation process is only compounded when the aim of 
repopulating it with cells is considered, as their addition will undoubtedly lead to changes 
in the properties of the resulting EHT graft.  Assuming repopulation is successful, the 
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concern then becomes the graft’s ability to match the mechanical properties (Young’s 
modulus between 0.2 – 0.5 kPa) of the healthy host tissue upon implantation.[43]  Matching 
the mechanical properties of the host tissue should be conducive to receipt of the proper 
signals by the cells in the graft, and result in its successful integration.  If, however, there 
is compliance mismatch between the graft and the host tissue, micromotion-induced 
encapsulation will occur, and the graft will fail.[5] 
 
1.5.2 Vascularization and Growth Promoting Factors: 
 The success of an EHT graft is critically dependent upon the extent to which it is 
vascularized.  Cells, particularly CM, cannot survive without access to nutrients or a 
mechanism to eliminate wastes and accomplish gas exchange.[2]  As mentioned previously, 
the dimensions of EHT constructs without a preformed and functional vascular network 
are limited to the observed diffusional range of solutes and gasses in vivo – about 200 
µm.[63]  In order to produce grafts with the larger dimensions necessary for replacing an 
infarct scar, strategies to overcome this limitation must be developed.  The creation of a 
vascular network within EHT constructs must provide the means to nurture the cells in 
both the in vitro and in vivo environments.  Methods for accomplishing this include the use 
of continuously perfusable vascular channels, or even blood vessels, to introduce culture 
media (in vitro) and blood (in vivo) into the EHT construct.[63, 93]  These same channels 
could then be surgically anastomosed to the host vasculature upon implantation, providing 




 Other modes of EHT graft vascularization could involve direct incorporation of 
vascular endothelial growth factor (VEGF) into the scaffold to induce angiogenesis and 
neovascularization by either or both of host and graft EC.  In conjunction with this, 
endothelial progenitor cells (EPC) might be seeded on the graft in hopes that they will also 
participate in the neovascularization process by differentiating into EC, recruiting other 
stem/progenitor cells, or secreting angiogenic paracrine signals.[78] 
 
1.5.3 Cell Sourcing and Expansion: 
 For EHT grafts to avoid immune rejection, the cell types incorporated in them must 
necessarily be autologous.  Thus, in a clinical scenario employing EHT as the therapy, the 
cells used to generate the EHT graft will be the patient’s own cells.[42, 78]  The possibility 
of simply using terminally differentiated CM from myocardial biopsies is precluded by the 
fact that these cells are essentially senescent, and display little potential for division or 
turnover beyond birth.[43, 78, 88]  The focus then shifts to identifying suitable stem or 
progenitor cell sources which can differentiate into the necessary cell types (CM, EC, and 
VSMC; adult CF are sufficiently proliferative and can be readily harvested).  Furthermore, 
generating grafts of clinically relevant size will require significant populations of 
phenotypically pure cells to be grown in vitro, which will be difficult to achieve using 
clonal expansion culture techniques.[78]  At the very least, this will pose additional 
challenges by increasing the lead time for producing EHT, as well as costs. 
 An extensive discussion of pertinent cell sources will not be presented here, but can 
be found in several reviews.[39, 42]  Briefly, ESC have been investigated for use in tissue 
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engineered grafts and EHT.  ESC are extremely advantageous in that they can differentiate 
into any cell type in the body, although effectively directing their differentiation, especially 
toward cardiac lineages, can be difficult.[42]  That aside, use of ESC in research that has 
clinical applications as its endpoint is irresponsible and shows lack of forethought.  ESC 
can be immunologically rejected, are perpetually mired in ethical debates over the origin 
of their cell lines, and the Food and Drug Administration (FDA) is unlikely to approve their 
use due to concerns over their ability to form teratomas.[94]  More practical sources of 
pluripotent autologous stem cells include ADSC, MSC, EPC, and BMC.  Several groups 
have published in vitro culture methods for directing these cell types toward CM and EC 
phenotypes, as well as methods for increasing proliferation and expansion toward the goal 
of producing necessary cell numbers for EHT graft seeding.[95-98] 
 
1.5.4 Bioreactors for Seeding and Preconditioning: 
 Since 3-D tissue constructs have so many unique properties that 2-D monolayer 
cultures lack, they demand a unique form of cell culture.  In the case of EHT grafts, the 
goal of culture is to produce functional myocardial constructs by imparting them with 
characteristics specific to myocardium, namely electrophysiological and mechanical 
properties.[42]  The ideal system for accomplishing this goal is a bioreactor that is 
specifically tailored to simulate the physiological environment and stimuli experienced by 
native myocardium.[93, 99]   
 Typically, a bioreactor serves several purposes, including the facilitation of uniform 
seeding of a scaffold via dynamic seeding conditions (i.e. perfusion and gentle, cyclical 
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stretch/compression); the enhancement of diffusion of gasses, solvents, and mass transfer, 
in general; simulation of physiological stimuli and external forces (e.g. fluid flow, shear 
stress, compression and tension, blood pressure, and electrical impulses; and maintenance 
of conditions to replicate the in vivo environment, such as temperature, pH, electrolyte, ion, 
and metabolite concentrations, and oxygen content.[99] 
 There is a great deal of evidence to indicate that dynamic seeding, as well as 
sustained dynamic culture conditions, can aid in producing EHT grafts with a high cell 
density and enhanced cell survival.  The use of perfusion, however, seems to be the 
consensus method for achieving the best results, as illustrated by the findings of Radisic et 
al. that use of a perfusion bioreactor increased cell density of EHT grafts to near 
physiological cell density, allowed for the generation of thicker (~ 5 mm) grafts, and 
facilitated mass transfer.[93, 100] 
 If a bioreactor is rationalized from a purely engineering design standpoint, it would 
be described as a system with both inputs and outputs.  In this case, the desired output is 
the production of a functional myocardial tissue substitute with CM that are electrically 
connected, conduct impulses, and respond to these impulses by producing a certain systolic 
force.[101]  With this constraint established, the task of the bioengineer then becomes to 
identify the most appropriate inputs which will produce the desired output.  These inputs 
are the stimuli applied to the EHT construct within the bioreactor, and should strive to not 
only approximate, but exceed, physiological levels.  In this way, a factor of safety is built 
into the EHT graft, and it should theoretically be able to handle the most elevated 
conditions of heart rate, blood pressure, and external stresses which could conceivably 
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occur in vivo.  Examples of such exaggerated conditions might be a pulsatile flow rate 
which mimics a heart rate of 200 bpm or a media inlet pressure of 200 mmHg.  The same 
principle should be applied to the repetitive electrical impulses and cyclical tensile 
stretching or compression that the graft is exposed to in order to precondition, or “train”, it 
to become a functional graft of cardiac muscle.  The next section of this review will focus 
on the mechanics of myocardium on both the cellular and tissue level to further expound 
on the role of dynamic stimuli in myocardial tissue engineering strategies.   
 
1.5.5 Applications of Cardiomyocyte and Myocardial Extracellular Matrix Mechanics: 
The state of the art in tissue engineering assumes the premise of biomimicry, or the 
ability of an engineered tissue construct to mimic the tissue which it is intended to replace, 
as central to its overriding goal: the replacement or regeneration of diseased or 
dysfunctional tissues.[102, 103]  This mandates that EHT not only appear analogous to 
healthy, native tissue, but also replicate the function of this tissue.  There are many specific 
tissue types for which tissue-engineering therapies hold promise, but the development of 
some present a considerably more difficult challenge than others.  Mimicking the structure 
and function of bone or skin, for example, is less daunting than the prospect of recreating 
muscle and nervous tissue.[102, 103]  Simply put, as the complexity of the tissue (in terms of 
structure and function) increases, the difficulty of reengineering it follows suit.  
 One aspect of particular importance in determining how closely EHT mimics its 
target tissue is mechanics.  A thorough characterization of EHT must be performed in order 
to determine its intrinsic mechanical properties, which may then be compared to those of 
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the native tissue as a means to predict EHT’s ability to perform the mechanical function of 
its analogue.[74]  As is evident from the development of the biphasic and multiphasic 
theories, these mechanical properties cannot be fully described without a prior 
understanding of the tissue architecture, its components (i.e. cells, extracellular matrix, and 
interstitial fluid), and their respective contributions to the overall mechanism(s) underlying 
the mechanical behavior of the tissue.[104]   
 This divergent approach to analyzing tissue mechanics may prove particularly 
useful in the development of tissue-engineered myocardium.  Myocardium, or cardiac 
muscle, is unique among tissues in that it plays an active mechanical role, synchronously 
contracting to pump blood into both the pulmonary and arterial circulation.[78, 103]  Like 
other types of muscle, it stands apart because it is motile and active, performing actual 
mechanical work as opposed to providing passive support or facilitating transfer of 
mechanical forces (e.g. bone, membranes, cartilage, ligaments, tendons).[105]  The 
component which imparts it with this dynamic character are the cardiac myocytes (CM), 
which collectively shorten (contract) to “pull” on their collagenous extracellular matrix 
(ECM) and compress their respective chamber walls, reducing the chamber volume (thus, 
increasing chamber pressure) and forcing blood out.[105, 106] 
 Since CMs play such an important role in the function of myocardium, it is 
desirable to develop a working knowledge of their mechanical behavior and characteristics, 
especially if the aim is to reproduce myocardial tissue.  Study of their cytoskeleton, 
intercellular junctions, extracellular matrix linkages and the interaction of these various 
mechanical components is warranted to gain a holistic understanding of the biomechanics 
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of myocardium.  These investigations could also aid in the completion of specific 
milestones in developing engineered myocardium, namely the efficient in vitro culture and 
differentiation of adult stem cells or cardiac progenitors into phenotypically accurate adult 
CMs. 
 
1.5.5.1 The Cardiomyocyte Cytoskeleton: 
Owing to their highly sophisticated mechanical function, CMs have developed one 
of the most intricate cytoskeletons found among all cell types.  In addition to an abundance 
of aligned actin and myosin filaments (the actinomyosin complex), the CM cytoskeleton 
consists of titin and a network of microtubules.[107]  The actinomyosin complex and titin 
constitute the bulk of the structure known as the sarcomere, repetitive units of which make 
up the length of myofilaments and occupy most of the cytoplasmic volume of the CM.  The 
combined action of sarcomeres is responsible for the macroscopic contraction of CMs.[106, 
107]  Following stimulation by an influx of Ca+2 ions, sarcomeres shorten via the sliding 
filament mechanism (modeled by cross-bridge theory), and return to their original length 
upon cessation of contraction with help from the spring-like recoil of highly elastic titin 
molecules.[104, 106, 107] 
  Microtubules emanate from the microtubule organizing center and extend to the 
periphery of the middle portion of CMs.  Consistent with the tensegrity hypothesis of 
cellular mechanics, they may act to bear compressive loads by buckling and unbuckling 
during CM contraction.[108-110]  In addition, there is evidence indicating that they are 
mechanically coupled to other elements of the cytoskeleton, helping to transduce both 
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intra- and extracellular forces throughout the cell and drive the overall intracellular 
response to loading.[107]  Evidence in the literature increasingly suggests that cytoskeletal 
proteins assume an invaluable role in mechanosensory and mechanotransduction, thus 
mediating cellular responses in normal development and in pathophysiological conditions 
(e.g. dilated and ischemic cardiomyopathy, pressure and volume overload 
hypertrophy).[111-122] 
 
1.5.5.2 Cytoskeletal-Extracellular Matrix Linkages: 
As crucial as the mechanical components of the cytoskeleton are to the functional 
role of CMs, the points where these elements attach and integrate with the ECM are critical 
in determining how myocardial tissue, and the heart as a whole, function.[3, 7, 123]  These 
linkages ultimately mediate the transfer of external forces (e.g. blood pressure driven by 
metabolic and physiological demand) imposed on the myocardium through the myocardial 
ECM into the CMs.  This pathway can also be reversed, as CM contraction imparts force 
on the ECM via these same linkages, manifesting as the contraction that is the pumping 
action of the heart.[3, 11] 
 These “linkages” are actually a complex of several cytosolic, transmembrane, and 
extracellular proteins, and are localized to specific areas on the periphery of each CM, 
known as costameres.[107]  Costameres are found at Z-disks between sarcomeres, and 
effectively form mechanical “tethers” which anchor the Z-discs to ECM proteins.  These 
tethers consist of a chain of proteins, beginning with talins, vinculins, dystrophins, and 
syntrophins in the immediately submembranous cytosol connecting to transmembrane 
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integrins and dystroglycan complexes, which, in turn, are bound to laminins of the 
ECM.[107, 124]  The tethers form a mechanical link between the actinomyosin complex and 
fibrillar collagens (type IV and I), the primary load-bearing components of the CM 
cytoskeleton and myocardial ECM, respectively.[3, 107]  Although this chain contains many 
links so as to make the connection seem almost indirect, it serves as the primary means of 
relaying mechanical signals between the two components of the tissue. 
 
1.5.5.3 Cell-Cell Linkages: 
Individual myocytes can transmit mechanical energy to and from their surrounding 
ECM, but it is the summation of this individual force over billions of myocytes which 
accounts for the muscular beating of the heart.  In addition to interacting with the ECM, 
CMs accomplish this by working in concert with one another.  They are connected at their 
longitudinal borders (intercalated disks) by adherens junctions, or cadherin/catenin 
complexes, which link the opposing ends of actin filaments.[107]  As actin filaments from 
opposing cells pull against each other, cadherins act as mechanosensors and reinforce the 
junctions.  This facilitates the bidirectional transfer of cytoskeletal tensile stress between 
cells in a manner which compounds the forces generated by sarcomeric shortening in 
individual myocytes.[107]   
 In both this section and the previous section, linkages in the directions of both the 
minor and major axes of the CM were discussed.  Taken together, these linkages allows 
the CM to sense and transmit mechanical stimuli with directional specificity.[107]  This 
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property means that CMs can integrate this information and act on it in a way which gives 
the most desirable biological response to changes in their mechanical environment.  
 
1.5.5.4 Using Models to Define Effective Mechanical Stimuli in Cell Differentiation: 
Gaining an understanding of intra- and intercellular mechanics of the CM, as well 
as the mechanics of CMs’ interactions with their surrounding ECM, is important in 
studying pathophysiological and pathological conditions of the myocardium.  Since it has 
been well established that CMs and their ECM interact through the phenomenon of 
mechanotransduction, and that this process elicits a biological response from the CMs, it 
is of interest to be able to predict the nature and extent of this response to a given 
mechanical stimulus.[107, 123] This is accomplished through the application of mathematical 
models which accurately characterize the constituents of the tissue, and, given a 
mathematically defined set of inputs, can output a prediction of how the tissue will respond. 
 Within the field of myocardial tissue engineering, for example, the goal is to 
develop an EHT construct with the ability to generate systolic force and use it to effectively 
replace the lost functionality of diseased myocardium.  A critical component of such EHT 
is donor-immunocompatible cells, specifically CMs.  Considering the criteria of 
immunocompatibility and physiological cell density (2 x 108 cells/cm3), the possibility of 
using allo- or xenogeneic cells is precluded, and a large number of CMs is necessary in 
order to properly populate EHT.[40, 41, 45]  Consequently, the cell source of choice becomes 
an adult stem or progenitor cell population with cardiac lineage potential, and the approach 
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becomes to culture, maximize proliferation, and differentiate these cells into a population 
with high phenotypic similarity to human adult CMs.[41] 
 The current body of work suggests that directed differentiation of these cells into 
CM requires the application of a mechanical stimulus to the cells in culture.  Groups have 
shown that periods of both static and dynamic stretch of monolayer and 3D in vitro cultures 
induce changes in CM and stem cells, alike.[125-128]  The question, then, is no longer: do 
stem cells respond to mechanical stimulation by exhibiting evidence of differentiation 
toward a cardiac phenotype, but becomes: what specific mechanical stimuli, delivered in 
what specific way, will result in the generation an accurate adult CM phenotype from 
cardiac precursors? 
 This begs a host of other questions about how forces imparted upon a culture 
substrate are transmitted to the cells being cultured on the substrate: How much of the 
original mechanical stimulus is transmitted to the cell (i.e. is it degraded, amplified, or 
altered)?  How does it propagate through the cell, and what type of force (i.e. compression 
or tension, magnitude, frequency) corresponds with what biological response (i.e. are there 
thresholds for a particular response)?  The answers to such questions can only be arrived 
at through the use of a model.  To further complicate things, the nature of these questions 
requires that the mechanical behavior of the cells and the mechanical behavior of the matrix 





Several in vitro culture systems have been designed to expose cells within them to 
mechanical stimuli of varying nature.[105, 125-128]  These stimuli can come in the form of 
uniaxial or biaxial strain, be either static or dynamic with disparate strain rates, strain 
percentages, duration of strain, and frequencies.  Cells can also be cultured on substrates 
of either natural or synthetic materials with different stiffness, dimensionality (2D or 3D), 
or degrees of anisotropy.[123, 129]    
So the question remains, given the existing evidence in the field as it relates to 
mechanical modeling of CM and myocardial ECM, which set of conditions will promote 
the most successful differentiation of cardiac progenitors into a mature CM phenotype?  
One must begin by defining the desired biological response and then must work backwards 
to determine the appropriate mechanical inputs.  The functions of key mediators in the 
biological response to mechanotransduction, such as mechanoreceptors, signaling 
molecules, and target effector proteins are involved in signaling pathways initiated by the 
receipt of mechanical stimuli.[107]  If thresholds can be determined for triggering the 
initiating events in the pathways of choice, a model (e.g. the tensegrity model) can be used 
to determine how stresses are transferred along cytoskeletal elements to specific organelles 
or structures where pathway initiation occurs.  Working back up the mechanical ladder, the 
extracellular loads required to precipitate these intracellular stresses can be determined, 
and the macroscopic loading of the EHT necessary for generation of these extracellular 





1.5.6 Surgical Considerations:  
 With a lack of intrinsic regenerative capability in the myocardium, the MI-induced 
necrotic core will be completely remodeled into fibrous tissue between 2-6 weeks post-
MI.[11, 39, 49]  The timing of therapy delivery in infarct treatment is an important and, as yet, 
unanswered question.  A graft implanted in the acute phase could be sabatoged by the 
hostile milieu of inflammatory cytokines associated with CM necrosis, while a graft 
implanted in the chronic, post-scar formation phase could be impeded from integrating 
with healthy tissue by the scar.[130]  In order to implant a construct immediately after MI, it 
would need to be ready before the event, in an “off the shelf” fashion.  This possibility is 
precluded by complications that arise due to the need for autologous cell sourcing and in 
vitro cell proliferation, seeding, and preconditioning in a bioreactor.  Such a process could 
take several weeks, if not months, to complete and could not benefit the patient 
immediately unless the MI was predicted.[39, 42, 43]  Consequently, patients are typically 
treated with PCI to abort MI and allowed to heal over the next 6 weeks before any surgical 
intervention is considered.[18]  While the infarct scar does form during this time, the extent 
of remote fibrosis and global remodeling is usually minimal.[11, 18]  The significance of this 
treatment approach is that surgeons will be presented with a decision when implanting EHT 
grafts: do they resect the infarct scar and then implant, or do they attach the graft directly 
to either the endocardium or epicardium (depending on the surgical access used; see 
discussion below)?   
 Whether or not grafting engineered heart tissue (EHT) directly to the fibrotic scar 
inhibits proper adherence and perfusion of the graft with the host tissue through an 
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inflammatory response is unclear.  A number of studies have reported positive outcomes 
when implanting EHT on top of infarct scars created in animal models.[50, 51, 58]  When EHT 
constructs are not placed directly on the epicardium over the scar, but rather at the 
endocardial surface (by means of EVCPP)[131] or in a depression made by resection of the 
scar tissue, solid engraftment has been repeatedly achieved.[44, 82, 132]  These opposing 
implantation methods will need to be compared for efficacy by performing both with a 
single type of EHT, then perhaps the difference, if one exists, can be elucidated. 
 An additional uncertainty that pertains to surgical methodology is the nature of the 
surgical access used.   Will EHT grafts be large and require attachment to the epicardium, 
so as to demand a full sternotomy?  Or will surgeons be able to insert a moderately sized 
EHT graft through a relatively small intercostal opening?  Better yet, what if there is the 
possibility that an EHT graft might be small enough to be implanted percutaneously via 
catheter?  And finally, how will an anastomosis of the vessels used to perfuse potential 
EHT grafts affect the choice of surgical approach?  
 In order to answer these questions, the first step which must be taken is determining 
an estimate of the required size of an EHT graft.  Given that a typical MI sufficient to cause 
heart failure leads to the death of about 50 g of myocardium, it can be estimated that the 
minimal dimensions required in an EHT graft for replacing a transmural infarct should be 
approximately 2.6 cm x 2.6 cm x 1.5 cm for a square geometry or 2.9 cm (diameter) x 1.5 
cm (height) for a cylindrical geometry.[39, 78, 133, 134]  If attempting to adapt EHT grafts to a 
catheter-based delivery, the access pathway of choice would be through the thoracic aorta 
and the aortic valve into the left ventricle because this approach offers the largest 
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anatomical dimensions (i.e. the largest vessel lumens).  The largest catheter size approved 
for use by the FDA in a translumenal aortic approach was 25 on the French scale, and the 
particular application was aortic heart valve replacement.[135]  This catheter size 
corresponds to a diameter of about 0.833 cm, which is much too small to accommodate a 
graft of the aforementioned dimensions loaded in almost any imaginable configuration.  
For EHT to one day be implemented using a trans-catheter approach, the graft dimensions 
will need to be decreased, or a method must be devised to sufficiently compress a construct 
containing live cells without damaging them.  Until such time, it appears that the surgical 
implantation method will be through some sort of “cut-down” access.[136]  
 
1.5.7 Myocardial Tissue Engineering in the Diseased Patient: 
 The vast majority of patients who could benefit from a clinically feasible and cost-
effective EHT have some form of cardiovascular disease (CVD).[43]  In fact, CVD 
encompasses high blood pressure (HBP), coronary heart disease (CHD) and its associated 
complications (MI and angina pectoralis), CHF, and congenital cardiovascular defects.[17]  
The American Heart Association estimates that approximately 90% of patients with CHD 
have been exposed to at least one of the following risk factors: hypercholesterolemia, 
hypertension, cigarette smoking and diabetes mellitus (DM).  Data show that the incidence 
of CVD in women with DM and a healthy weight was 54.8%, but rose to 78.8% among 
obese women.  Among diabetic men with a healthy weight, the prevalance of CVD was 
78.6%, whereas it climbed to 86.9% among obese men.[17]  Additionally, end-stage renal 
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disease and acute renal failure (ARF) are comorbidities of CVD.  Of first-time diagnoses 
of ARF, a combined 12.3% were associated with a hospitalization for either CHF or MI.[17]   
 These data serve to underscore the point that researchers developing EHT should 
rid themselves of the illusion that potential candidates for their therapy will be a tabula rasa 
of health.  Rather, they should prepare EHT constructs to withstand a hostile, diseased 
environment.  In the MAGNUM-trial discussed earlier, for example, 11 of the 20 
participants were hypertensive, 13 were hypercholesterolemic, 7 were diabetic, and 10 
were smokers.[41] 
 In terms of inflammatory processes, a few of the most threatening conditions to the 
long-term viability of EHT are atherosclerosis, graft arterial disease (GAD), and 
arteriolosclerosis.  Atherosclerosis is the most well-known of these diseases, as it is 
implicated in having a causal role in both CHD and peripheral artery disease.  The 
characteristic atheromas or lesions common to atherosclerosis present the potential for 
tissue calcification.[1, 17, 137]  GAD is distinguished from athero- and arteriosclerosis by 
characteristic toto-circumferential intimal thickening, and has been observed to occur 
predominantly in implanted allografts, which contain immunogenic cell constituents.[138]  
EHT constructs, however, should ideally consist of nonimmunogenic ECM proteins seeded 
with autologous cells, rendering them free from concerns about GAD or transplant 
vasculopathy.[138]   
 Finally, arteriolosclerosis, or the thickening of the intimal layer in arterioles due to 
hyperplasia or hyaline matrix deposition, could occur in EHT.[137]  EHT grafts implanted 
in hypertensive or diabetic patients would be at an increased risk of contracting 
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arteriolosclerosis because of the causal role of both hypertension and diabetes in 
development of arteriolosclerosis.[137]   
 Both atherosclerosis and arteriolosclerosis could have a major impact upon the 
viability of EHT constructs, because such constructs will most likely contain a preformed 
or preserved vascular network that will stenose or occlude if these diseases are present, 
leading to ischemia and necrosis of the cells in the construct.  
 
1.6 Summary and Conclusions: 
It is difficult to make conjectures about the ultimate success or failure of EHT 
constructs.  Given the requirements placed upon them and the mechanisms or processes 
that might be at work in vivo, producing an EHT construct that remains viable for some 
time will be a challenging task.  In the future, prevascularized scaffolds should be designed 
which allow for perfusion seeding and culture in vitro, as well as the possibility of surgical 
anastomosis at implantation for improved graft function and survival.  Scaffolds should 
possess a composition and architecture which mimic the native ECM in order to elicit 
favorable host responses; facilitate cell attachment and infiltration; and to maintain desired 
morphology, phenotype, and function.  In designing EHT grafts and methods to produce 
them, researchers should not lose sight of the limitations presented by the necessity of 
autologous cell sourcing, and should investigate in vitro culture methods to optimize clonal 
expansion of cell lines.  Nor should they overlook the potential diseased and hostile 
microenvironment that awaits their EHT graft when they are applying stimuli to 
precondition their EHT constructs.  Lastly, investigators should devote some thought to the 
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surgical approaches for implantation of EHT and consider the desires of surgeons 
themselves, as they will be the end-users of potential EHT grafts.  If researchers working 
to develop EHT can overcome the inherent challenges associated with it, they can alleviate 
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CHAPTER TWO: PROJECT MOTIVATION, SPECIFIC AIMS, AND 
SIGNIFICANCE 
 
2.1 Introduction and Clinical Relevance: 
Myocardial infarction (MI), the principal complication associated with 
cardiovascular disease, affects over 1,000,000 individuals annually.[1]  Incidences of acute 
MI are increasingly survivable, however, the associated transient ischemia causes tissue 
damage, scar formation, and initiates a degenerative progression toward congestive heart 
failure (CHF) in more than one fourth of affected patients.[2-5] Consequently, the prevalence 
of CHF is currently estimated at 5.7 million afflicted, and total expenditures for CHF 
treatment are expected to increase from 44.6 billion dollars in 2015 to 97 billion dollars by 
the year 2030.[6]  It is clear that CHF represents a vast economic burden and should be 
regarded as a significant public health concern. 
CHF develops as a result of global cardiac remodeling (i.e. left ventricular dilation 
and wall thinning) that occurs in response to the death of cardiomyocytes (CM) during MI.  
These CM are not regenerated, but are instead replaced by largely non-contractile, 
collagenous scar tissue.[5, 7-9] Mechanically speaking, the scar is a poor substitute for 
functional cardiac muscle, as it disrupts the continuity of the contractile syncytium of the 
myocardium. Persistence of the scar over time leads to maladaptive, compensatory CM 
hypertrophy, fibrosis, contractile dysfunction, and dilated cardiomyopathy en route to 
CHF.[3, 10-14] To prevent CHF, prospective therapies must aim to replace the infarct 




2.2 Current Standards of Care and Limitations:  
Coronary artery bypass grafting, percutaneous coronary intervention, ventricular 
reconstruction, and left ventricular assist devices either focus solely on revascularization 
or do not adequately restore functionality to infarct-damaged tissue.[15] Heart 
transplantation falls short as a solution, as demand for donor hearts far outpaces supply,[16, 
17] Success of stem cell therapy for MI in the form of intramyocardial (transendocardial) or 
intracoronary delivery of stem cells has been anecdotal.  Several clinical trials have yielded 
findings that suggest marginal improvement in cardiac function, but none have shown any 
sustained improvement beyond 18 months.  This is most likely due to poor cell engraftment 
and integration with host tissue, extensive apoptosis, and absence of cell differentiation.[18-
20]  
Tissue engineering approaches may address the need for effective cell delivery by 
providing a stable environment for regenerative cells in the infarcted area. [2, 7, 21, 22] Early 
efforts to generate a biomimetic, functional, tissue-engineered construct have shown 
promise with thinner grafts (<1 mm),[23, 24] but thicker grafts (7 mm to 15 mm) are 
necessitated because the infarct scar is nearly transmural in many cases.  Long-term 
survival and functionality of thicker, more clinically relevant-sized grafts implanted in 
animal models, however, has been hindered by insufficient vascularization within the grafts 
themselves, as well as lack of perfusion by the host’s blood supply.[21]  In order to replace 
the infarcted area with a functional graft of such thickness and sustain its constituent cells, 
vasculature is necessary to transport nutrients and wastes further than diffusion alone can 
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(≈100 μm).[4, 7, 25] As of yet, no tissue engineering approach exists which has addressed and 
overcome these limitations. 
The overarching goal of this project is to develop a biomimetic, acellular, and 
vascularized graft for replacement of infarct scar tissue.  The graft is to be in the form of a 
“vascularized flap” to allow for surgical manipulation and implantation via anastomosis 
(similar to CABG) of the graft’s major vessels to the recipient vasculature.   
It is hypothesized that this vascularized-flap graft, which will consist of a 
DCELLed myocardial ECM scaffold derived from the left ventricular wall of porcine 
hearts and relevant cardiac cell types derived from autologous adult stem cells, will 
integrate with the host cardiac conduction system and produce systolic force upon 
implantation.  In doing so, it will replace the lost functionality of cardiac muscle damaged 
by MI and avert (or possibly reverse) the remodeling which precipitates CHF.  Our 




Figure 2.1: Overview of proposed translational approach and clinical scenario: Patient suffers a 
myocardial infarction, has subcutaneous adipose tissue harvested, and adipose stem cells are isolated 
from the tissue; patient receives optimal medical management during the rest of the process until graft 
implantation.  Cells are cultured with the aim of growing large numbers for later repopulation by 
reseeding of the myocardial scaffold generated from xenogeneic sources (i.e. a pig).  The seeded 
construct is placed into a bioreactor wherein it is exposed to stimuli which mimic the cardiac 
environment in order to differentiate stem cells and condition the construct into a functional graft.  
The graft, consisting of autologous cells and nonimmunogenic scaffold, is implanted in the patient as a 
functional replacement for infarct scar tissue. 
 
2.3 Specific Aims: 
Four related and overlapping aims have been established toward achieving the 
overall goal of this research, and they are directed at understanding: 1) how to generate a 
DCELLed scaffold with the necessary features to overcome existing limitations of tissue 
engineering approaches; 2) the role and fate of DCELLed scaffolds in cardiac tissue 
engineering; 3) bioreactors, stem cells, and strategies for producing functional grafts; and 
4) desired outcomes and benefits of infarct scar replacement with functional grafts. 
Aim 1 (Chapter 3): To develop and characterize a decellularized, vascularized scaffold 
for use in myocardial tissue engineering 
Hypothesis: Acellular left ventricular porcine myocardium will serve as an ideal 
supporting material for tissue engineered myocardial grafts due to its low immunogenicity, 
potential as an excellent “niche” for inducing differentiation of stem cells toward cardiac 
phenotypes, and its network of preserved, patent vascular channels. 
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Approach: Scaffolds will be generated using a combination of reagents, including 
detergents, chelators, bases, and enzymes to remove all cellular proteins from porcine 
myocardium.  In doing so, scaffolds should: 1) have all potentially immunogenic proteins 
and molecules removed, 2) retain the biochemical structure, composition, architecture, and 
relative quantities of all ECM proteins (e.g. collagens type I, III, and IV, elastin, 
fibronectin, and laminin), and 3) provide a means of nourishing reseeded regenerative cells 
(i.e. an inherent vasculature). 
Innovation: In addition to the properties listed above, the myocardial scaffold will 
preserve the native vasculature of the xenogeneic tissue and its connection to the coronary 
artery and cardiac vein to allow for convenient surgical manipulation and implantation.  
This will be in the mode of a “free flap transfer” with anastomoses of the above vessels to 
specific locations, providing a strategy for graft implantation that can be adopted quickly 
in the clinic. 
Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their 
in vivo degradation rate 
Hypothesis: Scaffolds which resist in vivo degradation for longer than 8 weeks will 
provide implanted cells sufficient stability and time to integrate with host tissue, improving 
functional outcomes.  Treatment with a specialized cross-linking agent will mitigate the 
severity of the immune response to implanted scaffolds. 
Approach: As shown in previous studies, treatment of scaffolds with penta-galloyl 
glucose (PGG), a plant-derived antioxidant and matrix-binding polyphenol, will protect 
scaffolds from calcification, mitigate immune rejection, and prevent excessive matrix 
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metalloprotease-driven degradation. Myocardial scaffolds will be treated with two 
different concentrations of PGG and implanted subdermally in rats. At 4, 8, and 12 weeks, 
scaffolds will be explanted and examined histologically and immunohistochemically to 
characterize the host response, as well as the extent of degradation; results will be 
compared to non PGG-treated scaffolds.  
Innovation: Tissue engineers who employ scaffolds as a significant component of 
their prospective therapy have struggled with questions surrounding the fate of scaffolds 
once implanted (i.e how long should they persist, should they be remodeled, and how long 
should remodeling take in order to assure the optimum therapeutic benefit?).  Our approach 
aims to answer these questions, determine the in vivo degradation rate of the scaffold, and 
to elucidate the precise nature of the host response to the scaffold (i.e. inflammatory vs. 
remodeling) including delineation of the source(s) of any stem cells that may be involved. 
Aim 3: To condition cell-seeded myocardial constructs in vitro into functional grafts 
Hypothesis: Exposure to conditions mimicking the physiological environment of 
the myocardium will induce stem cell differentiation and maturation of cell-seeded 
constructs into functional myocardial grafts. 
Approach: A bioreactor will accommodate constructs seeded with hADSCs, 
fibroblasts, and endothelial progenitor cells.  It will allow for precise control of physical 
and biochemical conditions (pressures, electrical stimulation, and media compositions). 
Constructs will be exposed to these conditions for 4 weeks to direct differentiation of stem 
cells toward electrically integrated and synchronously contracting cardiomyocytes. 
Resultant grafts will be examined for evidence of physiologic maturation using histology, 
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gene and protein expression, and by measuring excitation thresholds, calcium transients, 
fractional shortening, and force generation; results will be compared to unstimulated 
control constructs. 
Innovation: Using bioreactors to deliver the stimuli necessary to differentiate and 
condition stem or progenitor cells into cardiac cells helps produce more functional 
myocardial grafts.  The precise application of these stimuli in terms of what combination 
of stimuli to use, how to coordinate them, and the magnitude and frequency of their 
application will be determined by the studies outlined in this aim.  
Aim 4: To develop an animal model of infarction and demonstrate feasibility of 
surgical replacement of infarct scar with tissue-engineered constructs  
Hypothesis: A porcine model of infarction and surgical approach to construct 
implantation must be developed and optimized. 
Approach: Coronary artery ligation in pigs will be used as an infarct model, and 
electrocardiography (EKG), echocardiography (ECG), blood chemistry, and histology will 
ascertain induction of MI. For implantation, the scaffold’s major vessels will be 
anastomosed to the host vasculature, and the flap-like portion of the scaffold will be affixed 
to the exposed viable myocardium with fibrin glue and sutures.  Two rounds of 
implantation will be conducted: the first to evaluate the degree of hemostasis and vascular 
integrity, and the second to evaluate the subacute host response.  For the former, pigs with 
healthy hearts will be implanted with a scaffold and observed for 1 hr.  For the latter, pigs 
at 4 weeks post-MI will undergo infarct scar resection and replacement with a scaffold and 
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be allowed to survive for 1 week. EKG, ECG, histology, immunohistochemistry, and 
electrophysiology methods will be used to evaluate the responses. 
Innovation: This aim will demonstrate the feasibility of the proposed surgical 
implantation method while allowing for identification of challenges and aspects of the 
procedure in need of revision.  This will set the stage for a larger, full-scale study of the 
efficacy of tissue-engineered myocardial grafts in the future. 
 
2.4 Project Significance: 
Building upon recent advances in stem cell biology and tissue engineering, the 
proposed research will develop a meaningful therapy and further it toward application in 
the clinic.  We expect the outcomes of this translational approach to have a positive impact 
upon efforts to treat a growing population of patients suffering from complications of 
coronary heart disease. Also, it could represent a significant step toward better 
understanding of the complex interaction between cells and extracellular signals in the 
cardiac environment.  This research will not only enable clinicians to prevent or reverse 
the progression towards CHF—undoubtedly saving lives and improving the quality of life 
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CHAPTER THREE: DEVELOPMENT AND CHARACTERIZATION OF AN 
ACELLULAR MYOCARDIAL SCAFFOLD ENRICHED WITH PATENT 
VASCULAR NETWORKS AND BIOCOMPATIBLE CELL NICHES 
 
3.1 Introduction: 
 The prevailing paradigm in the field of tissue engineering advocates the combined 
use of cells and scaffolds for therapeutic application to the target tissue.  Among the 
biomaterial scaffolds under investigation, none have recently gained as much attention as 
acellular tissue matrices.  These DCELLed extracellular matrix (ECM) scaffolds have been 
successfully generated by subjecting tissues from a number of sources to various 
combinations of chemical, enzymatic, and physical agitation, breaking up and removing 
cells and cellular proteins in the process.[1, 2]  The remaining ECM acts as an agreeable 
“niche” for reseeded cells, complete with the appropriate binding sites, mechanical 
properties, and architecture necessary to induce formation of a tissue-engineered construct 
that is physiologically comparable to native tissue.  The function of ECM proteins does not 
differ among species, and thus their structure has been highly conserved over the course of 
evolution.  As such, these proteins should not perturb the host immune system when 
implanted in an allogeneic or even xenogeneic capacity.[3]  Another major advantage 
offered by DCELL is that the resulting scaffold is left with an intact vascular network, a 
design which nature has perfected and would be painstaking, if not impossible, to duplicate 
from the bottom-up.  This vascular network can be used to sustain cells seeded onto 
DCELLed scaffolds once the resulting constructs are implanted. 
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 Porcine hearts are also approximate in size to human hearts, which is important 
considering that hearts with different ventricular volumes will experience different 
pressures, and thus, have different wall stresses and amounts of constituent collagen to bear 
those stresses.[4]  In terms of mechanics, this means that scaffolds generated with porcine 
hearts are macromechanically equipped to withstand forces in the human cardiac 
environment, as well as micromechanically amenable to attachment and proper 
mechanotransduction of seeded cells.  
Whole heart and myocardial patch DCELL has been demonstrated by a number of 
groups.[5-11]  Typically, remnants of the DCELL process are composed of extracellular 
matrix (ECM) proteins native to the myocardium and the native vascular network.  Few 
studies, however, have attempted a comprehensive, parallel analysis of both the vascular 
and myocardial matrices focusing on DCELL efficacy, elastic moduli and burst pressures 
of the intrinsic coronary arteries, patency of capillary perfusion, exact amounts of 
collagen and elastin, and identification of important basement membrane proteins, among 
others.  In our view, complete and efficient DCELL of such complex tissues appeared 
problematic and required a comparative analysis of several DCELL methods. 
An optimal DCELL technique for this application should fulfill the following 
criteria: 1) remove all potentially immunogenic proteins and molecules, rendering the 
implant biocompatible; 2) preserve the biochemical structure, composition, architecture, 
and relative quantities of all matrix proteins including basement membrane, thus 
generating an agreeable biological and biomechanical “niche” for reseeded cells; 3) 
provide a means of nourishing reseeded regenerative cells by preserving the natural 
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vasculature; and 4) allow for convenient surgical manipulation, implantation, and 
reconnection to the host vasculature.  
 To this end, we DCELLed porcine myocardium and its constituent vasculature 
using four different procedures comprising combinations of sodium dodecyl sulfate 
(SDS) and sodium hydroxide (NaOH) in a comparative study of their ability to remove 
cells and cell remnants and preserve the features of the native ECM.  The scaffold was 
uniquely shaped as a “flap” so that the native vasculature could be used in a three-fold 
manner: first, to facilitate DCELL by perfusion, second, to serve as a conduit for 
recellularization with appropriate cells, and third, to allow for surgical manipulation and 
implantation via anastomosis of the graft’s vessels with the recipient vasculature (similar 
to coronary bypass surgery).  We systematically evaluated both the myocardial and 
coronary arterial ECM and investigated their ability to support the attachment and 
survival of relevant cardiac cell types. 
  
3.2 Methods and Materials: 
3.2.1 Decellularization of Porcine Myocardium: 
 Whole hearts were obtained from healthy, adult pigs at a local abattoir.  
Immediately following harvest, 50 mM ethylenediaminetetraacetic acid (EDTA) in warm 
phosphate buffered saline (PBS) was injected into the left coronary artery branch at the 
aortic trunk to prevent clotting in the vasculature, and the hearts were transported on ice 
for immediate processing.  A 1 cm thick, 6-8 cm wide, and 12 cm long “flap” of 
myocardium was excised from the left-anterior ventricular wall, with care not to sever the 
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coronary artery or cardiac vein, and these vessels were cannulated with barbed Luer 
connectors (Cole-Parmer) secured with zip-ties in order to facilitate perfusion (Figure 
3.1).  Larger, open-ended vessels severed during excision of the flap were closed with 4-0 
silk suture (Ethicon).  The flaps were then subjected to combined perfusion and 
immersion of solutions in a continuous-flow DCELL system.  The system comprised a 
series of fluid reservoirs and a multi-channel peristaltic pump (Masterflex, Cole-Parmer) 
which circulated 2 L of solution through and around each scaffold.  The inflow reservoir 
was elevated 90 cm above the cannulated ends of vessels, generating a hydrostatic 
pressure of about 80 mmHg and a flow rate of about 200 ml/min (largely dependent on 
tissue resistance).  A solution of 30 mM EDTA in PBS (pH=7.5) was perfused for 12 h to 
clear any remaining clotted blood from the vasculature, followed by 1% SDS and 0.1 M 
NaOH solutions in sequence and in various durations for 10-15 days, while solutions 
were changed every 2 days.  The four separate DCELL treatment groups (n=4 scaffolds 
per group) were as follows: Group 1: 2 days SDS followed by 8 days NaOH, Group 2: 5 
days SDS followed by 5 days NaOH, Group 3: 10 days SDS followed by 2 days NaOH, 
Group 4: 15 days SDS.  DCELL efficacy was gauged by monitoring changes in scaffold 
color and mass.  Following completion of the DCELL process, scaffolds were immersed 
and rinsed overnight in 70% ethanol and 3 changes (one overnight) of PBS on an orbital 
shaker.  For post-SDS DCELL studies, Group 4 scaffolds (n=3) were further subjected to 
treatments of either 24 h perfusion with DNAse/RNAse (Worthington Biochemical) 
solution (720 mUnits/mL each) in PBS containing 5 mM magnesium chloride at pH 7.5, 




Figure 3.1: A pedicled “flap” of A) native myocardium excised from the left ventricular wall of the porcine 
heart and a representative image of the decellularized (Decelled) scaffolds resulting from perfusion 
decellularization.  The cannulae used to connect the vasculature to the perfusion system are shown secured 
with orange zip ties.  Red arrows indicate the open end of the coronary artery prior to cannulation (Native) 
and the inlet to the coronary artery after cannulation (Decelled).  Similarly, blue arrows indicate the same 
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features for the cardiac vein.  Arrows also indicate the direction of anteriograde blood and decellularization 
solution flow.  Areas designated by circles indicate origins of specimens of decellularized coronary arterial 
extracellular matrix (CA ECM) and decellularized myocardial extracellular matrix (MYO ECM) used in 
histological, immunohistochemical, DNA, biochemical, mechanical, and cell-seeding analyses.  Time-course 
plot B) of the mean recorded masses of scaffolds exposed to 4 different decellularization methods.  Results 
of a C) PicoGreen® quantitative assay for DNA are shown which compare the DNA content of both 
decellularized MYO ECM and CA ECM samples generated with various decellularization treatments to that 
of native myocardium and native coronary arteries, respectively.  DNA content of D) MYO ECM samples 
from scaffolds generated with the Group 4 decellularization treatment and subsequent exposure to various 
reagents as measured by PicoGreen® assay.  DNA content of Group 4 and native myocardium represented 
in D are carried over from C for comparison (*: indicates statistical significance from all other groups, 
p<0.0001).  Images of DAPI-stained sections E) from MYO ECM and CA ECM of decellularized porcine 
myocardial scaffolds from Group 4 and Group 3, showing residual nucleic acids (blue, white arrows; 10X, 
bar=100 μm).  Images of H&E-stained sections F) from MYO ECM and CA ECM of scaffolds from Group 
4 and Group 3, showing residual “pools” (black arrows) of nucleic acids (blue; 10X, bar=100 μm). 
 
3.2.2 Histology and Immunohistochemistry: 
 Samples of myocardial ECM (“MYO” in Figure 3.1A) and coronary arterial 
ECM (“CA” in Figure 3.1A) were examined by histological staining with Hematoxylin 
and Eosin (H&E), Gomori’s trichrome, Movat’s pentachrome, and Verhoeff-Van 
Gieson’s stains.  Immunohistochemical (IHC) analysis was performed on formalin-fixed 
and paraffin-embedded sections using heat-mediated antigen retrieval (10 mM citric acid 
buffer at 95-100 °C for 10-15 minutes) followed by incubation with  antibodies to 
collagen IV (2 µg/mL, Abcam), laminin (4 µg/mL, Abcam), actin (2 µg/mL, Abcam), 
cardiac myosin heavy chain (4 µg/mL, Abcam), or fibronectin (4 µg/mL, BD 
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Biosciences) and application of Vectastain DAB kit (Vector Labs) reagents for detection.  
For pore size determination, images (n=25) of H&E-stained sections of MYO ECM from 
each group were analyzed using ImageJ software (NIH) to determine the mean diameter 
of pores in both longitudinal (n=210) and transverse (cross-sectional) (n=278) directions.   
 
3.2.3 DNA, Collagen and Elastin Quantification: 
 DNA content of MYO ECM (n=8) and CA ECM (n=10) and samples of similarly 
located native tissues (myocardium: n=8, coronary artery: n=10) was measured using a 
Quant-IT PicoGreen® kit (Invitrogen).  Lyophilized samples of MYO ECM (n=8), CA 
ECM (n=8), native myocardium (n=8), and native coronary artery (n=8) were analyzed 
for desmosine content by radioimmunoassay (RIA) and for hydroxyproline content by 
amino acid analysis as previously reported,[12] and collagen and elastin content were 
calculated as previously described.[13, 14]  
 
3.2.4 Mechanical Properties:  
 Rectangular 2.5 x 1 cm specimens of DCELLed porcine MYO ECM (n=4) were 
either left with the epicardium attached or had the epicardium removed (n=4).  Similar 
samples (n=4) of native porcine myocardium with and without the epicardium were 
prepared for comparison.  Specimens were secured to a frame with 10 N load cell (MTS 
Systems), submerged in PBS at 37 °C, and preconditioned for 10 cycles between 0-15% 
strain at a rate of 3.0 mm/min.  After 2 minutes rest, they were subjected to 3 cycles to 
40% strain at 3.0 mm/min.  Tangential slopes of each stress-strain curve between 35-40% 
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strain were averaged and taken as the Young’s modulus.  Samples of native porcine 
coronary arteries (n=8) and DCELLed CA ECM (n=8) isolated from DCELLed porcine 
myocardial flap scaffolds were subjected to burst pressure measurements as previously 
described.[15]   
 
3.2.5 Evaluation of Scaffold Vasculature:  
 A native porcine heart (obtained as above) was injected with 50 mM EDTA in 
warm PBS at the left coronary arterial branch from the aortic trunk to clear the 
vasculature of any clots.  The left coronary artery and superior portion of the cardiac vein 
were cannulated with barbed Luer connectors (Cole Parmer).  A cannulated, acellular flap 
scaffold was embedded in concentrated (126 mg/mL) Knox gelatin to seal any open-
ended vascular channels created during the excision portion of the DCELL process.  Red 
and blue-pigmented polymethyl methacrylate (PMMA) from Batson’s #17 Anatomical 
Corrosion Kit (Polysciences Inc.) were sequentially injected into the vasculature of both 
the native heart and scaffold.  Red PMMA was infused anteriogradely through the 
coronary arterial inlet, and blue PMMA retrogradely through the cardiac vein inlet.  After 
polymerization, a cast of the vasculature was obtained by tissue maceration.  Vascular 
casts were imaged on a dissection microscope and ImageJ software was used to measure 
the diameters of blood vessels.  
 For injection and imaging of fluorescent dyes, fluorescein isothiocyanate (FITC)–
dextran and rhodamine B isothiocyanate (RITC)–dextran (Sigma) were simultaneously 
injected into the scaffold vasculature (FITC-dextran anteriogradely through the arterial 
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inlet and RITC-dextran retrogradely through the venous inlet).  The scaffolds were 
immediately imaged macroscopically using an in vivo imaging system (IVIS® Lumina 
XR, Caliper Life Sciences).  The system generated images of photon density on a 
greyscale which were artificially colored using the accompanying Living Image® 
software (Caliper Life Sciences). 
 Carbon black spherical particles of 2-12 μm in diameter (Sigma) were passivated 
via overnight incubation in 100% fetal bovine serum (FBS, Atlanta Biologicals), washed 
2X in PBS, suspended in PBS at a concentration of 2x106 particles/mL, and injected into 
the vascular inlets of a Group 4 scaffold.  Movat’s pentachrome stain was used to 
examine 5 μm-thick sections of MYO ECM distal (at the apical end of the scaffold) to the 
inlet cannulae. 
 
3.2.6 Cell Seeding and Analysis: 
 Cylindrical, 5 mm-diameter punch biopsies (n=4) of MYO ECM were taken from 
DCELLed porcine myocardial scaffolds from Group 4, sterilized in 0.1 % peracetic acid 
(Sigma) in PBS for 1 h, washed 3X in sterile PBS, and lyophilized.  For initial 
cytotoxicity studies, approximately 5x106 rat dermal fibroblasts (Cell Applications) at 
passage 11 were seeded onto the dry scaffold samples and cultured statically for either 7 
or 14 days.  At each time point, seeded scaffold samples were stained for viability using a 
Live/Dead kit (Invitrogen).   
 For seeding of neonatal rat cardiomyocytes (Lonza), 1 mm3 samples of MYO 
ECM from Group 4 scaffolds (n=3) were sterilized with peracetic acid and washed as 
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described above, seeded with 2 x 106 cells at passage 2, and cultured statically for 7 days.  
Samples were analyzed by immunofluorescence with primary antibodies to connexin43 
(2 μg/mL, Abcam), actin (2 μg/mL, Abcam), cardiac myosin heavy chain (4 μg/mL, 
Abcam), and α-sarcomeric actinin (2 μg/mL, Abcam), secondary antibodies AlexaFluor 
488 and 594 (4 μg/mL, Invitrogen), and 4',6-diamidino-2-phenylindole (DAPI) nuclear 
counterstain. 
 
3.2.7 Statistical Analysis: 
 Statistical analysis was performed using JMP software (SAS Institute Inc.).  One-
way analysis of variance (ANOVA) and Fisher’s least significant difference method for 
post-hoc comparison of mean values (with α=0.05) were used.  All quantitative data are 
represented as mean ± standard deviation.  Error bars represent ± standard error. 
 
3.3 Results 
3.3.1 Removal of Cellular Components: 
 Scaffold color and mass loss were indicative of effective muscle cell removal, as 
scaffolds initially of red-brown color became progressively paler throughout the DCELL 
process before becoming white and translucent (Figure 3.1) and wet masses decreased 
with time.  Notably, NaOH treated scaffolds displayed a higher rate of mass removal than 
SDS treated scaffolds (Figure 3.1B).  Upon switching from SDS to NaOH as called for 
by each treatment, the mass removal rate increased by more than a factor of three.  The 
treatment for Group 4 (SDS alone) removed 49.6±1.4% of the original tissue mass, while 
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the other three treatments, which all incorporated varying lengths of NaOH exposure, 
resulted in an average 58.8±1.3% removal of the initial mass (p=0.0006).  These results 
indicate that NaOH is a more rapid and more efficient DCELL agent as compared to 
SDS. 
 Histological analysis of MYO and CA ECM (Figure 3.2A) illustrated removal of 
cell nuclei and cytoplasmic proteins from native tissues, leaving voids in the resulting 
scaffold.  IHC analysis confirmed complete removal of actin and cardiac myosin heavy 
chain muscle proteins from both tissues (Figure 3.2B).  Data in Figure 3.6 also reflect 
effective DCELL, as the disparity between the weight percentages of matrix proteins in 
DCELLed and native tissues was caused by removal of cell proteins. 
Quantification of DNA showed that all DCELL treatments which employed NaOH 
(Groups 1-3) cleared 95-98% of DNA from myocardial and arterial tissues.  However, 
DNA content was not significantly different in Groups 1-3.  The treatment in Group 4 
(SDS alone) reduced DNA content by 33.2% in the myocardium and only 27.5% in the 
coronary arteries (Figure 3.1C).  H&E- and DAPI-stained sections of Group 4 scaffolds 
showed positive staining for nucleic acids which had “pooled” in sub-epicardial and sub-
intimal areas of the MYO and CA ECM, respectively, while Group 3 scaffolds were 
completely devoid of nucleic acids (Figure 3.1E and F).  Quantification of DNA in 
MYO ECM from Group 4 scaffolds perfused with additional solutions, described as post-
SDS procedures, including DNAse/RNAse or NaOH, resulted in further reduction of 




Figure 3.2: Histological images of A) native porcine myocardium and decellularized (Decelled) porcine 
myocardial ECM (MYO) stained with H&E and sectioned in the longitudinal and transverse (cross-sectional) 
directions with respect to cardiomyocytes, depicting the cylindrical voids left in their absence (40X, bar=20 
μm); H&E-stained native porcine coronary artery and decellularized porcine coronary arterial ECM (CA; 
10X, bar=100 μm).  Decellularized sections are representative of all four treatment groups.  Cell nuclei (blue), 
cytoplasmic proteins (dark pink), and collagen (light pink) are shown.  B) Immunohistochemical (IHC) 
staining of native and decellularized (Decelled) porcine myocardium (MYO) for actin and cardiac myosin 
heavy chain (cardiac MHC; 40X, bar=20 μm).  IHC of native and decellularized porcine coronary artery 
(CA) for actin (10X, bar=100 μm).  Decellularized sections are representative of all four treatment groups.  
IHC positive staining = brown.  Inserts = IHC negative controls.  L = lumen and black arrows indicate the 




Figure 3.3: Histology of native porcine myocardium and decellularized (Decelled) porcine myocardial ECM 
(MYO) from Group 4 scaffolds (40X, bar=20 μm) and native porcine coronary artery and decellularized 
porcine coronary arterial ECM (CA) from Group 4 scaffolds (10X, bar=100 μm) stained with Movat’s 
pentachrome, which shows nuclei (dark red), collagen (yellow-orange), elastin fibers (maroon), and 
cytoplasmic proteins (red).  Native porcine myocardium and decellularized porcine myocardial ECM from 
Group 4 scaffolds (40X, bar=20 μm) and native porcine coronary artery and decellularized porcine coronary 
arterial ECM from Group 4 scaffolds (20X, bar=50 μm) stained with Gomori’s trichrome, which shows nuclei 
(dark purple), collagen (blue-green), elastic fibers (purple), and cytoplasmic proteins (red).  Native porcine 
myocardium and decellularized porcine myocardial ECM with epicardium from Group 4 scaffolds (20X, 
bar=50 μm) and native porcine coronary artery and decellularized porcine coronary arterial ECM from Group 
4 scaffolds (10X, bar=100 μm) stained with Verhoeff-Van Gieson’s (VVG) stain for visualization of nuclei 
(grey/black), elastin fibers (black), and collagen (pink).  Images of decellularized sections for all stains are 




3.3.2 Preservation of Matrix Architecture and Mechanical Integrity: 
 H&E-stained histological sections cut in the longitudinal and transverse planes of 
DCELLed MYO ECM reflected retention of the native myocardial structure and 
organization (Figure 3.2A).  Taken together, images from these two planes illustrated the 
cylindrical voids left within scaffolds following removal of cardiomyocytes.  Quantitative 
analysis of the pores in these images showed they had mean dimensions of about 20 x 40 
μm among all treatment groups (Table 1).  Histological sections of DCELLed CA ECM 
displayed elliptical and oblong pores vacated by smooth muscle cells and fibroblasts, 
intact internal elastic lamellae, and little delamination of the vessel tunics (intima, media, 
adventitia; Figures 3.2, 3.3, 3.4, 3.5).  Uniaxial tensile testing of DCELLed MYO ECM 
samples showed that scaffolds from all groups had a higher elastic modulus than that of 
native tissue (p<0.0001).  Group 1 scaffolds (with epicardium attached) had a 
significantly greater modulus than scaffolds from other groups (p=0.0011).  Separation of 
the epicardium from MYO ECM samples was not found to have a significant effect upon 
the modulus (Figure 3.6C). 
 Tubular segments of DCELLed CA ECM from all groups exhibited burst 
pressures which were not significantly different from those of native coronary arteries 





Figure 3.4: Immunohistochemistry (IHC) of native porcine myocardium and decellularized porcine 
myocardial ECM, showing the degree of preservation of collagen IV (Coll IV), laminin, and fibronectin in 





Figure 3.5: Immunohistochemistry (IHC) of native porcine coronary artery and decellularized porcine 
coronary arterial ECM, showing the degree of preservation of collagen IV (Coll IV), laminin, and fibronectin 







3.3.3 Preservation of ECM Proteins and Basal Lamina: 
 Gomori’s trichrome, Movat’s pentachrome and Verhoeff-Van Gieson’s-stained 
sections illustrated the preservation of collagen and elastin following DCELL in both 
MYO ECM and CA ECM (Figure 3.3).  Notably, elastin was diffuse in the CA ECM 
(Figure 3.3) but was also observed in the epicardium and microvascular channels within 
the MYO ECM (Figure 3.7).  These results were consistent among scaffolds from all 
treatment groups and indicate excellent preservation of collagen and elastin.  To evaluate 
preservation of basement membrane components, we performed IHC for collagen IV, 
laminin, and fibronectin. These were all present within native tissues and localized to the 
peri-cellular interstitium (Figure 3.4 and 3.5).  IHC of sections from Group 4 confirmed 
excellent retention of collagen IV, laminin, and fibronectin in both the MYO and CA 
ECM following DCELL (Figures 3.4 and 3.5, Table 2).  Scaffolds from groups exposed 
to NaOH (Groups 1, 2, and 3), however, displayed a trend of increasingly diminished 
staining of these proteins as length of NaOH exposure increased (Figures 3.4 and 3.5, 
Table 2).  IHC of sections from Group 1 scaffolds displayed sparse labeling of collagen 
IV in comparison to other groups and little to no labeling of either laminin or fibronectin.  
Images of these sections are not shown due to their similarity to images of sections from 
Group 2 scaffolds.  
 Quantification of collagen and elastin content using total hydroxyproline and 
desmosine analysis showed that MYO and CA ECM were composed mainly of collagen 
and elastin, with slight differences among the various groups (Figure 3.6).  Elastin 
content was significantly different only between Group 2 and Group 4 in the MYO ECM 
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(p=0.0005; Figure 3.6A) and between Group 2 and Group 3 in the CA ECM (p=0.0432; 
Figure 3.6B).  Both types of matrices from all DCELLed treatment groups had mean 
collagen and elastin weight percentages which were significantly different from those of 
native tissue (p<0.0001; Figure 3.6A and B).  The ratio of mean collagen weight 
percentage to mean elastin weight percentage for native myocardium was 19.5.  This 
ratio increased significantly in samples of DCELLed MYO ECM from all treatment 
groups, and, among treatment groups, was only significantly different between Groups 1 
and 4 (p=0.0457, Table 3).  This same ratio was 4.3 in native coronary arteries, and it was 
not significantly different from that of CA ECM in any of the groups (Table 3).   
 
Figure 3.6: Biochemical quantification of collagen and elastin content of A) decellularized myocardial ECM 
samples generated with four different decellularization treatments as compared to that of native myocardium 
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(*: indicates statistical significance from all other groups, p<0.0001; **: p=0.0275; ***: p=0.0005).  Collagen 
and elastin content of B) decellularized coronary arterial ECM samples generated with four different 
decellularization treatments as compared to that of native coronary arteries (*: indicates statistical 
significance from all other groups, p<0.0001; **: indicates significance from all groups except Group 3, 
p<0.0001; ***: p=0.002; #: p=0.0419; ##: p=0.0432; ###: p=0.0009).  C) Young’s elastic moduli of 
decellularized myocardial ECM samples generated with four different decellularization treatments as 
compared to that of native myocardium (*: indicates statistical significance from all other groups, p<0.0001; 
**: indicates statistical significance from all other groups in “without epicardium” group, p=0.0011).  Groups 
of samples with and without the epicardium attached were tested.  D) Burst pressures of decellularized 
coronary arterial ECM segments generated with four different decellularization treatments as compared to 




3.3.4 Preservation of Vascular Integrity and Patency: 
 Simultaneous injection of FITC- and RITC-conjugated dextran into arterial and 
venous vascular inlets showed extensive perfusion of scaffolds with fluorophores (Figure 
3.7A and B).  An overlaid image of both emission spectra demonstrated that the 
fluorophores had actually mixed within the same vessels (Figure 3.7C), and an overlaid 
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image of the fluorescent channel with a white-light photograph of the scaffold (Figure 
3.7D) illustrated localization of fluorophores to the scaffold vasculature. Corrosion casts 
of a scaffold from Group 4 demonstrated retention of structure and patency of both 
macro- and microvasculature following DCELL.  Intact capillaries 5-8 μm in diameter 
were observed in casts of native myocardium as well as DCELLed scaffolds (Figure 
3.7).  Carbon microspheres injected through the vascular inlets of a scaffold from Group 
4 were observed to accumulate within capillaries in histological sections of distal portions 
of the scaffold (Figure 3.7M and N).  Microvasculature was also routinely observed in 
histological sections, and was illustrated by staining of internal elastic lamina or laminin 




Figure 3.7: Top Left Panel: Macroscopic images of a decellularized porcine myocardial scaffold from 
Group 4 following injection with A) fluorescein isothiocyanate (FITC, red) through the arterial inlet and B) 
rhodamine isothiocyanate (RITC, blue) through the venous inlet. C) Merged image of images A and B 
showing colocalization of fluorescent dyes within arteries and veins. D) Merged image of image C and a 
white-light image of the scaffold displaying fluorescent dyes confined to the vasculature.  Bottom Left 
Panel: Corrosion casts of the vasculature of E, F) native left-ventricular porcine myocardium and a G, H) 
decellularized porcine myocardial scaffold from Group 4, showing preservation of both G) macro- and H) 
microvasculature following the decellularization process.  A 500 μm-diameter needle was included in the 
frame as a scale reference (black bar in E-H=500 μm). Right Panel: Representative images across all 
decellularization treatments of I) H&E- and J) VVG-stained sections of decellularized vasculature from 
scaffolds showing the coronary artery (CA) and adjacent cardiac vein (CV; 2.5X, bar=500 μm). Micrographs 
of K) VVG staining and L) IHC for laminin in sections of microvasculature from Group 4 scaffolds showing 
preservation of elastin (black) and laminin (brown) around vessels, respectively (40X, bar=20 μm). 
Micrographs M, N) of decellularized myocardial scaffold vasculature from Group 4 following injection of 
2-12 μm–diameter, carbon particles via the vascular inlets.  Sections were from sites distal (apical portions 
of scaffold) to inlets, and black carbon particles are shown localized to small vessels (M: 10X, bar=100μm; 
N: 20X, bar=50 μm). 
 
3.3.5 Cytocompatibility: 
 Samples of MYO ECM from scaffolds exhibited excellent cytocompatibility to 
fibroblasts after 7 and 14 days in culture (Figure 3.8A).  Rat neonatal cardiomyocyte-
seeded samples labeled for connexin43, actin, cardiac myosin heavy chain (MHC), α-
sarcomeric actinin, and DAPI appeared viable and positive for these markers.  Although 
no tests of functionality were performed, cells appeared to interconnect and self-organize 




Figure 3.8: A) Images of decellularized porcine myocardial ECM from Group 4 scaffolds seeded with rat 
dermal fibroblasts (FB) and cultured for either 7 (top) or 14 (bottom) days.  Cells were labeled with Live/Dead 
reagents at each time point.  Live cells were labeled with calcein AM (green) and dead cell nuclei were 
stained with ethidium homodimer (EthD-1, red; 20X, bar=50 μm). B) Immunofluorescence (IF) images of 
decellularized porcine myocardial ECM from Group 4 scaffolds seeded with neonatal rat cardiomyocytes 
(CM) and cultured for 7 days.  Scaffolds were stained for α-sarcomeric actinin, cardiac myosin heavy chain 
(MHC), actin, connexin43 and DAPI (40X, bar=20 μm). 
 
3.4 Discussion 
3.4.1 Evaluation of Decellularization Efficiency: 
 In this study, we have taken a systematic and thorough approach to developing a 
naturally vascularized, acellular myocardial flap, addressing the key features and 
characteristics of the myocardial matrix, the major arteries and veins, and the intrinsic 
microvasculature.  Several groups have successfully DCELLed myocardium in either 
whole or excised portions of both rat and pig hearts using a wide range of chemical 
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agents and physical methods.[5-11, 16]  Many reported on characteristics (e.g. acellularity, 
biochemical composition, vascularity, thickness) of the resulting scaffolds and their 
applicability to tissue engineering efforts.  However, with regard to optimization of a 
DCELL method, these studies vary in the comprehensiveness of their analysis.   
 Our choice of chemical agents for DCELL was predicated upon previously 
published results from studies which used SDS [2, 6, 8, 11] and upon our previous experience 
with NaOH as a DCELL agent.  The latter has long been used in “hot alkali” methods for 
elastin isolation (indicating its suitability for preserving elastin),[13] and we previously 
observed extensive removal of DNA and collagen from carotid arteries treated with 0.1 
M NaOH at 37˚C.[15]  In several pilot studies, we used this same concentration of NaOH 
to decellularize myocardium at room temperature, and did not observe any noticeable 
degradation of the collagenous matrix components (data not shown).  We surmised that 
the lower temperature reduced protein degradation kinetics so as to remove cellular 
proteins without causing extensive damage to the collagenous ECM.  Thus, it was of 
interest to investigate the combinatorial effect of SDS’s ability to solubilize plasma 
membranes and denature proteins with NaOH’s affinity for solubilizing protein and 
degrading nucleic acids.[2]    
 
3.4.2 Removal of Cellular Material: 
 Despite its reputation as an effective DCELL reagent,[1, 2, 8, 11, 17] it has been 
suggested by some that SDS may leave cellular remnants when used in DCELL of MYO 
ECM.  However, there is scant evidence furnished by the authors in support of this 
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contention.[9]  Our own histology and IHC results demonstrated that every DCELL 
treatment we investigated, including that which used solely SDS following EDTA (Group 
4), was effective in disrupting cell and nuclear membranes and in completely removing 
intracellular proteins from both the MYO ECM and CA ECM.  Measurements of the 
dimensions of pores within our DCELLed scaffolds are consistent with those previously 
reported.[7]  DNA quantification was carried out to provide an additional measure of 
acellularity, and with the exception of the Group 4 treatment, all DCELL methods left 
only small amounts of residual DNA.  Although quantitative assays, as well as H&E- and 
DAPI-stained sections, confirmed that Group 4 scaffolds contained visible amounts of 
residual DNA (Figure 3.1), none of the corresponding histological stains or IHC showed 
muscle proteins or other apparent cellular remnants (Figure 3.2).  Furthermore, the 
nucleic acids in these sections were not observed in small, concentrated areas (which 
would be indicative of intact nuclei), but rather seemed faint and diffuse, occasionally 
“pooling” within pores of the matrix.  This was especially evident in areas adjacent to 
denser portions of the matrix, such as the epicardium, adventitia, and internal elastic 
lamina, where resistance to diffusion of large molecules is potentially greater.    
 In replicating a similar SDS-based protocol developed by Ott et al., Akhyari and 
colleagues showed only a 43% reduction of native DNA content.[11, 16]  Weymann et al. 
DCELLed an intact porcine heart using perfusion of 4% SDS over 12 h, concluded with 
perfusion of PBS for 24 h, and reported an 82% reduction in DNA content.[8] While SDS 
was effective in lysing the nuclear membranes, it likely did not interact with this newly 
extra-nucleated, or free DNA.  This lack of interaction is explainable, given that SDS is a 
87 
 
strongly anionic molecule and DNA is negatively charged along its phosphate backbones.  
NaOH, by contrast, is exceedingly effective in breaking down DNA, as it causes both 
denaturation[18] and hydrolysis of the molecule.[19] 
To reduce content of residual DNA within Group 4 scaffolds, we prepared a new 
set of scaffolds using the Group 4 treatment and compared the effects of three prospective 
post-SDS “washing procedures” upon levels of residual DNA.  The DNAse/RNAse and 
NaOH (2 hours) treatments were effective in removing some residual DNA, but did not 
achieve the very low levels of residual DNA observed in groups with significant 
exposure to NaOH (2 days or more).  Despite this, we demonstrated that minor additions 
to our Group 4 treatment could result in further removal of DNA to acceptable limits.  
 
3.4.3 Preservation of Basal Lamina Components: 
 Basement membrane proteins contain important cell binding moieties, and any 
alteration of their conformation by chemical or physical means during DCELL could 
render them nonfunctional.[16, 20]  Laminin is a vital link in the chain which binds the 
cardiomyocyte cytoskeleton to the collagenous ECM components, thereby facilitating 
transfer of mechanical forces and stimuli between the two.[21, 22]  It has multiple domains 
which allow it to simultaneously bind integrins, proteoglycans, and collagen IV, making 
laminin the all-purpose “glue” of the basement membrane.[4, 23]  Attachment to laminin 
has also been shown to be necessary for cardiomyocyte survival in vitro, indicating its 
ability to mediate important cell signaling pathways. [24, 25]  Collagen IV assembles into 
an open network overlaying the predominant structural ECM proteins.[18]  It serves as the 
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linkage between fibrillar collagens and both laminin and fibronectin.  Fibronectin acts as 
an important intermediary between cardiomyocytes and the basal lamina, binding 
integrins, proteoglycans, and collagens.[23]  Although these are minor components within 
the ECM, they will likely play a major role in the attachment, mechano-transduction, 
differentiation, maintenance of phenotype, and ultimately, functionality of reseeded cells.   
 In our studies, DCELL treatments which employed NaOH altered and/or removed 
basement membrane proteins.  While collagen IV and fibronectin appeared less affected 
by this exposure, laminin was aggressively degraded by NaOH (full degradation at 48 h 
exposure to 0.1 M NaOH).  Scaffolds from Group 4 (SDS alone) retained all basement 
membrane proteins we attempted to identify by IHC.  
 
3.4.4 Preservation of Collagen and Elastin: 
 Quantitative analysis showed that collagen and elastin were the predominant 
components of both myocardial and coronary matrices within scaffolds from all groups.  
Aside from studies which reported Western blotting results[16] and qualitative or semi-
quantitative results,[5-10] to our knowledge, no other attempts were made to quantify these 
important matrix proteins.  Elastin plays an important mechanical role in normal cardiac 
tissue, as it facilitates passive recoil of the matrix following muscle contraction and 
distension of the collagenous components within both the MYO and CA ECM.[23, 26]  
Akhyari et al. reported that DCELL with a similar method reduced elastin content relative 
to native tissues,[16] but our data show that elastin content is largely preserved, 
particularly within the CA ECM.   
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3.4.5 Evaluation of Mechanical Properties: 
 Overall, the elastic moduli of MYO ECM and CA ECM did not differ 
significantly from native tissues, which suggests that DCELL procedures assessed in this 
study did not alter their mechanical properties.  The elastic moduli we report here (0.4-
0.9 MPa) for DCELLed MYO ECM is somewhat lower than that reported by other 
groups, but this does not indicate that our scaffolds are by any means mechanically 
deficient.  This disparity can be attributed in part to differences in mechanical testing 
methods (e.g. strain rate, modulus calculation method, preconditioning, preloading, and 
cross-sectional area measurement techniques for calculation of engineering stress).  Our 
mechanical testing procedure was most comparable to that described by Eitan et al. in 
terms of preconditioning and strain rate, but it was not clear as to which specific portion 
of the stress-strain curve was used for calculation of their reported elastic modulus.[10]  
Our myocardial matrix is also considerably less stiff than another acellular porcine MYO 
ECM generated with an SDS-based protocol, which had a reported modulus of 5.219 
MPa (strain rate was 6.0 mm/min – twice the rate used in the current study).[6] 
Importantly, both the above DCELL protocols employed trypsin extensively 
(Sarig et al.: 0.05% (w/v) for 96 hr and Wang et al.: 0.01% for 2.5 weeks).[7, 9]  Trypsin is 
a serine protease known to partially degrade elastin, an observation confirmed by our 
own work with this enzyme (data not shown).  Acellular myocardial matrix generated by 
the first trypsin protocol[9] was reported to be completely devoid of elastin, and while 
recently published results from the second group confirm the presence of elastin 
histologically, no quantitative data was provided.[7 
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3.4.6 Vascular Integrity and Patency: 
Corrosion casts of scaffolds demonstrated that our DCELL procedure leaves the 
inherent vasculature intact to the extent of preserving the patency of microvasculature 
and capillaries.  Simultaneously anterio- and retrogradely injected fluorescent dyes were 
able to move freely through the scaffolds’ vascular tree and mix with one another.  In 
addition, carbon microspheres appeared within distal microvascular channels following 
their injection into the scaffold’s main vascular inlets.  These observations confirm that 
the microvasculature and capillary beds linking the arterial and venous circulation are left 
intact by our DCELL process.  Using a similar perfusion SDS-based protocol, Ott et al. 
presented evidence of vascular preservation with corrosion casting results, but also by 
heterotopically connecting the vasculature of their whole, DCELLed rat heart to the aorta 
of a recipient rat and observing perfusion of the scaffold with host blood.[11]  
Microvasculature is absent in trypsin-exposed scaffolds, possibly complicating 
subsequent efforts to maintain viability of reseeded cells and limiting feasibility of 
reperfusion or graft integration upon implantation.[9, 16] 
 
3.4.7 Cytocompatibility and Cardiomyocyte Cell Seeding: 
Several groups have already established DCELLed MYO ECM as an acceptable 
substrate for supporting reseeded cells.[5, 6, 9-11, 16]  Relevant cardiac cell types seeded onto 
samples of DCELLed MYO ECM from scaffolds in Group 4 attached, maintained a 
cardiac phenotype, and remained viable for up to 14 days in static culture.  These data 
support the cytocompatiblity of our scaffolds and their suitability for maintaining 
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cardiomyocyte cell phenotype, although more definitive studies must be conducted to 




3.4.8 Analysis of Optimal Decellularization: 
The acellular myocardium is an outstanding matrix scaffold with promising tissue 
engineering applications for in vitro testing, as well as for in vivo regeneration.  Our 
results suggest that a rational design and selection of DCELL methods for myocardium 
needs to take into account several criteria which serve the intended final application.  
These criteria were used to comment on some of the positive and negative effects of each 
of the DCELL reagents we investigated, including EDTA (Table 4).   
Our comparative study shows that scaffolds DCELLed with SDS alone exhibit 
excellent preservation of major and minor ECM components but are not fully DNA-free 
despite extended perfusion with SDS, which removed all detectable cell proteins.  Post-
SDS treatments with nucleases may reduce DNA content further and thus provide 
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acceptable scaffolds for implantation.  NaOH, on the other hand, is very effective at 
removing all traces of DNA but also removes some of the basement membrane 
components.  Currently, there is no definitive evidence to support residual exogenous 
nucleic acid content as being a critical determinant of the success or failure of implanted 
scaffolds or constructs.[27]  Producing a DNA-free scaffold is neither the sole, nor 
necessarily the most important, criterion for determining whether a scaffold is optimal, 
and it must be weighed against other criteria in judging a scaffold’s suitability for tissue 
engineering applications.  There is evidence, however, that basement membrane proteins 
play an important role in cell survival, attachment, and interactions with the ECM.[16, 23-25]   
Thus, in selecting a scaffold for regenerative medicine applications, we lend more 
credence to preservation of native ECM characteristics than we do to absolute removal of 
DNA.  For this reason, our future work will be conducted using scaffolds from Group 4 
which have been treated to further remove residual DNA.  Other scaffolds we generated 
are also suitable materials for tissue engineering.  Some may see merit in using them, 
especially since their lower DNA content may assuage fears of immunogenicity or other 
unforeseen negative effects.  Ongoing studies focus on cell-seeding and preconditioning 
of constructs made from our scaffolds, and on implantation studies to assess 
biocompatibility and feasibility of implantation techniques.  
 
3.5 Conclusions: 
To the best of our knowledge, this is the first study which has carried out a 
comprehensive, parallel analysis of both the vascular and myocardial matrices in a 
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myocardial flap containing intact coronary arteries, veins, and associated 
microvasculature.  DCELL of such complex tissues was challenging and required a 
comparative analysis of detergent versus alkaline DCELL methods.  Our scaffolds are 
porous, retain collagen and elastin content and structure, exhibit excellent mechanical 
properties, and are cytocompatible.  Moreover, scaffolds retain laminin, fibronectin, and 
collagen IV.  We’ve also preserved the vasculature’s integrity and patency down to the 
capillary scale, as shown by several assays.  Together with our demonstration of 
cytocompatibility and support of cardiomyocyte survival, these results indicate that our 
scaffold is ideally suited for repopulation with relevant cardiac cell types as a tissue-
engineered construct for myocardial repair.  Given its composition, intact vasculature 
tree, mechanical properties, and geometry, we believe constructs produced from this 
scaffold have the potential to functionally integrate with healthy host myocardium and to 
be nourished by direct anastomotic connection with the host’s own vasculature.  We also 
believe such constructs may be useful as physiologically accurate models for in vitro 
studies of cardiac physiology and pathology.  
  
3.6 Updates to These Methods: 
It is noteworthy that our process of tissue preparation and DCELL changed from 
those depicted in Figure 3.9 since these studies were conducted.  To make preparation of 
the tissue for DCELL less labor-intensive, we elected to decellularize the entire porcine 
heart via retrograde perfusion of the aorta to generate scaffolds for use in future studies 
(Figure 3.10C).  We designed a new vessel to accommodate an entire porcine heart using 
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SolidWorks software, and machined three of these containers with the help of Clemson 
University Machining and Technical Services (Figure 3.10B and D). The critical point 
of this method involved preventing the outflow of solutions from the heart at too high of 
a rate.  It was necessary to maintain pressure within the left ventricle so that the main 
path travelled by solutions was into the coronary arteries, through the microvasculature, 
and out through the veins.  As such, the pulmonary veins at the posterior of the heart 
needed to be closed to prevent solutions from preferentially flowing rapidly through the 
left ventricle, into the left atrium, and out of these severed veins.  We sealed the veins 
with suture or a plugged cannula secured with zip-ties (in the case of large openings).   
Upon achieving complete DCELL of the organ, regions of interest were dissected and 
used for experiments in Aims 2, 3, and 4.  The reagents used and the sequence in which 
they were used did not change, however, and characteristics of scaffolds generated with 
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In myocardial tissue engineering, the optimal therapeutic approach is one of 
delivering a graft containing functional, autologous CM that will integrate electrically and 
mechanically with existing healthy myocardium.  Delivery of a sufficient number of new 
CM to replace CM lost in an MI requires a thick graft, nourished by an organized 
vasculature.  The optimal scaffold must not only support and nourish the replacement CM, 
it must also resist significant degradation by the host until these CM can integrate with 
native CM and until the graft’s vasculature can form connections with native vasculature 
of the host.  The important questions then become 1) how long do these processes take, 
and 2) what is an acceptable degree of degradation?   
Since our scaffold is composed of ECM, which is normally in a constant state of 
turnover via degradation and synthesis, it is expected that some degree of remodeling will 
occur in our implanted grafts.  Over time, host CM, endothelial cells, vascular smooth 
muscle cells, and especially macrophages and cardiac fibroblasts will likely infiltrate the 
myocardial grafts and degrade the scaffold ECM while replacing it with endogenous, fully 
remodeled ECM that incorporates the delivered cells into the tissue.  Groups who have 
implanted ECM or other biologic scaffold-based grafts in the myocardium have observed 
cell and vascular integration as early as 4 days and consistently at 4 weeks and beyond.[1-
6]  Despite the rapidity with which integration can occur, scaffolds should not be considered 
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dispensable before the 3-week period encompassing the acute and subacute host responses 
has elapsed.[7, 8] Furthermore, in light of the thickness of the grafts and the potentially 
inhospitable environment into which they will be placed, the scaffolds should remain 
largely intact for up to 8 weeks to ensure that their constituent cells have ample time to 
integrate with host tissue and vascular supply.  
To learn more about the possible host response to our scaffolds, we implanted them 
in an in vivo model that represented a very active immune site, so that if the material was 
immunogenic, we would be certain to observe a response.  The model, subdermal 
implantation in juvenile rats, does so because the integumentary system boasts a strong 
presence of immune cells, including Langerhans cells and dendritic cells, and because the 
adaptive immune system in these juvenile animals is sufficiently developed and, overall, 
vigorous.[9] 
 
4.2 Biocompatibility Study 1: 
4.2.1 Methods: 
4.2.1.1 In Vitro Cytotoxicity Assessment: 
 The indirect cytotoxicity of scaffolds was evaluated according to methods adapted 
from ISO standard 10993-5.  Possible extractables were eluted from high density 
polyethylene (HDPE; negative control) and scaffolds via incubation of (n=6), 5 x 5 mm 
samples of each material in culture media (DMEM with 10% FBS) at 37 °C for 7 days. 
NIH 3T3 fibroblasts were then seeded into two 24-well plates at 50,000 cells/well (n=3 
wells/condition) and cultured for 3 days in standard media prior to being cultured with 
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extraction media containing possible cytotoxic eluates for 7 days.  Upon 7 days of culture 
with extraction media, cell viability was examined using a tetrazolium-based MTS assay 
(Promega) and a Live/Dead® assay (Invitrogen).  In each assay, measurements collected 
from the cells exposed to extracts were compared to those of cells cultured in either 
negative (normal media) or positive (70% ethanol) conditions to quantify the extent of 
cytotoxicity.    
 
4.2.1.2 Scaffold Sample Preparation for Implantation:  
DCELLed scaffolds were prepared according to the original method of dissection 
and DCELL as described in Chapter 3.  Following DCELL, a 10 mm-diameter biopsy 
punch was used to cut pieces of scaffold, and the resulting cylinders were cut in half to 
create the final samples used for implantation.  Prior to implantation, the samples were 
sterilized by immersion and gentle agitation in 0.1% (w/v) peracetic acid in PBS for 1 h, 
followed by rinsing in 4 changes of sterile PBS.  Peracetic acid has been demonstrated to 
be an effective antibacterial and antimicrobial agent by means of oxidation, and has been 
used successfully in our lab as a non-degradative wet sterilization method.[10-12] 
 
4.2.1.3 Subdermal Implantation Procedure: 
In accordance with an approved animal use protocol, 16 juvenile Sprague-Dawley 
rats were anesthetized with buprenorphine at 0.03-0.05 mg/kg and acepromazine at 0.5 
mg/kg administered subcutaneously.  A small incision was made in the center of the dorsal 
area of each rat about 2 cm inferior to the scapulae, and, using blunt dissection, two pockets 
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were created between the dermis and fascia lateral to the incision (one pocket in each 
direction).  A scaffold sample was placed into each pocket, and the incision was closed 
using staples.  Rats were allowed to recover and were housed individually for the remainder 
of the study.   
 
4.2.1.4 Explantation and Histological Evaluation: 
At both 4 and 8 weeks post implantation, (n=8) rats were euthanized via CO2 gas 
(Euthanex system) followed by bilateral pneumothorax.  Scaffold samples and small 
amounts of their adjacent host tissues were excised and fixed in 10% neutral buffered 
formalin and processed for histological examination. 
Parafin-embedded samples were sectioned at 5 µm and stained by H&E and 
immunohistochemistry (IHC) for CD68, a marker for monocytes/macrophages, and CD8, 
a marker for cytotoxic T-lymphocytes. 
 
4.2.2 Results: 
4.2.2.1 In Vitro Cytotoxicity Assessment:  
 Preliminary testing of the scaffolds revealed no evidence that they contained 
cytotoxic leachables.  Two methods, Live/Dead staining (Figure 4.1A) and an MTS assay 
(Figure 4.1B) were used to measure cytotoxicity.  Results were reported as comparisons 
to measured values from fibroblasts grown in normal cell culture media.  Neither assay 
demonstrated a significant difference in viability between cells exposed to extract media 
from scaffolds and cells grown with normal media.  The assays were proven to be effective 
A B C 
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in measuring cytotoxicity by the inclusion of both a positive and negative control in the 
experimental design.  The positive control resulted in a great increase in cell death, and the 
negative control saw no significant deviation from the normal control in the Live/Dead 
assay.  Rather unexpectedly, cells from the negative control displayed a significant 
reduction (40%) in cell viability compared to normal cells as measured by MTS assay, 




Figure 4.1: In vitro cytotoxicity assessment:  Live/Dead® A) and MTS® B) assays for cytotoxic effects 
of myocardial scaffolds.  In each assay, the reported value for each group is relative to the measured value 
for NIH 3T3 fibroblasts under standard culture conditions (i.e. a value of 1 in A and 100% in B; *: indicates 
statistical significance from control, p<0.0001 in A and B; **: indicates statistical significance from control, 
p=0.0005 in B). 
 
4.2.2.2 Explantation and Histological Evaluation: 
DCELLed myocardial scaffold samples implanted in rats were almost completely 
degraded at 8 weeks post-implantation.  In a few cases (2 of 8 rats) at this time point, it 
was not possible to macroscopically identify any remaining scaffold upon explantation.  
H&E staining, as well as IHC for CD8 and CD68, revealed the presence of large 
populations of immune cells, including macrophages and lymphocytes, inside the scaffolds 
and at the implant-host tissue interface.  This was consistent in histological sections of 
explants from both time points, seemingly indicative of a chronic inflammatory response 
(Figure 4.2).  It was also noted that a significant number of cells in the IHC sections did 
not stain positively for either marker, indicating that they were not macrophages, 




Figure 4.2: Histological analysis of explanted scaffolds from Biocompatibility Study 1: Representative 
images of H&E staining of decellularized myocardial scaffolds following subdermal implantation in juvenile 
rats for 4 weeks show heavy infiltration of leukocytes within and around the scaffolds (S); dashed black line 
denotes scaffold-host tissue interface.  Representative images of IHC for CD8 and CD68 show T-cells and 
monocytes and/or macrophages, respectively, are present within the scaffolds.  Representative images of 
H&E staining of explanted scaffolds at 8 weeks post-implantation show persistent and, in some cases, 
increased presence of leukocytes within and around scaffolds in comparison to scaffolds explanted at 4 
weeks.  The amount of identifiable scaffold in each sample explanted at 8 weeks was also greatly diminished 







  In our experience with implanted scaffolds, we had not observed an inflammatory 
response of this magnitude.[13-15]  Furthermore, as discussed previously in this document, 
the expected response to an acellular scaffold should not involve an aggressive or 
protracted immune response.  We hypothesized that this response could have been due to 
insufficient rinsing of the scaffold prior to implantation (instead of perfusing wash 
solutions through the scaffold as was done with DCELL solutions, scaffolds were simply 
immersed in wash solutions with agitation on an orbital shaker), and therefore to the 
presence of residual SDS from DCELL or peracetic acid from sterilization methods.   
To test for residual SDS, we retroactively performed an assay to quantify the SDS 
concentration (described in further detail in methods section for Biocompatibility Study 2) 
in lysates of leftover, unimplanted scaffolds.  It was found that the SDS concentration in 
the pre-implanted scaffolds was 2.14 +/-1.17 µg/cm3 tissue.  In searching for some context 
as to whether this concentration was sufficient to induce cytotoxicity, we came across a 
study which focused upon determining whether SDS used to decellularize pulmonary 
valves could be removed from the tissues, and correlated residual SDS concentrations with 
cytotoxicity and metabolic activity as measured by lactate dehydrogenase (LDH) and MTS 
assays, respectively.[16]  The authors found that after 5 wash cycles with PBS, they could 
reduce the SDS concentration to under 50 µg/mL, and that this concentration did not result 
in any cytotoxicity or reduction in metabolic activity.  Yet another study cited the threshold 
toxicity concentration (defined as a 10% decrease in cell viability) of SDS as 0.047 mM, 
or roughly 13.6 µg/mL (in this case, specific gravity dictates 1 mL=1 cm3).[17]  Given that 
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the SDS concentration within our scaffolds was nearly 25-fold and 6-fold less these figures, 
respectively, we ruled out residual SDS as the cause of any heightened immune response. 
Similarly, previous studies conducted by our lab involving peracetic acid 
sterilization of implanted scaffolds did not result in any negative outcomes associated with 
immune or inflammatory responses.[11]  In these cases, simple repetitive washing of the 
scaffolds with PBS on an orbital shaker (identical to the method used here) was sufficient 
to remove peracetic acid. 
In the absence of any other obvious explanation for the response we observed, it 
was worth delving deeper into the results of similar studies, both internal and external to 
our lab.  Previous scaffolds we implanted were not only generated from vastly different 
tissues (thus, of different structure and composition), but were also either fixed with PGG 
or seeded with ADSC, both of which have been shown to mitigate the immune response.[13, 
14, 18] 
Our conventional thinking about host responses to implants has been informed by 
observations of responses to non-biological, and thus, less bioactive materials.  It is narrow-
minded to assume that the host response to a material composed of ECM proteins should 
proceed in the same manner.  Instead, the host uses the only real means at its disposal to 
respond to the presence of this material – leukocytes (e.g. lymphocytes, monocytes, and 
macrophages).  Together, these cells dictate the nature of the response to the material and 
direct its remodeling through mechanisms traditionally associated with inflammation.[19, 20] 
One could argue that fibroblasts also play a role in the host response to biologic 
scaffolds because they are capable of both synthesizing and degrading (via secretion of 
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matrix metalloproteases; MMPs) ECM components.[21]  Their synthesis of MMPs, 
however, is largely mediated by signaling from TNF-α and TGF-β1 – cytokines produced 
by leukocytes, so it is unlikely that fibroblasts could direct the remodeling or degradation 
of a biological scaffold on their own.[22]  
In addition, there is further evidence in the literature to suggest that what we viewed 
as an aggressive inflammatory response was simply a normal response to a non-crosslinked 
biologic scaffold.  While our previous studies with PGG-treated scaffolds showed limited 
involvement of macrophages in the host response, several studies conducted by the 
Badylak group demonstrated a prominent role of various subsets of macrophages, 
neutrophils, and monocytes in the response to implantation of non-chemically modified 
scaffolds.[20, 23-25]   
It has been established that macrophages are possessed of significant plasticity, 
changing, or “polarizing”, to fit the conditions of the local environment.   While there are 
multiple phenotypes (M1, M2a, M2b, and M2c), polarization generally refers to the polar 
extremes of either an M1 (classically activated, proinflammatory) or M2 (alternatively 
activated, immunomodulatory and remodeling) phenotype.[23, 24, 26]  Enough is known about 
these two distinct populations that they can be identified by certain markers: inducible 
nitric oxide synthase (iNOS), CD80, and CCR7 for M1, and CD206, CD163, and Fizz1/Ym 
for M2.[23, 27]  In general, it has been observed that desirable outcomes with implanted 
biological scaffolds (i.e. remodeling into appropriate, functional tissue as opposed to scar 
tissue formation) correlate with a shift from the M1 to the M2 polarity as the host response 
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progresses.[20]  With this in mind, it became of interest to identify the types of macrophages 
present within the implant site at different time points. 
An additional observation from this first study was that not all cells which had 
infiltrated the scaffolds stained positively for markers of monocytes, macrophages, and 
lymphocytes.  This is not surprising given that we have previously found that other types 
of scaffolds (DCELLed porcine carotid arteries and DCELLed porcine pericardium) 
implanted in this same model attracted cell infiltrates that stained positive for vimentin, 
prolyl-4-hydroxylase, and alpha-smooth muscle actin in addition to macrophages.[13, 14]   
In light of the questions surrounding the outcomes of this study, we planned a 
subsequent study to investigate means to forestall complete degradation of the scaffold and 
to more closely examine the identities, functions, and origins of cells at the implant site in 
order to gain a better understanding of the host response and the ultimate implant fate. 
 
4.3 Aims for Biocompatibility Study 2: 
 In the eventual clinical adaptation of this approach, we believe that extending the 
in vivo lifespan of the scaffold so as to partly preserve it up to 12 weeks or beyond will 
lead to more favorable outcomes with respect to myocardial graft integration and 
incorporation of constituent cells.  To test if this was possible, we employed penta-galloyl 
glucose (PGG), an ECM protein-binding, plant-derived polyphenol, as a cross-linking 
agent to impart the scaffolds with greater resistance to degradation by the host.  Indeed, 
previous studies conducted by our laboratory demonstrated that treatment of scaffolds with 
PGG protected them not only from excessive matrix metalloprotease-driven degradation, 
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but also prevented calcification while mitigating the severity of the immune response 
(Figure 4.3).[15] 
Figure 4.3: Effects of PGG as assessed by 
histology and cytokine array: Histology and 
IHC performed on decellularized carotid 
artery scaffolds following subdermal 
implantation in rats for 4 weeks.  Scaffolds 
treated with PGG show decreased 
susceptibility to calcification and deposition 
of osteogenic proteins in comparison to 
scaffolds not treated with PGG (nontreated), 
as reflected by alizarin red staining for 
calcium (Azn Red), and IHC for osteopontin 
(OPN) and alkaline phosphatase (ALP).  
PGG-treated scaffolds also displayed 
immune-modulatory characteristics, as fewer 
CD68 positive cells were identified within 
them than in nontreated scaffolds (as assessed 
by IHC), and less TNF-α was observed in 
PGG-treated scaffolds in a cytokine array 







We expected that myocardial scaffolds treated with PGG would demonstrate 
improved resistance to degradation over non-treated scaffolds, and the degradation profile 
of PGG-treated scaffolds would be sufficiently gradual to allow regenerative cells 
delivered within them in the future to integrate with host cells and provide functional 
benefits.  If at least a portion of the scaffold remained at 8 weeks post-implantation, this 
expected outcome was considered met.  
This study was also intended to analyze the host biological response to the 
implanted myocardial scaffold, specifically in terms of macrophage polarization.  The 
results allowed us to determine whether this biomaterial elicited a classical inflammatory 
response or a more constructive, remodeling response.  Given PGG’s purported anti-
inflammatory properties, we expected to observe a significant reduction of inflammatory 
cells within and around the implant site of PGG-treated scaffolds as compared to non-
treated scaffolds.  Similarly, we expected to observe a greater ratio of M2 to M1 
macrophages and greater recruitment of stem cells, indicative of a more regenerative 
response, in the PGG-treated scaffolds. 
Cellular infiltration, vascularity, and collagen content were analyzed in order to 
evaluate the structure of the tissue that was formed as a result of the host response.  We 
also intended to determine the phenotype of the previously unidentified cells by staining 
for common markers of fibroblasts, smooth muscle cells and mesenchymal and 





4.4 Biocompatibility Study 2: 
4.4.1 Methods: 
4.4.1.1 Quality Control Characterization of Scaffolds: DNA Quantification, SDS 
Quantification, and alpha-1, 3-galactose Screening: 
4.4.1.1.1 DNA Quantification: 
Picogreen and Oligreen assays for double-stranded DNA (dsDNA) and single-
stranded (ssDNA), respectively, were carried out on (n=6) samples from randomly selected 
areas of the DCELLed scaffolds used in this implantation study.  Briefly, samples were 
completely digested in 1 mL of papain digestion buffer and run against a standard curve 
generated from known concentrations of a supplied DNA standard in order to determine 
the DNA content of each sample.  
 
4.4.1.1.2 SDS Quantification: 
In addition to acellularity, it was also important to demonstrate the removal of SDS 
from scaffolds following DCELL.  Residual SDS in an implanted scaffold could be 
cytotoxic to the immediate host cells and elicit an aggressive inflammatory response if its 
concentration was sufficiently high and/or persistent.  The same digested scaffold samples 
(n=6) described above in DNA quantification methods were also used in this assay.  The 
assay was derived from a previously published method and designed around a phase 
separation principle.[28]  It involved an aqueous phase comprised of slightly alkaline PBS 
(pH=8.0) and toluidine blue dye, as well as a chloroform organic phase, and the two phases 
were combined in a single test tube.  A small volume (5-10 µL) of digested scaffold was 
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added to the aqueous phase, the two phases were mixed by inversion, and the mixture was 
incubated at room temperature.  The critical mechanism of the assay was the binding of 
toluidine blue to SDS.  This complex was able to traverse the interface between the two 
phases due to the amphiphilic nature of SDS.  The SDS-toluidine blue complex then 
collected in the chloroform phase, and a volume of this phase was pipetted into a 96-well 
plate for spectrophotometric analysis of absorption at 600 nm.  The optical density of each 
sample of unknown SDS concentration was compared against a standard curve of samples 
of known SDS concentration, and the concentration of unknown samples was extrapolated 
(Figure 4.5B). 
 
4.4.1.1.3 Screening for alpha-1, 3-galactose: 
 The alpha-1, 3-galactose, or alpha-gal, carbohydrate is found in all non-primate 
mammals, and therefor triggers an aggressive immune response when introduced into 
humans.  This is particularly concerning given that porcine tissue contains this antigen, 
which must be removed from scaffolds intended for xenogeneic implantation in humans, 
lest an immune response lead to implant rejection and failure.[29]  Since alpha-gal is 
normally occurring in rats, its presence in the scaffold would not be detrimental to this 
particular implantation study.  However, with implantation in humans as a future goal for 
this scaffold material, it was prudent to demonstrate the removal of alpha-gal from the 
tissue as a result of the DCELL process.  
 Removal of alpha-gal was demonstrated using standard immunohistochemistry 
techniques.  Instead of a primary IgG or IgM antibody, biotinylated isolectin B4 generated 
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in the griffonia simplicifolia shrub was used to label alpha-gal.  Avidin/biotinylated 
enzyme complex (ABC; Vector Labs.) with horseradish peroxidase was applied to tissue 
sections, followed by the enzyme substrate, 3, 3'-diaminobenzidine (DAB).  As a result of 
this detection system, brown color was developed wherever alpha-gal was located.  
 
4.4.1.2 Scaffold Preparation and PGG fixation:  
Scaffolds were prepared by the method of whole heart DCELL and individual 
samples were prepared as previously described.  Scaffolds were exposed to differing 
concentrations of PGG (Omnichem Ajinomoto, Belgium), 0.15% and 0.3% w/v in 50 mM 
phosphate buffer, pH=5.5, containing 20% isopropanol for 24 h, or were left untreated as 
a control.  Scaffolds were then rinsed with PBS and sterilized for implantation as described 
above in the first implantation study.   
 
4.4.1.3 Subdermal Implantation in Rats:  
Forty-five male, juvenile Sprague-Dawley rats were randomly assigned between 
three groups: 1) non PGG-treated (NT), 2) 0.15% PGG-treated, 3) or 0.3% PGG-treated 
(n=5 rats/group/time point).  The corresponding scaffolds were subdermally implanted into 
each rat.  Anesthesia, surgical procedure, implantation (2 scaffolds/rat), closure, and 






4.4.1.4 Explantation and Semi-quantitative Histological Analysis:  
At 4, 8, and 12 weeks post-implantation, animals were euthanized as previously 
described, and the scaffolds and immediate surrounding tissue were excised and examined 
histologically to characterize the host response, as well as the rate and extent of 
degradation.  Following standard formalin-fixation and paraffin embedding, 5 µm-thick 
sections were prepared and stained via H&E and Masson’s trichrome methods.  Sections 
were imaged using an inverted Zeiss Axiovert microscope and accompanying AxioVision 
software.  Micrographs were obtained of high powered fields (400X magnification) at the 
scaffold/host tissue interface (10 images/section; n=30 images/condition).  Characteristics 
of the local host response, such as cellularity (cell infiltration), foreign body/multinucleated 
giant cell proliferation, vascularity, and collagen content were analyzed semiquantitatively 
using ImageJ software (NIH) to quantify these components of interest in the field of view) 
(Figure 4.7).   
 Macrophage polarization was assessed by immunofluorescence double-staining of 
formalin-fixed, paraffin-embedded, 5 µm-thick section.  Sections were deparaffinized and 
heat mediated antigen retrieval with 10 mM citric acid at ph=6.0 was performed.  Primary 
antibodies for known markers of M1 and M2 macrophages, C-C chemokine receptor type 
7 (CCR7, Cell Applications; 1:250 dilution) and CD206 (Santa Cruz Biotechnology; 10 
µg/mL), respectively, were applied and sections incubated overnight at 4 °C.  Nuclei were 
counter-stained with DAPI.  Sections were imaged using an inverted Zeiss Axiovert 
microscope equipped with mercury lamp, and accompanying AxioVision software.  
Micrographs were obtained of high powered fields (400X magnification) at both the 
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interior of the scaffold (3 images/condition) and the scaffold-host tissue interface (3 
images/condition).  ImageJ software was once again used to process the images and count 
numbers of positively-stained cells for each marker (Figure 4.10).  Resulting data was used 
to compare the response in different groups and time points. 
 
4.4.1.5 Statistical Analysis: 
 Wherever possible, analysis of variance (ANOVA) was performed to identify 
differences in population means and to test for significant effects of overall factors (i.e. 
time point and treatment).  Post-hoc comparisons between means of individual conditions 
(treatment and time point) were performed using Fisher’s least significant difference test 
(LSD).  In all tests, a p-value of 0.05 or less had to be calculated to attain statistical 
significance.   
 
4.4.2 Results: 
4.4.2.1 DNA Quantification: 
 PicoGreen and OligGreen assays of pre-implanted scaffold lysates displayed 
approximately 92% and 84% reductions in dsDNA and ssDNA from native levels, 




Figure 4.4: Screening of myocardial scaffolds for DNA content: Results of PicoGreen® and OliGreen® 
quantitative assays for double-stranded (dsDNA) and single-stranded (ssDNA) DNA, respectively, in 
samples of native porcine myocardium and myocardial scaffolds prior to implantation (*: indicates statistical 
significance from native, p<0.0001). 
 
4.4.2.2 SDS Quantification: 
As shown in Figure 4.5A, the residual SDS content of scaffolds at different steps 
of the washing process following complete removal of cells was determined.  SDS 
concentration is reduced significantly to innocuous levels following the first wash step and 
remains stable for the duration of the washing procedure.  While the measured value in the 
final step in Figure 4.5A is very near zero, these were not the data from the samples used 
in the actual study; they only serve as a demonstration that SDS can be removed from 































found to be 2.402+/- 0.867 µg/cm3 tissue, which was not significantly different from the 
value measured for Biocompatibility Study 1. 
 
Figure 4.5: Screening of myocardial scaffolds for SDS content: A) Results of a quantitative assay for SDS 
content in samples of myocardial scaffolds from each of the stages of rinsing following decellularization with 
SDS.  The rinsing process is reflected by moving from left to right on the ordinate (ddi H2O = distilled, 
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deionized water, EtOH = ethanol).  B) Image of the well plate used in the SDS assay, depicting toluidine blue 
bound to SDS from the organic phase of test reactions.  Upper wells are from scaffold samples, with each 
successive rinsing step represented from left to right.  Lower wells are samples of known SDS concentration, 
which increased from right to left, used to generate a standard curve. 
 
4.4.2.3 Screening for alpha-1, 3-galactose: 
 Examination of histological sections of pre-implanted scaffolds stained for the 
presence of alpha-gal showed that the antigen had been completely removed from the tissue 
during DCELL (Figure 4.6).  This was the case in both the arterial and myocardial matrices 
of scaffolds, although only samples of the myocardial matrix were used in this study.  
Sections of explanted scaffolds stained for this antigen displayed diffuse positive staining, 
indicating that endogenous alpha-gal had been deposited by the infiltrating rat cells (data 
not shown).  
 
Figure 4.6 (below): Screening of myocardial scaffolds for alpha-1, 3-galactose: A) Micrographs of native 
A-D) and decellularized E-H) porcine myocardium and constituent coronary artery stained via 
immunohistochemistry (IHC) for evidence of the alpha-gal epitope, showing its removal as a result of the 
decellularization process. IHC positive staining = brown; A, B, E, F 10X, bar=100µm; C and D 40X, 







4.4.2.4 Semi-quantitative histological analysis of cellularity, foreign body giant cell 
proliferation, vascularity, and collagen content: 
H&E and Masson’s trichrome staining of histological sections of explanted 
scaffolds provided ideal images for analysis of these characteristics using ImageJ software 
(Figure 4.7).  Individual components of interest were readily identifiable to the naked eye, 
as well as to the software. 
 
Figure 4.7: Histological evaluation of explanted scaffolds from Biocompatiblity Study 2:  Micrographs 
of explanted scaffolds stained with hematoxylin and eosin (H&E) A and B) and Masson’s trichrome C and 
D).  The former show collagen and cytoplasm (pink), nuclei (navy blue), and red blood cells (bright red), 
while the latter show collagen (royal blue), multinucleated foreign body giant cells (FBGCs) and cytoplasm 
(red), and nuclei (maroon).  ImageJ was used in conjunction with H&E images to count nuclei and blood 
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vessels (black arrows in B), and with Masson’s images to count FBGCs (black circles in C) and measure the 
area of collagen within the field of view (All images 40X).  
 
4.4.2.5 Cell infiltration, Figure 4.8A: 
ANOVA identified a significant effect of group.  PGG-treated groups were not 
significantly different from one another, but both had significantly fewer infiltrating cells 
than the NT control (0.15%, 0.3% < NT; p<0.0001).  ANOVA also identified a significant 
effect of time point.  Significantly less cell infiltration was observed at 12 weeks than at 4 
or 8 weeks, and cell infiltration was not significantly different between 4 and 8 weeks (12 
< 4, 8; p<0.0001).   
 
4.4.2.6 Vascularity, Figure 4.8B: 
ANOVA identified a significant effect of group.  0.3% PGG-treated and NT groups 
were not significantly different from one another, but both had significantly more 
vasculature than the 0.15% PGG group (0.15% < 0.3%, NT; p<0.0001).  The amount of 
vasculature between PGG-treated groups was not significantly different until 12 weeks, 
with a significant uptick in the 0.3% PGG group.  ANOVA also identified a significant 
effect of time point.  Significantly less vasculature was observed at 12 weeks than at 4 or 
8 weeks (although this effect does not hold for the 0.3% PGG group, which had 
significantly more vascularity than the other groups at this time point).  Vascularity was 





of histological images 
of explanted scaffolds 
from Biocompatiblity 
Study 2:  A) Number of 
nuclei as counted by 
ImageJ per high 
powered field (HPF), or 
each micrograph taken 
at 40X (400X total) 
magnification; images 
were those described in 
Figure 4.7. Scaffolds 
were treated with either 
0.15% PGG or 0.3% 
PGG, or not treated 
(NT) with PGG at all 
prior to implantation.  
Scaffolds in each of the 
groups were explanted 
at either 4 weeks (4 
Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation; #: indicates statistical significance from all 
other groups except one another and 0.15% PGG, 4 Wk, p<0.0001; *: indicates statistical significance 
between specified groups, p=0.0008. ANOVA indicated there was a statistically significant effect of 
treatment; cell infiltration in 0.15% PGG and 0.3% PGG < NT, p<0.0001.  ANOVA indicated there was a 
statistically significant effect of time point; cell infiltration in 12 Wk < 4 Wk and 8 Wk, p<0.0001.  B) 
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Number of blood vessels as counted manually per HPF; images were those described in Figure 4.7.  
Explanted scaffolds were grouped according to the same conditions as described in A; #: indicates statistical 
significance from all other groups except one another and 0.3% PGG, 4Wk and 12 Wk, p<0.0001; *: indicates 
statistical significance between specified groups, p=0.0006; **: indicates statistical significance between 
specified groups, p<0.0001.  ANOVA indicated there was a statistically significant effect of treatment; 
vascularity in 0.15% PGG < 0.3% PGG and NT, p<0.0001.  ANOVA indicated there was a statistically 
significant effect of time point; vascularity in 12 Wk < 4 Wk and 8 Wk, p=0.0012.  
 
4.4.2.7 FBGC count, Figure 4.9A: 
ANOVA did not identify a significant effect of group (p=0.1725).  There were no 
significant differences between groups within the same time point.  0.3% PGG and 0.15% 
PGG groups were the closest to being significantly different from one another (p=0.1507).  
ANOVA identified a significant effect of time point.  Fewer FBGC were observed at each 
successive time point in every group (4 > 8 > 12; p < 0.0001).  While there appeared to be 
a trend of decreasing FBGC presence in the NT group, none of the means at different time 
points within this group were significantly different.  In contrast, both of the PGG-treated 
groups experienced a significant decrease in FBGC presence between 4 weeks and 12 
weeks. 
 
4.4.2.8 Collagen Content, Figure 4.9B: 
ANOVA identified a significant effect of group.  Scaffolds from PGG-treated 
groups contained significantly more collagen than the NT group, and the 0.15% group 
contained significantly more collagen than the 0.3% group (0.15% > 0.3% > NT; 
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p<0.0001).  ANOVA also identified a significant effect of time point.  A significant 
increase in collagen content was observed at each successive time point in every group (4 
< 8 < 12; p < 0.0001).  
Figure 4.9: Semi-
quantitative analysis 
of histological images 
of explanted scaffolds 
from Biocompatiblity 
Study 2:  A) Number of 
foreign body giant cells 
(FBGC) as counted 
manually per high 
powered field (HPF), or 
each micrograph taken 
at 40X (400X total) 
magnification; images 
were those described in 
Figure 4.7. Scaffolds 
were treated with either 
0.15% PGG or 0.3% 
PGG, or not treated 
(NT) with PGG at all 
prior to implantation.  
Scaffolds in each of the 
groups were explanted 
at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation; *: indicates statistical 
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significance between specified groups, p≤0.0214 in all cases.  ANOVA indicated there was no statistically 
significant effect of treatment, p=0.1725.  ANOVA indicated there was a statistically significant effect of 
time point; FBGC number in 12 Wk > 8 Wk > 4 Wk; p < 0.0001.  B) Collagen content per HPF as measured 
by ImageJ; images were those described in Figure 4.7.  Explanted scaffolds were grouped according to the 
same conditions as described in A; *: indicates statistical significance between specified groups, p≤0.0481 
in all cases (not all significant differences are shown).  ANOVA indicated there was a statistically significant 
effect of treatment; collagen content in 0.15% PGG > 0.3% PGG > NT, p<0.0001.  ANOVA indicated there 
was a statistically significant effect of time point; collagen content in 4 Wk < 8 Wk < 12 Wk, p<0.0001.  
 
 
Figure 4.10: Evaluation of explanted scaffolds from Biocompatiblity Study 2 by immunofluorescence:  
Micrographs of explanted scaffolds stained with antibodies to CD206 (green) and CCR7 (red); nuclei were 
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counterstained with DAPI (blue).   ImageJ software was used to count cells that stained positively for each 
protein, and data were analyzed to characterize the nature of the host response to scaffolds. 
 
4.4.2.9 Semi-quantitative histological analysis of macrophage polarization:  
 The ratio of cells which stained positively for CD206 to cells that stained positively 
for CCR7 in areas within the scaffold is shown in Figure 4.11A.  Initially, at 4 weeks after 
implantation the macrophage population overwhelmingly favored polarization toward an 
M1 phenotype, but the ratio reverted significantly back in favor of M2 macrophages as 
implantation time increased.  The ratio overwhelmingly favored M2 macrophages at later 
time points in both PGG-treated groups, but did not change significantly over time in the 
NT group (although it did favor M2 macrophages and did show a trend of increasing M2 
polarization).  ANOVA to test for overall effects was not possible because small sample 
size did not provide sufficient degrees of freedom. 
 The ratio of cells which stained positively for CD206 to cells that stained positively 
for CCR7 in areas immediately surrounding the scaffold is shown in Figure 4.11B.  At 4 
weeks post-implantation, the NT group already showed that much of the macrophage 
population consisted of M2 macrophages, while macrophages in the PGG-treated groups 
tended be split between the two phenotypes or slightly favored the M1 phenotype.  Over 
time, just as they did at the interior of the scaffold, the macrophages in the PGG-treated 
groups shifted drastically toward an M2 phenotype.  In the NT group, the ratio remained 
in favor of M2 but decreased significantly at the 8 and 12 week time points.   ANOVA to 
test for overall effects was not possible because small sample size did not provide sufficient 
degrees of freedom. 
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 The percentage of total macrophages (CD206+ and CCR7+ cells) which stained 
positively for CD206 within the scaffold is shown in Figure 4.12A.  There was an overall 
trend of increasing M2 percentage with time regardless of treatment with PGG.  The NT 
group had a slightly greater percentage of M2 macrophages than the PGG-treated groups 
at 4 weeks, but this was only weakly significant (p<0.0845).  As seen in Figure 4.12B, this 
same trend applied to cells at the scaffold-host tissue interface.  In fact, in NT scaffolds M2 
macrophages predominated throughout all time points, whereas PGG-treated scaffolds 
displayed a dramatic M1 to M2 shift in between 4 and 8 weeks post-implantation. 
 
Figure 4.11 (below): Semi-quantitative analysis of immunofluorescence images of explanted scaffolds 
from Biocompatiblity Study 2: A) Ratio of CD206+ (M2) macrophages to CCR7 (M1) macrophages at the 
interior of scaffolds per high powered field (HPF), or each micrograph taken at 40X (400X total) 
magnification, as counted by ImageJ; images were those described in Figure 4.10.  Scaffolds were treated 
with either 0.15% PGG or 0.3% PGG, or not treated (NT) with PGG at all prior to implantation.  Scaffolds 
in each of the groups were explanted at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-
implantation; *: indicates statistical significance from all other groups, p<0.0003; **: indicates statistical 
significance from all other groups except for 0.15% PGG at 12 weeks, p=0.0322.  B) Same ratio as described 
above, but determined from cells observed in tissues immediately surrounding the scaffolds; images were 
those described in Figure 4.10.  Explanted scaffolds were grouped according to the same conditions as 
described in A; *: indicates statistical significance from all other groups except for 0.15% PGG at 8 and 12 
weeks, p<0.0001; **: indicates statistical significance from all other groups except for 0.15% PGG at 12 
weeks, 0.3% PGG at 12 weeks, and NT at 4 weeks, p=0.0002; #: indicates statistical significance from other 

















Figure 4.12: Semi-quantitative analysis of immunofluorescence images of explanted scaffolds from 
Biocompatiblity Study 2: A) Percentage of total macrophages positive for CD206+ (M2 macrophage 
marker) in each image of the interior of scaffolds as counted by ImageJ; the remainder were positive for 
CCR7 (M1 macrophage marker).  Images were high powered fields (HPF), or micrographs taken at 40X 
(400X total) magnification; images were those described in Figure 4.10.  Scaffolds were treated with either 
0.15% PGG or 0.3% PGG, or not treated (NT) with PGG at all prior to implantation.  Scaffolds in each of 
the groups were explanted at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation; 
$: indicates weak statistical significance from other groups at same time point, p<0.0845; #: indicates 
statistical significance from other groups at same time point, p<0.0061; *: indicates statistical significance 
between specified groups, p=0.0164; **: indicates statistical significance between specified groups, 
p=0.0168.  B) Same percentage as described above, but determined from cells observed in tissues 
immediately surrounding the scaffolds; images were those described in Figure 4.10.  Explanted scaffolds 
were grouped according to the same conditions as described in A; #: indicates statistical significance from 
other groups at same time point, p<0.0001; ##: indicates statistical significance between specified groups, 
p<0.0352; *: indicates statistical significance between specified groups, p<0.04; **: indicates statistical 
significance between specified groups, p=0.0003.  
 
4.4.3 Discussion: 
4.4.3.1 General Observations: 
In summary, PGG treatment decreased cell infiltration as compared to NT 
scaffolds, and cell infiltration decreased over time among all treatment groups.  Vascularity 
appeared to correlate almost exactly with this trend.  FBGC presence decreased 
significantly over time in the PGG-treated groups, and displayed a trend of doing so in the 
NT group.  Collagen content significantly increased over time in all groups, and PGG 
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treatment significantly increased the cumulative amount of collagen formed at the implant 
site with respect to the NT group. 
It was clear that PGG-treated scaffolds degraded less over time, and that treatment 
of scaffolds with higher concentrations of PGG exaggerated this effect.  This was not only 
evident macroscopically at explantation, but also microscopically in sections of the NT 
scaffold, as scaffold remnants were considerably more difficult to identify in that group 
than in the PGG-treated groups.  Scaffold remnants were readily identifiable in PGG 
groups, even at 12 weeks after implantation.  This was not surprising given that our group 
previously showed PGG treatment of collagenous scaffolds decreased the activity of 
MMPs when in implanted scaffolds, and demonstrated PGG treatment reduced the 
susceptibility of collagen and elastin to collagenase and elastase degradatio.[11, 18] 
Despite the trend of decreasing vascularization in scaffolds over time, closer 
histological inspection of all groups at 12 weeks post-implantation seemed to indicate a 
great number of vessels within and around the implant site.  Numbers of vessels in these 
areas also seemed to be increased relative to the distal, surrounding dermis, although we 
collected no quantitative data in support of this observation.  Along with an angiogenic 
effect, the implant site was also rich with collagen.  We did not stain for collagen type III 
or prolyl-4-hydroxylase, so we cannot claim this was newly synthesized collagen.  There 
was, however, a noticeable, localized difference in shades of blue and pink staining in 
Masson’s and H&E stains, respectively.  This seemed to suggest a difference in the 
structure, and therefore, in both type and age of these areas of collagen. 
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From previous studies conducted in our lab, we know PGG slows the degradation 
of scaffolds, presumably through the physical action of crosslinking ECM proteins; but 
also by modulating the activity of immune cells.  The observation that neovascularization 
and angiogenesis in the implant area was reduced with PGG treatment seemed to correlate 
with the observed reduction in the number of infiltrating leukocytes, as they likely arrived 
at the site via the vasculature.   
FBGC presence was not significantly different between the groups, but it was 
interesting to see their numbers decline significantly over time, especially in the PGG 
treated groups.  There was also a slightly greater number of FBGC in the 0.3% PGG group 
than in the 0.15% PGG group (although not significant).  Taken together with the late 
increase in vascularity observed in the 0.3% PGG group, this might suggest that fixation 
with a greater concentration of PGG leads to a more chronic inflammatory response, or at 
least a delay in the host’s ability to respond to the presence of the implant.  
Increased collagen content with PGG treatment could be reflective of either better, 
more organized remodeling of the implant or the formation of dense, collagenous scar 
tissue at the site.  Formation of collagenous tissue could also have less to do with scarring 
and be more the product of appropriate remodeling for the implant site given its proximity 
to the dermis, which is mostly collagenous.  Alternatively, higher collagen content in the 
PGG-treated groups, especially earlier on, could be the result of scaffolds’ increased 
resistance to degradation.  Thus, the collagen being measured in these groups may not be 
newly synthesized endogenous collagen, but simply stubborn remnants of the scaffold.  
This theory is contradicted by the fact that the group treated with a greater concentration 
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of PGG did not have the greatest collagen content, as one would assume the higher 
concentration would cause more crosslinking and impart greater resistance to degradation.  
In addition, most of the scaffold area in histological sections was highly cellularized, so 
the image analysis method used to measure collagen content would not have recognized 
these areas of scaffolds as collagenous.  
   
4.4.3.2 Macrophage Polarization: 
 Macrophages in both the scaffold interior and at the scaffold-host tissue interface 
displayed a shift in polarization from the M1 phenotype to the M2 phenotype.  This effect 
was less pronounced in the NT group, however, as the population seemed to remain 
roughly split between the two phenotypes over the course of the study.  This shift occurred 
primarily between 4 and 8 weeks following implantation.  After 8 weeks, the macrophage 
population remained predominantly of the M2 phenotype. 
 It is difficult to say how these M2 macrophages arrived at the scaffold interior.  
There were very few M2 macrophages at 4 weeks in the PGG groups’ interface, but their 
number drastically increased at 8 weeks in the scaffold interior.  There were also relatively 
high numbers of M2 macrophages at 4 weeks in the NT group’s interface, but no drastic 
increase in M2 macrophages at 8 or 12 weeks in the scaffold interior.  Taken together, these 
observations seemed to indicate that M2 macrophages arrived at the scaffold interior via 
the many newly formed vessels in the area.  However, if one considers that both vascularity 
and cell infiltration were decreasing over time in all groups, it suggests that M2 
macrophages did not simply arrive at the scaffold interior as M2 macrophages, but either 
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arrived as monocytes and differentiated into M2 macrophages, or existing M1 
macrophages in the area shifted to an M2 phenotype.  Again, given the decreases in both 
cellularity and vascularity over time, the latter seemed the more likely scenario. 
 Several studies investigating the response to implanted biological scaffolds – with 
or without a cellular component – have associated adverse outcomes (chronic 
inflammation, loss of implant functionality, and scar tissue formation) with a macrophage 
population of predominantly M1 phenotype.  Conversely, responses that involved 
macrophage populations shifting from M1 phenotype to predominantly M2 phenotype 
were correlated with positive, constructive responses (recruitment of stem cells, formation 
of functional tissue).[20] 
 While the results of this study indicated that a shift from M1 to M2 phenotype 
occurred in macrophages at the implant site, it was difficult to make conclusions about the 
overall outcome based upon the tissue which was formed.  Because of the implants’ 
subdermal location, the highly vascularized collagenous tissue they were transformed into 
could be appropriate in such a site.  On the other hand, it was not clear that this tissue was 
not granulation or scar tissue.  The resultant tissue will need to be studied in more detail to 
determine the exact matrix constituents, their source, and the identities of cells before 
conclusions can be made regarding its fitness for the implant site.   
 There is evidence that chemical cross-linking of biologic scaffolds (via 
carbodiimides or glutaralehyde) limit the ability of macrophages to respond to and remodel 
the material, leading to a pro-inflammatory, M1-dominated response.[20, 24]  One study 
which focused on carbodiimide-crosslinked scaffolds noted an M2 to M1 shift between 2 
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and 4 weeks post-implantation, and a persistence of this condition out to 16 weeks.[24]  Our 
results with PGG-crosslinked scaffolds in this study contradicted these findings, 
demonstrating an M1 to M2 shift after 4 weeks of implantation.  We have no particular 
insight as to the cause of this disparity, other than the differing crosslinking mechanisms 
of the two chemicals, PGG and carbodiimide, must have caused different changes in 
structure of the scaffolds, leading to differences in the way cells responded to the material. 
Additionally, we have shown previously that PGG reduced the infiltration of 
macrophages into scaffolds composed primarily of collagen when those scaffolds were 
implanted in the same model used here.[18]  This result would seem to support the above 
claims that chemical crosslinking inhibits macrophage response, but the explanted 
scaffolds in this case were stained only against CD68, a pan-macrophage marker (not 
specific for polarization), so we could not comment as to whether this resulted in an M1-
dominated macrophage response.  Interestingly, PGG treatment did reduce cellular 
infiltration of scaffolds in the current study, but this did not result in a predominantly M1 
response, as the above study involving crosslinking predicted.  
 Limitations of this study included a lack of staining to identify specific phenotypes 
of non-monocytes, non-macrophages, and non-lymphocytes; a lack of methods to assess 
whether endogenous matrix was synthesized and, if so, what specific matrix components 
were produced.  This study also would have benefitted from the use of another method to 
measure M1 and M2 macrophage presence, such as qRT-PCR to determine gene 





 Studying the host response to biologic scaffolds is as much a matter of curiosity as 
it is practicality.  By virtue of their composition, these materials cannot be “inert”, as the 
conventional definition of biocompatibility would have us believe is a requisite for safety 
upon implantation.  Instead, they are “bioactive” and can be degraded or transformed to 
serve whatever purpose the host determines is most beneficial.  This response is mediated 
by cells of the immune system, which normally participate in inflammation and wound 
healing.  Because these cells are traditionally associated with these processes, and because 
these processes commonly have a negative connotation, it is our first instinct to perceive 
the responses to biological scaffolds in a negative manner.  But, when we understand that 
these cells constitute the only available apparatus for remodeling or repurposing an 
implanted material, we can focus on discovering the mechanisms at work behind the 
immune cell-mediated host response and developing a better understanding of the 
characteristics of the remodeled tissue.  This will serve to better inform our thought 
processes and opinions on the safety and effectiveness of therapies, particularly tissue 
engineering therapies, which are predicated upon the use of biological scaffolds.  
 The studies discussed above were designed to examine the host response to the 
myocardial scaffolds whose generation was described in Chapter 3.  We aimed to gain 
insight into how and why the scaffold would be remodeled, and to apply this to knowledge 
to our overall translational approach.  In particular, we wanted to know how long the 
scaffold would persist before it was degraded, and understand what type of local 
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microenvironment would be presented to cells that might eventually be delivered to 
damaged hearts using the scaffold as a vehicle.  
 Our results allowed us to answer these questions in a general sense.  We learned 
that fixation with PGG can extend the lifetime of scaffolds up to, and possible beyond, 12 
weeks – presumably a sufficiently long period for delivered cells to integrate with host 
tissue in future implantations of recellularized scaffolds.  We also learned that while the 
response to this scaffold does involve some elements of the classical inflammatory 
response (FBGCs), over time the environment becomes less pro-inflammatory as 
evidenced by the predominance of M2 macrophages.  Lastly, although we were unable to 
thoroughly describe the functionality, or “appropriateness”, of the tissue ultimately formed, 
it was clear that this scaffold encouraged angiogenesis, which is a very desirable quality 
for our purposes in generating functional, vascularized muscle.   
 Moving forward, we will be able to use either PGG-treated or non-treated scaffolds 
in these therapies, depending upon the desired degradation profile.  The response to 
scaffolds may also prove to be drastically different at the eventual target site, the heart, and 
when there is an autologous cellular presence within the scaffolds, as would be the case 
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CHAPTER FIVE: DEVELOPMENT OF A PLATFORM FOR IDENTIFYING 
DRIVING FACTORS IN THE DIFFERENTIATION OF STEM CELLS 
TOWARD A CARDIOMYOCYTE PHENOTYPE 
 
5.1 Introduction: 
In its infancy, Vacanti and Langer described tissue engineering as an 
interdisciplinary effort to create “functional substitutes for damaged tissue”.[1] As the field 
grew, more groups continued to develop scaffolds and attempted to repopulate, or “seed”, 
them with cell types relevant to the tissue being replaced.[1-3] It was soon recognized that, 
regardless of the source or type of cells used, static seeding and culture methods were 
insufficient to produce organized, highly populated constructs with well-differentiated and 
functional cells, and the importance of incorporating extracellular factors such as 
mechanical, electrical, and biochemical stimuli was realized.  In order to mimic the 
structure and function of native tissue more closely, tissue engineers began seeking a means 
to allow their constructs to mature, or be “conditioned”, by these extracellular stimuli, and 
they developed bioreactors for this purpose.  Bioreactors are specially designed, self-
contained systems which provide for the adjustment and control of specific conditions (e.g. 
pH, oxygen concentration, nutrient supply, mechanical forces, and electrical impulses) to 
simulate the dynamic surroundings and processes which support the functions of native 
tissue.[2, 4]  
 As critical as delivering the correct stimuli to cells may be, choosing a source of 
stem cells with the appropriate characteristics may be even more important.  Large 
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quantities of cells are necessary to produce recellularized tissue-engineered grafts, so these 
cells must be either abundant at the source or proliferative to the extent necessary to 
repopulate scaffolds at the cell density of native myocardium (200 million cells/cm3).[5]  
These cells must also be compatible with the recipient’s immune system and be of the 
proper phenotypes (i.e CM, cardiac fibroblasts, vascular smooth muscle cells, and 
endothelial cells) which comprise the myocardium (or possessed of the ability to 
differentiate into them).  In view of these criteria, the cell source of choice should be 
autologous cells (i.e. from the recipient patient) which are clonally expanded, differentiated 
ex vivo, and implanted as a component of a tissue-engineered therapy.   
Recently, the approach of using IPSC generated from fibroblasts, BM-MSC, or 
other terminally differentiated adult cells has been popularized.  This approach can be used 
in myocardial tissue engineering strategies as an autologous therapy if the somatic cells 
used to generate IPSC are harvested from the patient for whom the tissue-engineered graft 
is intended.  This method uses transfection of either retroviral vectors or episomes 
containing plasmid DNA or other vectors to first dedifferentiate the somatic cells into 
IPSC.[6]   
These cells can then be differentiated into a CM phenotype followed by specialized 
low attachment/suspension culture techniques to generate embryoid bodies and subsequent 
treatment with WNT signaling molecules.[7, 8]  There are also protocols that use the 
principle of induced pluripotency, but differentiate somatic cells in to CM in a more direct 
process, without an intermediate step wherein IPSCs are generated.[9]   
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A major disadvantage of using IPSCs is that concerns remain over their stability 
once dedifferentiated, specifically whether the epigenetic reprogramming strategies, either 
retroviral or molecular, might cause unintended changes in expression or regulation of 
other genes.  This could lead to undesirable consequences once the pluripotent cells are 
differentiated and implanted, such as tumor formation.[10-12]  While they may seem highly 
conjectural, these concerns could derail progress of any therapies based on IPSCs toward 
clinical translation.  
After consideration of available cell sources and their respective pros and cons, we 
identified ADSCs as the most ideal fit in view of the criteria presented above.  These cells 
are highly abundant within subcutaneous fat, with about 100-300 x 106 cells/100-500 g of 
adipose tissue.  More importantly, harvest of this tissue is accomplished through a 
minimally invasive liposuction procedure, which can generate between 100 mL to 3 L of 
lipoaspirate per procedure.  Processing of lipoaspirate to isolate ADSC is also a well-
established process that can be automated and even performed in the operating room.[13, 14]   
The ability of ADSC to differentiate into CM, EC, and VSMC lineages has not been 
widely demonstrated. However, it has been well-established that they can become 
osteoblasts, chondrocytes, and adipose cells.  Given this demonstrated multipotency, it’s 
not far-fetched to believe they can differentiate into CM, EC, or VSMC if subjected to the 
right conditions.  Additionally, in vitro cultures of ADSC have shown a reduction in major 
histocompatibility complex expression with progressive passages, possibly suggesting they 
could be used allogeneically.[14]  This mode of use would need to be proven safe in separate 
clinical trials, as it is possible that expression of these complexes is only suppressed in 
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vitro, and could return once the cells are transplanted into a new host.  Furthermore, a 
comprehensive post-hoc analysis of their effectiveness in an array of clinical trials for MI 
treatment was recently conducted, and many of the results appeared promising.[15]  
The studies described in the next few sections were aimed at evaluating the 
potential of select stimuli that mimic the cardiac environment to cause differentiation of 
ADSC toward a CM phenotype.  They were designed as part of the overall project aims, 
and in accordance with the tissue engineering paradigm of using bioreactors to apply 
stimuli to scaffolds seeded with stem cells.  As will be detailed in the introduction to each 
study, evidence from the literature was also used to construct detailed aspects of these 
experiments and the methods and systems used within.  
 
5.2 Pilot Study: Differentiation of hADSC Cultured Statically on Decellularized 
Myocardial Scaffolds: 
5.2.1 Introduction:  
 There is little evidence in literature of a robust protocol for differentiation of 
hADSC or MSC into CM.  Successful studies are anecdotal, especially in human cells, and 
the efficiency of differentiation protocols is low (≈50% of original cells were differentiated 
at best).[16, 17]  Some studies demonstrated that varying the surface chemistry of the 
substrate for cell growth, such as coating with laminin, can have a positive effect.[16]  Others 
have shown that varying surface topography of the substrate can also have a 
cardiomyogenic effect.  In addition, effects of both these variables on differentiation have 
been enhanced by the concurrent application of 5-aza-2-deoxycitidine (AZT), a DNA-
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demethylator.[16, 18]  In brief, AZT inhibits the action of DNA methyltransferase enzyme, 
leaving portions of the genome unmethylated and therefore more accessible to binding by 
transcription factors that may be upregulated as a result of signaling cascades activated by 
changes to the substrate or the application of other stimuli.[19]   
These studies supported the idea that a possible mechanism for inducing cell 
differentiation was simply the characteristics of the substrate (i.e. structure and 
composition), so we were interested in studying the effect of our DCELLed myocardial 
scaffold, which was shown to preserve proteins that mediate cellular attachment (e.g. 
laminin, collagen IV, and fibronectin) and therefore play a role in mechanotransduction.  
By virtue of this characteristic, they may have the potential to affect differentiation of cells 
grown on scaffolds, even in the absence of dynamic mechanical stimuli. 
 
5.2.2 Methods: 
5.2.2.1 Scaffold preparation, cell seeding, AZT stimulation, and cell culture: 
 Human adipose-derived stem cells (hADSC) were seeded onto DCELLed, sterile 
myocardial scaffolds (prepared by whole heart DCELL and peracetic acid sterilization as 
previously described) at 3x106 cells/scaffold and cultured for 7 days.  In addition, hADSCs 
were seeded in standard, 6-well, tissue-culture plastic plates at 50,000 cells/well and 
cultured during the same period; this group served as a negative control for the effect of 
the scaffold.  At this point, scaffolds and well plates were either treated with 9 µM AZT 
for 24 h or left untreated (n=1 for scaffolds; n=6 for well plates).  Cells in all conditions 
were then cultured for an additional 3 weeks before being processed for analysis via 
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histology, immunofluorescence and IHC, quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR), Western blotting, and ELISA to evaluate gene and protein 
expression of the CM markers alpha-actinin, connexin 43, troponin T, troponin I, beta 
myosin heavy chain, and desmin. 
 
5.2.2.2 Isolation of mRNA and protein: 
 Cells on scaffolds and culture plates were harvested and processed to isolate mRNA 
and cellular protein using Trizol™ reagent (Invitrogen).  For cell on scaffolds, scaffold 
samples (n=1) were first flash frozen in liquid nitrogen, fractured into small pieces using a 
Biopulverizer (BioSpec, Bartlesville, OK) and then processed according to the Trizol 
isolation process for mRNA and protein.  
 For cells on well plates, culture media was aspirated and wells (n=3) were rinsed 
with warm, sterile PBS.  One mL of Trizol reagent was added to each well and the wells 
were incubated for 5 min at room temperature.  A cell scraper (BD Biosciences) was used 
to scrape cells free of the culture surface, and the solution was collected in a sterile, 
nuclease-free tube.  To lyse cells, the solution was aspirated and forcefully passed through 
a 26-guage needle several times.  The sample was processed according to the Trizol 
isolation process for mRNA and protein. 
 
5.2.2.3 Histology, immunofluorescence, and IHC staining: 
Following standard formalin-fixation and paraffin embedding, 5 µm-thick sections 
were prepared and stained with H&E. 
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Formalin-fixed, paraffin-embedded, 5 µm-thick sections were deparaffinized and 
heat mediated antigen retrieval with 10 mM citric acid at ph=6.0 was performed.  Primary 
antibodies for alpha-actinin, troponin T, connexin 43, and desmin (Abcam; 4 µg/mL) were 
added to sections and incubated overnight at 4 °C.  At this point, sections were labeled with 
the correct secondary antibody for the application (i.e fluorescently conjugated for IF or 
biotinylated for IHC).  Sections were counterstained with dilute (1:1) hematoxylin in 
distilled, deionized water (IHC) or with DAPI (IF). 
 
5.2.2.4 Western blotting: 
 In order to normalize the amount of protein in samples used for Western blotting, a 
bicinchoninic acid (BCA) assay (Pierce) was used to quantify protein concentration in the 
samples isolated as described above.  To prepare samples for electrophoresis prior to 
blotting, the sample volume necessary to obtain 20 µg of protein was calculated, and 
diluted in reducing buffer containing 1 µL β-mercaptoethanol (βME)/20 µL.  
Electrophoresis and transfer were run at standard conditions.  Blots were labeled with 
primary antibodies to desmin, troponin T, and connexin 43 (Abcam, 1 µg/mL, 1 µg/mL, 
and 0.128 µg/mL) and detected using secondary antibody and other reagents supplied in a 
BM Chemiluminescence Western Blotting Kit (Roche).  Blots were imaged on a BioRad 
ChemiDoc system and bands were analyzed for relative intensity (densitometry) and 





5.2.2.5 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
 The concentration of isolated mRNA was measured using a NanoDrop 2000 
benchtop spectrophotometer (Thermo Scientific), and a total of 1 µg of mRNA was 
reverse-transcribed using M-MLV reverse-transcriptase enzyme and other reagents 
supplied in an Ambion RT kit (Invitrogen).  Resultant complimentary DNA (cDNA) and 
SYBR Green Master Mix (Invitrogen) were used to prepare reactions for qRT-PCR.  
Reverse transcription and PCR reactions were run on a RotorGene cycler (Qiagen).  
Relative expression of markers was calculated using the 2-ΔΔCt method.[20] 
 
5.2.2.6 Enzyme-linked immunosorbent assay (ELISA): 
 ELISA for troponin I was performed on samples of protein isolated as described 
above.  Samples were prepared to contain 10 µg protein, and were run using reagents and 
instructions supplied by a cardiac Troponin I ELISA kit (Calbiotech).  The blue color 
evolved by addition of the supplied detection reagent was measured spectrophotometrically 
at 450 nm.  Sample concentrations of troponin I were calculated according to the 
relationship between known concentration and OD established by the supplied standard 
curve samples.  
 
5.2.3 Results: 
5.2.3.1 Histology, immunofluorescence, and IHC staining: 
 H&E staining of seeded scaffolds showed the presence of hADSCs, mainly 
concentrated several layers-thick on the outer surface, although some pockets of cells were 
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identified within the scaffolds (Figure 5.1 middle).  Immunostaining for the above markers 
on scaffolds revealed cellular expression of alpha-actinin, connexin 43, and desmin 
(Figure 5.1 top and middle).  Correspondent staining of hADSC grown on culture plastic 
appeared less intense (Figure 5.1 bottom).  Upon inspection of these images, AZT 
treatment did not appear to affect the expression of the proteins in cells on scaffolds, but 
seemed to cause increased expression of CX43 and troponin T in cells grown on culture 
plastic.  Sections were imaged using an inverted Zeiss Axiovert microscope equipped with 






Figure 5.1. Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial 
Scaffolds by IHC and IF : At top, Images of IHC-stained sections of scaffolds seeded with hADSCs and 
cultured for 4 weeks show expression of the indicated proteins.  At 7 days, cell-seeded scaffolds and culture 
plates were either treated with 5-aza-2-deoxycytidine (+AZT) or not (-AZT). At middle, IF images of the 
same scaffolds show positively stained sections (green) counterstained with DAPI (blue) and H&E-stained 
sections display tissue morphology of seeded scaffolds. At bottom, IF images of cells on culture plastic 
stained in the same manner. IHC positive staining=brown; all images 40X, bar=20µm. 
 
5.2.3.2 Western blotting: 
When assayed for relative expression of the same markers by Western blotting, 
however, intensity of the bands produced by cells on culture plastic was greater than that 
of cells on scaffolds (Figure 5.2).  This relationship held regardless of treatment with AZT.  
Treatment with AZT significantly increased protein expression of troponin T and desmin 
in cells grown on culture plastic, and there was a trend suggesting the same effect in cells 
grown on scaffolds, although low sample numbers did not permit analysis for statistical 




Figure 5.2: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial 
Scaffolds by Western blotting: Western blotting and densitometry calculations of the resulting bands 
quantify relative expression of specific proteins in hADSCs seeded and cultured statically on scaffolds and 
hADSC cultured with standard methods on cell culture plastic.  Cells in each condition were also either 
treated with 5-aza-2-deoxycytidine (+AZT) or not (–AZT); *: indicates statistical significance from 
corresponding –AZT, p=0.0471. 
 
5.2.3.3 qRT-PCR: 
 Gene expression as measured by qRT-PCR showed that CX43 and troponin T were 
slightly upregulated in hADSCs on scaffolds as compared to hADSCs grown on culture 
plastic, while desmin and beta myosin heavy chain were both downregulated, all in the 






































to increase expression of any of the markers of interest when directly comparing cells 
grown on the two different substrates.  When the effect of AZT was studied within cells 
grown on the same substrate, AZT significantly increased expression of troponin T and 
βMHC, and showed a trend of increased expression of desmin in cells on culture plastic 
(Figure 5.3A).  AZT treatment also showed a trend of increased expression of desmin and 
βMHC in cells grown on scaffolds.  It did not significantly descrease expression of the 






Figure 5.3: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial 
Scaffolds by qRT-PCR:  A) Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
performed on RNA isolated from hADSC-seeded and cultured statically on scaffolds and hADSC cultured 
with standard methods on cell culture plastic.  Cells in each condition were also either treated with AZT or 
not treated.  Expression is reported as the fold change in expression of each gene in each group relative to 
expression in its non AZT-treated counterpart (represented with a value of 1); *: indicates statistical 
significance from non AZT-treated control, p=0.002; **: indicates statistical significance from non AZT-
treated control, p=0.029.  B) qRT-PCR performed on RNA isolated from the same conditions as above.  
Expression is reported as the fold change in expression of each gene in the scaffold group relative to 
expression in the culture plastic group (represented with a value of 1).  Cells in each condition were also 
either treated with AZT or not; *: indicates statistical significance from culture plastic group, p=0.045; **: 
indicates statistical significance from culture plastic group, p=0.0314; #: indicates statistical significance 
from culture plastic group, p=0.039; ##: indicates statistical significance from culture plastic group, 
p=0.0573. 
 
5.2.3.4 Enzyme-linked immunosorbent assay (ELISA): 
 ELISA for troponin I found none of this marker was present in cells grown on 
culture plastic regardless of treatment with AZT.  In contrast, cells grown on scaffolds were 
found to express troponin I, and treatment with AZT appeared to enhance expression of 





Figure 5.4: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial 
Scaffolds by ELISA: Enzyme-linked immunosorbent assay (ELISA) was used to quantify expression of 
troponin I in protein isolated from hADSCs seeded and cultured statically on scaffolds (S) or on cell culture 
plastic (P).  Cells in each condition were also either treated with 5-aza-2-deoxycytidine (+AZT) or not (–
AZT); hADSCs cultured with standard methods on cell culture plastic (P) did not contain measurable 
amounts of the protein. 
 
5.2.4 Discussion: 
 The markers studied here all play critical roles in the functionality of CM (as 
discussed in sections 1.5.5.1 and 1.5.5.2).  CX43 is a gap junction protein through which 
calcium ions are transported in order to facilitate propagation of an excitation stimulus.  






















Relative cardiac troponin I Content of 
hADSCs on Scaffolds vs. Culture Plastic
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T and I are components of the troponin complex, which forms part of the larger 
tropomyosin complex.  The troponin complex is found near the heads on myosin filaments 
and normally impedes their binding to actin filaments unless the complex is bound by a 
calcium ion.[23]  Thus, this complex represents an important intermediary in the mechanism 
of sliding filament muscle contraction.  Desmin is an important intermediate filament 
protein which links the contractile apparati of CM with one another at Z-disks and to other 
components of the cell, including the nucleus and mitochondria.  Collectively, this 
maintains the structural and mechanical integrity of CM during contraction, and aids in 
both force transmission and longitudinal load bearing.[24, 25]  It may also play a role in 
connecting the sarcomere to the ECM within desmosomes, thus forming a mechanical 
linkage between the ECM and sarcomere useful in mechanotransduction.  Similar to 
desmin, alpha-actinin plays a mechanical role by anchoring the actin filaments in CM to 
the Z-disc.[26] 
 In light of their functions, it is clear to see why we chose these proteins as the focus 
of this initial differentiation experiment.  Since we were studying the effect of the substrate 
on the differentiation of bound cells, it was incumbent upon us to select markers with an 
established role in the attachment and mechanotransduction pathways of CM.   
When cultured on scaffolds, hADSCs expressed cardiac genes and proteins 
regardless of treatment with AZT (which was expected to increase marker expression), 
implying that the myocardial scaffold might possess some intrinsic characteristics that 
cause this expression.  These characteristics likely include the composition (collagen, 
elastin, fibronectin, basement membrane proteins) and architecture (pore size, ECM 
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organization), which together provide signals to hADSC through mechanotransduction that 
may upregulate the gene and protein expression of these markers.[27]    
 There was also some evidence that treatment of cells grown on either substrate with 
AZT might have increased expression of these markers, but more supporting data must be 
collected before this claim can be made.  When deciding whether to include AZT as part 
of a differentiation protocol, some consideration must be given to nonspecific and 
widespread deleterious changes the chemical could produce in the genome and its structure.  
AZT has been commonly studied as an anti-cancer treatment, mainly because it has the 
ability to induce cytotoxicity by causing DNA damage (i.e. strand breaks)[28]  Dosages and 
concentrations used in these studies were on par with those used here, so some of these 
effects could be imparted on hADSCs seeded on scaffolds.  These effects, and consequently 
the use of AZT, may be undesirable outside of the context of cancer treatment or other 
more suitable applications. 
 It was noteworthy that hADSCs grown on culture plastic (i.e. “undifferentiated” 
cells) expressed CX43, troponin T, and desmin in at least a minimal level.  In retrospect, 
we found that some groups who have carried out extensive analysis of the expression 
profile of hADSCs found that CX43 is normally expressed in these cells.  Since they have 
been theorized to be of a perivascular phenotype, they may employ CX43 in intercellular 
signaling with endothelial and smooth muscle cells as part of their normal function.[13]  
It would be more beneficial in the context of an experiment such as this, which is 
focused on differentiation of cells, to measure a marker that is not constitutively expressed 
in the initial, undifferentiated phenotype.  However, given the importance of CX43 to CM 
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function, it will still be critical to demonstrate its expression in the differentiated cell 
population.  As such, we will continue to measure it in future differentiation experiments 
with the aim of demonstrating the development of a CM phenotype.  
That said, in order to posit differentiation of these cells in experiments where 
dynamic stimuli will be applied, increased expression of these markers must be observed 
with respect to unstimulated control cells, as well as expression of other cardiac markers 
in the stimulated cells with little to no expression in the control cells (i.e. differential 
expression suggesting a change in phenotype).  This effect was best illustrated in this study 
by ELISA for troponin I, which was only present in cells grown on scaffolds.  In addition, 
there was some indication that culture of hADSCs on scaffolds resulted in increased 
expression of a few of these markers with respect to cells grown on culture plastic, as seen 
in the IF staining.  Aside from those specific results, this study largely demonstrated the 
opposite outcome, specifically Western blots which showed greater expression of CX43, 
troponin T, and desmin in cells cultured on plastic as opposed to scaffolds.  It’s possible 
that this result was skewed by the presence of solubilized matrix proteins in samples of 
seeded scaffolds.  This extracellular protein could have contributed to the total 20 µg of 
protein which is normally run in all samples to normalize them so they may be 
quantitatively compared.  Consequently, the protein samples from the seeded scaffolds 
might have contained a smaller proportion of cellular protein compared to those samples 
isolated from cells grown on tissue culture plastic.  So, while samples from both groups 
were found to contain the proteins of interest, samples from the cells on culture plastic 
might not have contained more of those proteins if there had been a correction for the 
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extraneous extracellular proteins.  A control will need to be devised to account for the 
presence of these proteins in future experiments wherein the undifferentiated control group 
consists of cells grown on culture plastic. 
   
5.2.5 Conclusion:     
 Use of myocardial scaffolds as a substrate for hADSC growth precipitated 
expression of cardiac genes and proteins regardless of treatment with AZT (which was 
expected to increase marker expression).  Although evidence of increased expression of 
these markers in cells on scaffolds with respect to cells on culture plastic was less abundant, 
the structure and composition of myocardial scaffolds could be an inductive mechanism 
for cardiomyogenic differentiation of hADSCs.   
This study focused only on the effect of the DCELLed myocardial scaffold as a 
substrate in differentiating hADSCs into CM.  Its findings, while of interest, neglected 
variables such as electrical and mechanical stimuli which we believe are necessary to 
achieve full differentiation of stem cells into a CM phenotype.  The system described in 
the next section of this chapter was designed with the idea of incorporating such factors in 
mind.  
 
5.3 hADSC Differentiation with Flexcell System:  
5.3.1 Introduction: 
To date, many groups have recognized the need for reproducing the physiological 
stimuli observed in the cardiac macro- and microenvironments in order to generate more 
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biomimetic constructs or grafts.  Eschenhagen and colleagues demonstrated the beneficial 
effects of the application of mechanical strain on engineered heart tissue, noting increased 
CM alignment, sarcoplasmic protein organization, and concomitant enhancement of 
contractile force generation in the stretched constructs.[29] The effects of electrical 
stimulation have been studied and reviewed extensively by Vunjak-Novakovic’s group, 
among others, who have shown that culturing myocardial tissue-engineered constructs in 
the presence of electrical fields with defined parameters can encourage development of 
electrical connectivity and excitability of CM, as evidenced by increased expression of 
connexin 43, lowered excitation thresholds, and increased stimulus capture rates.[30, 31] Few 
groups, however, have taken these two most defining stimuli of the cardiac environment 
and applied them simultaneously to cell-seeded constructs.[32]  Even fewer have recognized 
the natural interplay between them in the excitation-contraction coupling of the 
myocardium and attempted to mimic this within a bioreactor by carefully synchronizing 
timing, duration, and characteristics of electrical impulses and mechanical forces.[33-35]   
Wang et al. recently investigated the effects of coordinated electrical and 
mechanical stimuli on DCELLed myocardium scaffolds reseeded with rat mesenchymal 
stem cells. They observed positive immunostaining for the cardiac markers myosin heavy 
chain, sarcomeric α-actinin, cardiac troponin T, connexin43, and N-cadherin but did not 
analyze gene and protein expression of the cells within their constructs following culture 
and stimulation.  Most importantly, they did not observe contractile behavior in their 
constructs, nor did they find any direct evidence of electrical activity or connectivity 
between the constituent cells.[35]  It is likely this is due to their use of too few seeded cells; 
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the roughly 833,000 cells/cm3 density of their constructs did not allow for the necessary 
proximity of cells to produce intercellular connectivity.  
As discussed in previous sections, cells within a tissue-engineered graft should be 
functional (contractile and able to integrate with the host cardiac conduction system) upon 
implantation.  Otherwise, the graft does not help alleviate the mechanical dysfunction 
which leads to remodeling and CHF.  Thus, characterizing changes in stem and progenitor 
cells which have been exposed to physiological stimuli in bioreactors becomes a key 




5.3.2.1 System Design:  
This platform was designed to integrate the mechanical and electrical stimulation 
of cells seeded on DCELLed myocardial scaffolds, and to allow for precise control of the 
characteristics of these two stimuli.  Design inputs included:  1) means of applying a 
uniaxial tensile force of up to 140 mmHg to a cell-seeded construct, with the ability to 
control characteristics of the waveform 2) means of applying at least 2 V electrical stimulus 
to seeded constructs, with the ability to control other characteristics of the waveform 3) 
means to coordinate the timing of delivery of these two stimuli to the construct, and in such 
a manner so as to allow for changing how the two waveforms overlap in successive 
experiments 4) allow for conventional culture of seeded constructs in a standard incubator 
with standard media, and facilitate convenient changing of media every 2-3 days 5) 
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accommodate a sufficient number of experimental replicates to achieve statistical 
significance among experimental groups in measured endpoints. 
A commercially available system sold by Flexcell International Corp. served as the 
basic component around which this platform was designed (Figure 5.5).  The system was 
sold under the name FX-5000™ Compression System, and was comprised of a main 
controller housing with pressure regulators, valves, and transducers used to precisely 
control the flow of compressed air into a baseplate upon which four 6-well plates were 
attached (Figure 5.5B and C).  The bases of the 6-well plates were hermetically sealed 
against rubber gaskets on the baseplate by means of telescoping bolts that clamped the well 
plates to the baseplate (Figure 5.5E).   
The system functioned by pumping compressed air into the space beneath the 
baseplate and the well plates above, forcing the membrane at the bottom of each well 
upward (Figure 5.6F).  The result was that the membrane moved upward like an inflating 
balloon when air was pumped into the baseplate and returned downward to a flat position 
when air pressure was released.  This movement was very similar to the motion of the left 
ventricular free wall during diastole and systole, and was used to simulate just that.  The 
accompanying Flexcell software was used to create a pressure waveform modeled after the 
left ventricular pressure waveform observed during the cardiac cycle (Figure 5.6A).  A 
pressure transducer was used to measure the real-time pressure applied to the silicone 
membrane, and the data was fed to a custom-written LabView program.  This program was 
designed to deliver an electrical pulse which was triggered when the pressure reading 
reached a specific value input by the user (Figure 5.6A an C).  In other words, the LabView 
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program was used to tightly control the relative temporal delivery of both mechanical and 
electrical stimuli to samples contained within the well plates.  This fact allowed us to 
simulate the excitation-contraction behavior of cardiac muscle in an effort to expose 






Figure 5.5: Design of Flexcell system:  A) Schematic illustration of main components of the Flexcell system.  
B) An incubator containing the modified Flexcell® system comprised of tubing, baseplate, and 6-well plates 
with silicone membranes pumps air into the baseplate shown in C, where E) telescoping bolts are used to 
seal the edges of F) modified 6-well plates against a rubber gasket.  D) Flexcell controller (2 bidirectional, 
software-controlled valves inside) and data acquisition (DAQ) modules, which collectively enable all 






Figure 5.6: Detailed operation of Flexcell system:  A) Screenshot of display from computer used to 
control the Flexcell system.  The window at back left is the Flexcell software, running the programmed 
regimen and displaying pressure waveform data collected by the Flexcell controller’s pressure transducers.  
The window at front right is the LabView program, displaying pressure waveform data from a pressure 
transducer which was tapped into the positive pressure line running to the Flexcell baseplate.  This data was 
acquired by one data acquisition (DAQ) module and fed into the LabView program; this program triggered 
an electrical pulse, output by a second DAQ module, every time the pressure fell within a user-defined 
range (in this case, at the rising edge of each pressure wave).  A, C) This trigger is illustrated by two virtual 
LEDs in the LabView display (dashed yellow ovals), which indicate the status of the pulse by lighting up 
with an “ON” or “OFF”.  E,F) Pressure from air pumped into the baseplate (blue arrows in F) with 6-well 
plate sealed atop it causes upward deflection of the silicone membrane in each well.  Scaffolds are shown in 
F with horizontal ends fixed in place at the sides of each well.  When the membrane deflects upward under 
pressure, a resultant uniaxial tensile force (black arrows with yellow outline in E and F) is applied to the 
scaffold.  F) Heat map illustration of the potential field and graph of electrical potential vs. position 
generated from a Comsol™ model based upon the well and electrode dimensions and the applied electrical 
pulse.  The region of interest (R.O.I.), or the area of scaffold where the effects of mechanical stimuli and 
electrical stimuli will both be applied to seeded cells, is indicated with a dashed box.  B, D) Auxiliary setup 
for plates receiving only electrical stimuli; these plates could not be kept in the same incubator as those 
receiving mechanical stimuli because said incubator was set at a higher temperature to offset the cooling 
effect of running compressed air through the baseplate.  D) The LabView program responsible for 
delivering the electrical stimulus to electrical only plates; the characteristics of the pulse (amplitude, 







5.3.2.2 Modified Flexcell Well Plate Design: 
We modified Flexcell Bioflex® 6-well plates by attaching customized, plastic well 
inserts to the lid of each plate using a combination of cyanoacrylate glue and silicon sealant 
in order to provide a watertight seal (Figure 5.7A, B, F, H).  The inserts were designed to 
accommodate a 1-2 mm thick, 3.5 cm x 2 cm rectangular scaffold sheet that had been 
seeded with cells.  Inserts held the sheets stretched directly above the silicone membrane 
by providing fixation points for the edges of each sheet at the periphery of the well on 
opposing sides (Figure 5.7E and Figure 5.6F).  Once stretched across the diameter of the 
well, each sheet was clamped between the bottom of the insert and a ring which fastened 
to the insert via a snap hook mechanism (Figure 5.7E).  This ensured that as the membrane 
deflected upward under pressure, the seeded scaffolds were subjected to a uniaxial tensile 
force (Figure 5.6E).  A lock-in-groove feature was included between the rings and inserts 
to prevent slippage of the sheets over time due to cyclical application of tensile force 
(Figure 5.7C and D).   
The inserts also incorporated fixtures for two cylindrical, 3 mm-diameter, carbon 
electrodes which were positioned parallel to each other but perpendicular to the direction 
of the tensile force (Figure 5.7F, G, and H).  The electrodes (one positive, one negative) 
were wired to electrical adapters through a network of wires attached to the lid of the plate 
(Figure 5.7G).  The wiring and inserts were both attached to the undersides of the plate 
lids to facilitate media changes in the wells.   
Plates were connected to the electrical signal output from the LabView program, 
and the pulses delivered to them resulted in the development of an electrical field within 
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each well, the direction of which was parallel to that of the tensile force applied to the 
scaffolds (Figure 5.6F).  Scaffolds lay directly below the electrodes such that cells seeded 






Figure 5.7: Design of Flexcell plates and well inserts:  A) CAD rendering of a well insert and the B) 3D-
printed ABS plastic part produced from the same SolidWorks file.  C) Protrusions from the bottom of the 
well inserts were designed to lock with grooves on the accompanying locking ring shown in D.  E) Scaffold 
sheets were secured near the bottoms of wells at both ends by stretching the sheets across the well inserts and 
then placing a locking ring over them.  Sheets were clamped between the two parts and held securely by 
means of the lock-in-groove feature described above; compression was maintained by 4 snap-hooks (black 
arrows) that retained the locking ring in close apposition.  F)  Fully-assembled lid of a Flexcell plate used for 
groups receiving electrical stimulation, with well inserts attached by super glue and silicone sealant.  G) 
Carbon electrodes (black rods) were used to create an electrical potential within each well, and are shown 
connected to larger wires (yellow and green) via thin platinum wire (black arrows).  The ends of the electrodes 
fit inside hollowed-out channels, allowing them to slide up and down with the motion of the scaffold as it 
was mechanically stretched.  For groups that did not receive mechanical stimulus, electrodes were not 
attached and plates were not wired.  H) Each circuit, consisting of a positive and negative electrode, was 
wired to a single connector (black part at left) that conducted electrical impulses produced by a data 
acquisition module. 
 
5.3.2.3 Experimental Setup:  
We surmised there were 4 major stimuli that determined the nature and degree of 
hADSC differentiation into CM: mechanical stimulation (M), electrical stimulation (E), 
substrate properties (S; scaffold vs. no scaffold/silicone membrane only), and 
pharmacological stimuli (P; AZT-treated).  We used the Flexcell system’s ability to 
accommodate many samples (n=24) to our advantage in achieving this aim – to discover 
which of these stimuli had the greatest impact on hADSC differentiation, and to determine 
if there was any synergistic effect between them in this respect.  For the first experimental 
run using the Flexcell system, 4 different conditions were tested: 1) M+E+S, 2) M+S; 3) 
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M+S+P; 4) E+S (referred to hereafter as E+M, M, M+AZT, and E, respectively).  We used 
one, 6-well plate per condition (n=6), and hADSC were seeded onto each scaffold via 
injection through a small-diameter needle at various points in the area between the two 
electrodes.  Upon completion of 3 weeks of culture under the conditions listed above, the 
scaffolds were collected in order to characterize the extent of hADSC differentiation into 
CM.  
At the conclusion of culture in this system, sections of seeded scaffolds from each 
well were divided up and processed for various methods of evaluation: 1) fixation in 4% 
paraformaldehyde for histology and immunofluorescence/IHC; 2) isolation of protein and 
RNA via homogenization and Trizol® reagent for Western blotting and qRT-PCR, 
respectively; 3) preservation in cell culture media for tests of cell/tissue functionality and 
viability, including Live/Dead assay and live cell calcium imaging using Fluo-4. 
Statistical analysis techniques, including multivariate analysis of variance 
(ANOVA) and post-hoc contrast analysis of means via Fisher’s least significant difference 
test, were used to determine main effects and interactions of the 4 stimuli tested on the 
measured outcomes. 
 
5.3.2.4 Preparation of Scaffolds: 
Scaffolds were prepared by first dissecting 2.0 x 3.8 cm rectangular segments of 
DCELLed myocardial scaffold generated via whole heart DCELL.  Then, 1-2 mm thick 
layers of these segments were sheared off using a scalpel to generate scaffold sheets.  
Sheets were washed 3X (1 h, 3 h, 1 h) before being sterilized with 0.1% peracetic acid in 
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PBS at pH 7.4 (2X; 30 min, 1 h).   Sheets were then washed with sterile PBS 3X (1 h, 3 h, 
1 h) in preparation for cell seeding. 
 
5.3.2.5 Cell Seeding and AZT stimulation: 
Each sheet was incubated overnight at 37 °C in DMEM with 10% FBS.  
Immediately prior to seeding, the excess media was removed from the sheets and they were 
incubated another 2 h at 37 °C in an attempt to slightly dehydrate the scaffolds.  The 
rationale was that cell solution would be more likely to penetrate a slightly dehydrated 
scaffold than one that was swollen with media, increasing the effective density of seeded 
cells.  We used a cell culture scale-up apparatus, the CellSTACK® (Corning), to produce 
sufficient numbers of cells for this study.  Once the sheets were secured to the inserts, a 
suspension of hADSCs was injected at several random points in the center of each sheet, 
and a total of 3.1 x 106 cells were seeded onto each sheet.  The remainder of the cell 
suspension solution was drop-seeded onto the upper surface of each sheet, and the seeded 
scaffold sheets were placed in wells with no media and incubated for 4 h at 37 °C to allow 
cells to attach to the sheet.  About 6.5 mL of media was placed in each well and the sheets 
were cultured statically for another 20 hours.  At this point, scaffolds in the M+P+S 
(M+AZT) group were treated with 9 µM AZT and cultured for an additional 24 h, while 






5.3.2.6 Construct Attachment and Stimulation Parameters: 
Seeded myocardial scaffolds were placed across the space between the two 
extensions of each well insert, and clamped into place using the rings as previously 
described (Figure 5.7E). 
In its final configuration, a 3.6 cm2 rectangular area of hADSC-seeded myocardial 
scaffold received user-controlled, synchronized, and cyclic mechanical and electrical 
stimulation (Figure 5.6F).  This area would serve as the region of interest (R.O. I.) for all 
methods performed to assess differentiation.  These stimuli were adjusted to mimic those 
of the native cardiac environment as closely as possible, with a cyclic pressure waveform 
(0-120-0 mmHg amplitude in 350 msec with 450 msec static at 0 mmHg, 1.17 Hz or ~70 
BPM) and a 5V (2.78 V/cm), 20 msec-width, square-wave electrical pulse applied at the 
rising edge of every pressure wave.  
Prior to stimulating scaffold sheets with the above protocol, we thought it prudent 
to allow the newly seeded cells sufficient time to attach to the scaffold, and to ramp-up the 
mechanical stimulus in a stepwise manner so the cells could acclimate to the stress.  This 
was accomplished by applying waveforms similar in period and frequency to the one 
described above, but with amplitudes of 40 mmHg and 80 mmHg for 24 h each.  The results 
of this analysis will determine which stimulus or combination of stimuli should be used to 






5.3.2.7 Isolation of mRNA and protein: 
 An approximate 1 cm2 area of each scaffold was cut from the R. O. I. and mRNA 
and protein were isolated as previously described.   
 
5.3.2.8 Histology, immunofluorescence, and IHC staining: 
 An approximate 0.5 cm2 area of each scaffold was cut from the R. O. I. and fixed 
in 10% neutral buffered formalin.  These sample were histologically process and stained 
via IHC for alpha-actinin (Abcam; 4 µg/mL) as previously described.  Sections were 
counterstained with dilute (1:1) hematoxylin in distilled, deionized water.  Sections were 
imaged using an inverted Zeiss Axiovert microscope and accompanying AxioVision 
software.  
 An approximate 0.5 cm2 area of each scaffold was cut from the R. O. I. and fixed 
in 4% paraformaldehyde for 2 hours at 37 ºC.  Following adequate fixation, samples were 
rinse 3X in PBS and stored in PBS.  For IF staining, samples were cut into thin (<1 mm 
wide) strips and placed into wells of 96-well plates, where they could be subjected to heat 
mediated antigen retrieval and the various steps of the IF staining process.  They were 
incubated overnight at 4 °C with primary antibodies to actin and CX43 (Abcam; 4 µg/mL), 
and nuclei were counterstained with DAPI.  Samples were imaged using an inverted Zeiss 






5.3.2.9 Live/Dead Assay: 
 An approximate 0.5 cm2 area of each scaffold was cut from the R.O.I. and placed 
in wells of a 24-well plate which contained complete culture medium (DMEM with 10% 
FBS and 1% antibiotic/antimycotic) until they could be assayed.  When ready, the samples 
were cut into thin strips as describe above, rinsed 2X with warm PBS, submerged in a 
Live/Dead working solution containing calcein AM and ethidium homodimer-1, and 
incubated for 20 min at 37 ºC.  Samples were imaged using an inverted Zeiss Axiovert 
microscope equipped with mercury lamp and accompanying AxioVision software.  
 
5.3.2.10 Calcium Staining Assay:  
 An approximate 0.5 cm2 area of each scaffold was cut from the R.O.I. and placed 
in wells of a 24-well plate which contained complete culture medium (DMEM with 10% 
FBS and 1% antibiotic/antimycotic) until they could be assayed.  When ready, the samples 
were cut into thin strips as describe above using sterile surgical instruments and then placed 
back into their respective wells containing media.  An equal volume of 2X Fluo-4 Direct™ 
calcium reagent loading solution (Life Technologies) was added to the well and the plate 
was incubated at 37 ºC for 45 min.  Samples were imaged using an inverted Zeiss Axiovert 







5.3.3 Results:  
5.3.3.1 Isolation of mRNA and protein: 
 Appreciable amounts of mRNA and protein were obtained from the scaffolds, 
indicating a significant cellular presence on all of the scaffolds following the 3 week culture 
and stimulation period (data not shown).  There were sufficient amounts of each to perform 
the qRT-PCR and Western blotting for all markers of interest (up to 10), however those 
assays were not carried out prior to publication of this document.  
  
5.3.3.2 Live/Dead Assay: 
 Examination of Live/Dead staining of scaffolds revealed that all groups contained 
live cells along with some dead cells (Figure 5.8).  Some cells were observed to have nuclei 
which stained red, indicating they were dead, while their cytoplasm concurrently stained 
green, indicating they were alive.  Importantly, cells displayed an elongated morphology, 
and appeared to align with one another in a direction parallel to that of both the applied 
tensile stress and electrical field.  More cells were visible in the E and E+M groups than in 
the other groups.  It was also difficult to find cells spread evenly throughout the scaffold.  
They were not visible on every strip that was prepared and stained, and it appeared they 




Figure 5.8: Analysis of hADSC 
differentiation with Flexcell system:  
Images of cells contained within scaffold 
sheets exposed to the indicated stimuli and 
stained with Live/Dead™ assay reagents 
(calcein AM/live (green) and ethidium 
homodimer-1/dead (red)).  Stimuli were 
part of dynamic differentiation regimens 
within the Flexcell system.  Small areas of 
the sheets were cut into thin (< 1 mm wide) 
segments and stained with these reagents; 
second image from top 10X, bar=100µm; 














5.3.3.3 Calcium Staining Assay:  
 Fluo-4 Direct™ Calcium reagent stained intracellular Ca+2 within all groups 
(Figure 5.9).  The same elongated morphology and consistent orientation along directions 
of applied tensile force and electrical field observed with Live/Dead staining were observed 
in this assay.  Small nodules or pockets of calcium could be discerned throughout the 
entirety of the cells’ length, with clear voids which were presumably the locations of nuclei.  
It was unclear if the staining extended into the cytoplasm or was concentrated at the cell 
membrane.  Similar to the Live/Dead assay, more cells were observed in the E and E+M 
groups than in the other two groups. 
 
Figure 5.9 (below): Analysis of hADSC differentiation with Flexcell system:  Fluo-4 Direct™ Calcium 
reagent shows binding to intracellular calcium (green) of cells contained within scaffold sheets exposed to 
the indicated stimuli.  Stimuli were part of dynamic differentiation regimens within the Flexcell system.  
Small areas of the sheets were cut into thin (< 1 mm wide) segments and stained with this reagent; left column 







5.3.3.4 Histology, immunofluorescence, and IHC: 
 IF staining for actin and CX43 showed positive staining only in the E group.  Actin 
staining was definitive, but CX43 staining (green dots) was less intense and could have 
been background autofluorescence (Figure 5.10A, C, and E).  Portions of scaffolds from 
all groups were stained in the same manner, but an area of positively staining cells for 
either marker could not be found in these groups, even though some sporadic nuclei were 
identified.  It was noted that the area of cells depicted as staining positively here was found 
on a very thin piece of tissue.  Again, cell morphology was elongated, cells were oriented 
in the same direction, and some appeared in close enough proximity to allow for contact 
with one another. 
 
Figure 5.10 (below): Analysis of hADSC differentiation with Flexcell system:  A, C, E) 
Immunofluorescence staining of cells contained within scaffold sheets exposed only to an electrical stimulus.  
Cells showed positive staining for actin (red), but staining for connexin 43 (green) was less definitive.  DAPI 
(blue) was used as a nuclear counterstain.  Groups exposed to other stimuli from the Flexcell system are not 
shown because positive staining for either marker was not present.  Small areas of the scaffold sheets were 
cut into thin (< 1 mm wide) segments and stained; A 20X, bar=50µm; C and E 40X, bar=20µm.  B, D, F) 
Histological sections of cells contained within scaffold sheets exposed only to an electrical stimulus shown 
stained by immunohistochemistry (IHC) for alpha-actinin.  Groups exposed to other stimuli from the Flexcell 
system are not shown because of difficulties encountered in obtaining histological sections containing cells. 






 Sections from the E group stained positively for the presence of alpha-actinin as 
demonstrated by IHC (Figure 5.10B, D, and F).  These sections were known to contain 
cells because previous H&E staining of serial sections had shown the presence of cells 
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(data not shown).  We could not determine whether cells from other groups expressed this 
marker because we were unable to obtain sections from them that contained any cells.  In 
contrast to IF, IHC allowed for examination of how cells fit into scaffold interstices.  Many 
of them appeared to align in the predominant direction of collagen fibers (Figure 5.10F).  
One dense group of cells looked as if it was ensconced in a network of newly synthesized, 
or otherwise heavily remodeled, matrix; this area of matrix appeared very different from 
others (Figure 5.10B and D). 
 
5.3.4 Discussion: 
 Results of this experiment were not the complete battery they were intended to be; 
there was no quantitative data on protein or gene expression because Western blotting and 
qRT-PCR were not completed prior to publication of this document.  Despite this, amounts 
of mRNA and protein isolated from scaffolds will be sufficient for these methods to be 
completed in the future, and they will allow more substantive conclusions to be made.  
 Live/Dead staining and calcium staining confirmed the presence of live cells on 
scaffolds from all groups.  Calcium staining was much more diffuse, but it could be 
coincidental given that cell density on scaffolds was very heterogeneous, and portions of 
the R.O.I. used for calcium staining might have contained more cells than portions used 
for Live/Dead staining.   The particular appearance of calcium in these cells was intriguing 
because of how diffuse it appeared, spread throughout the cells.  The fact that the images 
shown here were taken from specimens with significant depth, as opposed to histological 
sections with only 5 µm of depth, is advantageous because close inspection of high 
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powered images revealed some nodules in the plane of focus while others (apparently still 
within the same cell) were slightly out of focus.  This could be taken to mean that calcium 
was dispersed through the entire volume of the cell cytoplasm, as one would expect in a 
CM.  Regardless of this observation, staining of calcium stores alone was far from 
definitive evidence that these cells had acquired a CM phenotype.  This is because calcium 
is rather ubiquitous, and is involved in processes (e.g. second messengers in signal 
transduction and enzyme cofactors) not necessarily specific to CMs.  It is regularly stored 
within mitochondria and the endoplasmic reticulum (the sarcoplasmic reticulum in muscle 
cells).[36]  It would have been helpful to have performed the same staining on both a positive 
and an undifferentiated control as references for how intracellular calcium deposits should 
appear in those situations (unfortunately, there is also a lack of other studies which have 
used Fluo-4 to label calcium in these instances).  Another more definitive test would 
involve stimulating the cells with agonists to calcium uptake, such as heptanol and 
carbachol, and monitoring the response.[36, 37]  Similarly, the provision of an electrical 
stimulus would provoke a spike in intracellular calcium concentration in a CM-like cell.  
 
5.3.4.1 Histology, immunofluorescence, and IHC: 
 Although positive staining for actin was observed, this particular antibody was not 
specific to cardiac muscle alpha actin, so other isoforms could be labeled here.  The signal 
did not localize to bands, as is sometimes seen in staining of CM.  CX43 staining was 
sparse, with widely dispersed dots that might be construed as positive staining (CX43 
normally appears as dots at intercellular junctions).  Alpha-actinin staining of cells was 
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similar to what we observed with the static differentiation study – positive staining along 
the body of the cells, but no distinctive banding from concentration at Z-disks as in CMs. 
 Since we identified cells in all groups with Live/Dead and calcium staining, we 
were somewhat surprised that we could not do the same with other cardiac specific markers 
such as those discussed above.  We did observe some nuclei (as stained by DAPI) in these 
groups, but no accompanying staining for the markers of interest.  This would seem to 
suggest that these few cells simply did not express these markers.  While that may well 
have been the reality, one conflicting observation was that positively stained cells shown 
in Figure 5.10 were found on a very thin piece of scaffold (probably only 0.25-0.5 mm 
wide) relative to other pieces (0.5-1.0 mm wide).  By virtue of being thin, the solutions 
used in the IF protocol may have come into closer proximity with the cells, enhancing their 
action and resulting in more intense staining.  In contrast, thicker pieces of scaffold may 
have created a physical barrier to the entry of these solutions, resulting in poor staining. 
 Our purpose behind employing the proceeding method, by which pieces of scaffold 
were stained without paraffin embedding, dealt with the drawbacks we encountered with 
the method used to obtain IHC results.  With paraffin-embedded and sectioned samples, 
we found it difficult to obtain sections with any cells.  The cells were contained in pockets 
so dispersed that many of our 5 µm sections failed to capture any.  With the exception of 
the E only group, we could not obtain sections with cells from any of the other groups, 
even when we staggered our sections 50 µm apart between every 2 or 3 serial sections.  
Since our R.O.I. was relatively small – 3.6 cm2 – and we had to use portions of it for other 
assays, we could not afford to be inefficient with our samples.  We decided that the best 
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approach to immunostaining was to use small portions of scaffold for each antibody, and 
to use IF to stain the samples without embedding.  This enabled us to stain more of the 
sample by avoiding the wasted sections associated with paraffin or cryo-embedding.  Not 
insignificantly, this strategy also maximized our chances of identifying all pockets of cells 
that might stain for our markers of interest. 
 
5.3.4.2 Design Iterations and Challenges: 
 The development of this system was not without its challenges, and, as a result, 
went through several iterations before taking on a final form.  In several tests of the system 
following this experiment, it was observed that the pH of the media from wells run on the 
Flexcell baseplate was slightly alkaline, as the phenol red indicator shifted from an orange-
red to a red-purple color.  When measured with a pH meter following several days of 
culture within the system, media from these wells had a pH of around 7.9.  Since we were 
using normal DMEM media buffered by bicarbonate and ambient CO2, we surmised that 
the local CO2 concentration within the wells was somehow too low.  A plausible 
explanation for this was our use of house compressed air, consisting of room temperature 
air with an atmospheric concentration of CO2 (≈0.035%), as the source of air which was 
pumped through the Flexcell baseplate.   
This was problematic because silicone is a gas-permeable material, so the 
compressed air with a much lower CO2 concentration was permeating the membrane and 
reducing the local CO2 concentration from its desired level of 5%.  In turn, this caused the 
bicarbonate buffer system equilibrium to shift toward alkalinity.  Additionally, the lower 
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temperature of the compressed air was found to reduce the temperature of the culture media 
from 37 °C to as low as 31 °C.  This, too, could have shifted the effective range of the 
buffer but, more importantly, may have also reduced enzyme activity and metabolic 
processes within the cells. 
 A simple solution would have been the addition of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) to the media since its buffering mechanism is not 
dependent upon CO2, but it was found that HEPES has been shown to produce free radicals 
when an electrical potential in excess of 0.8 V is applied to the molecule.  This precluded 
its use in our system, as we were using much greater electrical potentials than this figure 
and free radicals can produce oxidative damage in cells, possibly impacting their viability 
or their responses to the experimental treatments. 
 We therefore elected to change the source of the air pumped through the Flexcell 
to air from the incubator so that it possessed the correct CO2 concentration and temperature.  
However, we found that since this air was also heavily humidified, it presented a risk of 
damage to the vacuum pump and the Flexcell pump in our system.  It then became 
necessary to remove the water vapor from the incubated air by means of an inline dryer.  
This dryer used a silica desiccant that became saturated and required changing every 8-12 
hours.  Once implemented, it was found that this system normalized the pH of the media 
to around 7.5, but the temperature of the media did not recover to 37 °C as expected.  To 
correct this, the ambient temperature of the incubator was iteratively increased and the 
temperature of the media was measured until a temperature setting was determined which 
produced the desired media temperature of 37 °C.  
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 After these changes were made, the system functioned as intended and the culture 
conditions were all holding steady at their proper levels.  But, over the course of three 
experiments, the Flexcell controller proved to be unreliable, suffering hardware 
malfunctions in the midst of two of them.  This portion of the system was critical to the 
experiment, and its frequent downtime severely hindered progress in this study.  The 




Figure 5.11: Modification of Flexcell system:  A) Schematic illustration of main components of the second 
generation Flexcell system.  In order to better regulate temperature and pH, the system was modified to 
circulate air from within the incubator through the Flexcell controller and baseplate; the functions of all other 
components remained unchanged.  B) An incubator containing tubing, baseplate, and a compressed air 
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storage tank; the tank and as much tubing as possible were kept inside the incubator to reduce condensation 
of water vapor from the humidified incubator air.  C) An in-line dryer filled with silica gel dessicant was 
used to dehumidify air drawn from the incubator by a D) vacuum pump.  This was done to protect the vacuum 
pump and Flexcell controller against possible damage from the buildup of condensate. 
 
5.3.4.3 Cell Seeding Challenges: 
 The challenges presented by insufficient cell density to obtaining and evaluating 
results in this experiment prompted us to change our cell-seeding methods in a subsequent 
experiment.  This new experiment also incorporated the changes to the system design 
enumerated above.  We hypothesized that seeding lyophilized (freeze-dried) scaffolds 
would encourage more cell infiltration because the cell suspension would be drawn into 
the porous, dehydrated scaffold in the same manner that a dry sponge draws in water.  To 
test this, scaffolds sheets were prepared and sterilized via the same methods as the previous 
experiment.  Sheets were then placed in sterile petri dishes and lyophilized by first freezing 
at -80 ºC, followed by application of continuous vacuum at 1.6 mBar.   
We used a cell culture scale-up apparatus, the CellSTACK® (Corning), to produce 
sufficient numbers of cells for this study.  Each lyophilized sheet was injected with 25 µL 
of cell suspension at a concentration of 3.8 x 106 cells/mL at 20 evenly spaced points by 
means of a custom-designed and 3D-printed array of needle holes.   The array was 
positioned over the center of each sheet and a 26 gauge needle was passed through each of 
the holes successively until a uniform grid of points was injected.  Following injection, 
each sheet was then placed into a petri dish containing 11 mL of cells suspended in media 
at a concentration of 4.9x105 cells/mL.  Sheets were incubated in this cell suspension 
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overnight until they had rehydrated and swelled to their original volume.  Based upon the 
surface area of each sheet and the concentration of the surrounding cell solution, each sheet 
was coated at a cell surface density of at least 5.6x103 cells/cm2. 
 These seeded scaffolds were mounted on Flexcell plates and run on the redesigned 
Flexcell system for 3 weeks.  Subsequent Live/Dead staining and mRNA and protein 
isolation indicated that there were no cells on any of the scaffolds, even in the E only group 
scaffolds cultured in an incubator with normal settings.  After some careful consideration 
of possible causes, it was determined that injected cells did not remain inside scaffolds.  
Our understanding of this was that the lyophilized scaffolds initially repelled media until 
their outer surface could become hydrated.  Because of this, the injected media was 
expelled from the interior of the scaffold and the cells along with it.  Since scaffolds were 
immediately submerged in cell suspension following injection, there was not sufficient 
time for serum proteins in the culture media to adsorb to their surfaces.  This meant cells 
were deprived of any chance to attach to the scaffold, and were washed away once the 
scaffolds were placed in cell suspension.  Apparently, the scaffolds also failed to attract 
any cells whilst bathing in the cell suspension.  
 
5.3.4.4 Perspectives on Dynamic Stimuli in Cardiomyogenic Differentiation: 
 There have been a number of studies whose results support the positive effects of 
dynamic mechanical and electrical stimuli, as well as AZT, on the differentiation of various 
populations of stem or progenitor cells into CM-like cells.[18, 35, 38-42]  Our platform 
incorporates many of these strategies into one comprehensive system that should produce 
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similar results.  Some of these results should include increased gene and protein expression 
of most or all of the following: alpha-actinin, troponin-T, CX43, desmin, N-cadherin, β-
myosin heavy chain, cardiac alpha myosin heavy chain 6, cardiac alpha actin, cardiac 
myosin light chain-2α, titin, GATA4, Nkx2.5, and Islet-1.  Cells should also display 
responsiveness to electrical stimuli, measurable via multi-electrode arrays (MEA) and 
calcium transients with the Fluo-4 assay.   
Even though many of these markers were not measured in this experiment, 
histological methods showed that cells in all but one group demonstrated poor expression 
of the markers which were measured.  It is still unclear as to whether poor cell seeding, 
ineffective assays and methods, or undesirable environmental conditions were the cause.  
Low cell density, in particular, was cited by another group who conducted a similar study 
as the reason why the cells they were attempting to differentiate did not become electrically 
excitable.[35]  Cell density, of course, is a function of the cell seeding methods. 
Poor outcomes were likely a result of all three factors, but with more efficient cell 
seeding strategies and tighter control of the culture conditions, along with improved 
reliability of the Flexcell system, this platform should produce results that allow us to 
optimize differentiation of hADSCs and subsequent maturation of grafts produced with 
them.  Finally, with the addition of qRT-PCR and Western blotting results, it is almost 
certain that a clearer perspective will emerge as to the success or failure of this initial 






Through several design iterations, we successfully engineered a system with the 
desired features outlined in the previous sections of this chapter.  It is capable of delivering 
mechanical and electrical stimuli in a coordinated manner to cell-seeded myocardial 
scaffolds.  Based upon the initial results of experiments with this platform, it would be 
advisable to revise cell seeding methods so as to deliver as many cells to the scaffolds as 
is practical, and to make certain cells are retained within the scaffolds immediately 
following the seeding process.  Without an abundance of cells in the scaffolds, their 
differentiation may be adversely affected, and even evaluation of the effects of the 
experiment may become too challenging.  
In the future, this system will also serve as an efficient platform for testing the 
effects of seeding other cell types (e.g. cardiac fibroblasts, smooth muscle cells, or 
endothelial cells), in addition to hADSC, on the differentiation of the latter into CM and 
the overall development of the construct into a functional tissue.  We can also test the 
effects of changing the coordination of the mechanical and electrical stimuli.  For example, 
the electrical impulse can be alternatively delivered at the peak of the pressure waveform, 
simulating an excitation followed by a compression of sorts (the relaxation of applied 
tensile force).  It might be determined that this method is more effective at producing 
differentiation and contractility in hADSC than delivering the stimulus just prior to the 
beginning of the pressure waveform. 
Other changes that might improve the operation of the system include improving 
the reliability of the Flexcell control unit, which malfunctioned during two separate 
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experiments involving the platform.  Implementing continuous temperature and pH 
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CHAPTER SIX: FEASIBILITY STUDY OF MYOCARDIAL SCAFFOLD 
IMPLANTATION IN A PORCINE MODEL 
 
6.1 Introduction: 
As discussed in Chapter Two, one of our aims was to evaluate the feasibility of 
surgically implanting a tissue engineered myocardial graft in the manner we have 
previously described (Figure 6.1).  The success of our approach in addressing this problem 
hinges on the ability to connect the graft’s vasculature with that of the recipient.  Otherwise, 
the cells delivered within the graft will likely succumb to ischemia and die.[1]  The need for 
a vascular supply to the graft was driven by the need for the graft to be thick.  Without 
sufficient thickness, the graft would be largely ineffective in preventing or reversing 
ventricular remodeling.  But, a thick graft introduces the complication of diffusional 
limitations, so a vasculature becomes necessary to transport nutrients and wastes.  
We devised this animal study to demonstrate that tissue-engineered myocardial 
grafts (autologous stem cell-seeded myocardial scaffolds) could potentially be used to 
revitalize infarcted myocardium by replacing the scar tissue.  The goal was to show that 
the scaffold could be connected to a patient’s vasculature through anastomosis of its arterial 
and venous conduits to the aorta and pulmonary artery, respectively; and that an infarct 
scar could be resected and replaced with a portion of the scaffold while this vascular 
connection was maintained (Figure 6.1F and G).  
In this study, we strove to provide proof of concept for the clinical use of this novel 
scaffold.  We focused on the scaffold (without seeded cells) to both simplify and avoid 
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waste, as the implanted scaffolds did not need to contain cells in order to provide the 
information we were seeking.  Three sub-studies are proposed which, if successful, will 
provide sufficient supporting data for an NIH grant submission (Figure 6.2).  More 
specifically, the studies aim to prove: 1) that we can generate an infarct model in the pigs, 
2) that we can secure the scaffold in place, and 3) that the scaffold will integrate into the 
host tissue.  Perhaps most importantly, we wanted to show that all of this was possible 
without causing harm to the pigs. 
 
Figure 6.1: Overview of an animal model to test clinical implementation of myocardial grafts:  This 
depiction is representative of the therapy as it is intended to be used in human subjects.  A) Intended recipient 
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with infarcted heart has subcutaneous adipose tissue harvested and B) adipose stem cells are isolated from 
the tissue.  Cells are cultured with the aim of growing large numbers for later repopulation by reseeding C) 
of the myocardial scaffold D) generated from xenogeneic sources (i.e. a pig).  E) The seeded construct is 
placed into a bioreactor wherein it is exposed to stimuli which mimic the cardiac environment in order to 
differentiate stem cells and condition the construct into a functional graft.  F) In the operating room, the 
surgeon trims the graft to fit the size of the infarct, resects the infarcted tissue, G) attaches the flap area of 
the graft over the resection site, and anastomostically connects the graft’s arterial and venous vessels to the 






Figure 6.2: Overview of preliminary animal study to test clinical implementation of myocardial grafts:  
This flow chart illustrates the different groups in the feasibility study.  The expected outcomes and methods 
to assess them are indicated for each group.  In addition, critical decision points are identified wherein specific 
outcomes from each group must be observed in order to proceed to the next group.  Procedures in each 
successive group are more difficult, and thus present more risks.  
  
Pigs were chosen for this study because their cardiovascular anatomy, physiology, 
and pathologies are very similar to human aspects.  Also, pig models of MI are well 
established and widely accepted for testing such procedures.[2-4]  Smaller animals such as 
mice, rats, and rabbits (the originally proposed subjects for this study) were avoided 
because they have smaller anatomical features that would present undue technical 
challenges during surgery and recovery that may have directly resulted in poor outcomes.   
This is a feasibility pilot study that will form the basis for a larger, more extensive 
study.  We estimated the number of samples required for each assay to reach statistical 
significance once studies are completed at n=3.  For proposed studies, the estimated need 
is 12 pigs, which will be equally divided between 3 groups (n=3 per group, 3x3=9). Since 
survival rate for this type of surgery is estimated at about 70%, we added 3 more pigs to 
the study (1 pig/group).  For pigs to be of a sufficient size to avoid surgical complications 
stemming from the size of anatomical features, we expected they would need to weigh 
upwards of 35 kg; pigs were divided into three groups as described above.  
After quantitative data sets are obtained, analyses of variance for a completely 
random design will be done and means will be compared using Fisher's protected least 
significant difference test (LSD). 
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We hypothesized that our novel scaffold would allow for efficient integration into 
myocardium, and, by virtue of its direct connection to the host vasculature, it would rapidly 
become perfused and nourished by host blood, without significant post-op bleeding.  We 
expected to see positive scaffold integration and adequate perfusion after surgical 
connection to the host vasculature.    
Confirmation of our hypothesis will serve as the basis for a larger study of 
significant clinical relevance, where autologous ADSC will be seeded onto our scaffold, 
and, after maturation in vitro, the tissue construct will be implanted into post-infarcted 
hearts to help with regeneration and healing (Figure 6.1).  From this research we will also 
gain valuable insight into surgical techniques and procedures necessary for proper 
implantation of such constructs, which will help avoid complications and limit discomfort, 
distress, or loss of animals in future studies. 
 
6.2 Pilot Study: In Vitro Test of Surgical Attachment: 
6.2.1 Introduction: 
 Initially, we had planned to conduct these studies in smaller animals to minimize 
the costs of surgery and husbandry.  We wanted to avoid animals that were extremely small, 
such as rats and mice, so settled on using rabbits.  Studies using rabbit models of infarction 
are prevalent, but few have used the animals to investigate complicated surgical techniques 
that might prove necessary with these studies.[5-8]  Consequently, we were concerned that 
the size of the rabbits’ anatomical features in and of itself would cause surgical 




6.2.2.1 Porcine Heart Model: 
 To test the feasibility of the above methods in an in vitro, non-surgical model, an 
adult porcine heart obtained from a local slaughterhouse was used as a stand-in for a living 
heart that received a myocardial scaffold-graft (Figure 6.3A).  The left ventricular free 
wall was cut out of a whole, DCELLed porcine heart (Figure 6.3B) and further trimmed 
to fit a defect (simulating a resected scar) created in a fresh heart (Figure 6.3C, D, and E).  
The defect was not transmural, reflecting a scenario where the surgeon spares a layer of 
viable myocardium adjacent the endocardium when resecting the infarct scar.  The 
coronary artery and cardiac vein of the scaffold were anastomosed to the ascending aorta 
and the coronary sinus, respectively (Figure 6.3F and G).  The void was coated with a 
layer of Tisseel™ fibrin glue (Baxter), and the flap portion of the scaffold was pressed into 
the void (Figure 6.3H and I).  A running 4-0 prolene suture was placed at the periphery 
of the scaffold and weaved back and forth between the scaffold and the native heart in an 
attempt to better seal the severed vessels of the scaffold (Figure 6.4A, B, and C).   
The opening of the aortic anastomosis was accessed through the aorta and a syringe 
with attached Luer connector was used to cannulate the arterial conduit.  The syringe, 
which was loaded with water colored with red food dye, was depressed and the solution 
was forced into the scaffold vasculature. 
 
Figure 6.3 (below): In vitro test of scaffold implantation method, Part 1:  A) Illustration of the graft 
implantation method; in the operating room, the surgeon trims the graft to fit the size of the infarct, resects 
the infarcted tissue, attaches the flap area of the graft over the resection site, and anastomotically connects 
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the graft’s arterial and venous vessels to the aorta and the pulmonary artery, respectively. B-I) Demonstration 
of graft preparation and implantation in the laboratory.  B) The entire left ventricular free wall was cut away 
from a whole, decellularized heart and C) further trimmed to fit the size of a E) simulated defect created by 
removal of an imaginary infarct in a D) fresh porcine heart.  Anastomoses were made between F) the 
scaffold’s coronary artery and the heart’s aorta, and between G) the scaffold’s cardiac vein and the heart’s 
coronary sinus.  H) Tisseal™ fibrin glue was applied to the defect, and the flap portion was attached securely 





6.2.2.2 Rabbit Heart Model: 
 We performed the simulated implantation of the scaffold in a fresh rabbit heart 
(Animal Technologies; Tyler, TX) in the same manner as described above (Figure 6.5). 
The only difference in the two methods was that a much smaller portion of scaffold had to 
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be trimmed, and the portion needed to contain a vascular unit (an artery and vein that 
connect to one another through a capillary network, thereby supplying a piece of tissue 
with a functional vascular supply) (Figure 6.5A and B).  This vascular unit was tested for 
integrity by suturing open vessels and injecting water through both the arterial and venous 
inlet to verify there were no leaks.  
 
6.2.3 Results:  
6.2.3.1 Porcine Heart Model: 
 Injection of red dye into the arterial anastomosis resulted in its migration through 
the arterial vasculature and into the venous vasculature (Figure 6.4D, E, and F).  Veins 
were bulging with pressure, and after injection of more than 10 mL of dye solution, the 
whole flap portion began to bulge out from the native heart. (Figure 6.4D and E).  No 
leaks were observed in the major vessels throughout the flap portion of the scaffold, but 

















Figure 6.4: In vitro test of scaffold implantation method, Part 2:  A-C) Myocardial scaffold shown 
securely attached to the left ventricle of a fresh porcine heart, and with anastomoses of the coronary and 
venous conduits made to the fresh heart. D-F) Images of the scaffold following injection of water colored 
with red food dye through the aortic anastomosis. D, E) The scaffold shown bulging outward from the 
ventricular wall following dye injection. E, F) The scaffold’s vessels were clearly perfused with the dye, and 
apparent bulging of the cardiac vein demonstrated intact connections between the arterial and venous vascular 





6.2.3.2 Rabbit Heart Model: 
 Anastomoses of the major vessels were made, but it was clear during the procedure 
that they would not be functional.  It was not possible to find the opening of either 
anastomosis in order to inject fluid, so the functionality of the graft was not determined 




Figure 6.5: In vitro test of scaffold implantation method, Part 3:  A) Myocardial scaffold shown adjacent 
to a fresh rabbit heart, and an outline of an attempt to identify a functional vascular unit (an efferent artery 
and an afferent vein) to patch a B) defect created in the fresh heart.  B) Vascular unit after being cut from the 
myocardial scaffold and C, D) anastomoses of the coronary and venous conduits made to the fresh heart. C, 
D) The lower part of the vascular unit was secured to the defect in the fresh heart using fibrin glue. 
 
6.2.4 Discussion: 
 Migration of dye from the arterial to the venous circulation in the porcine model 
demonstrated that the scaffold possessed intact arterioles, venules and capillaries.  The 
scaffold’s bulging veins showed that the anastomoses and, to some extent, the interface 
between the scaffold and the native heart held pressure.   Bulging of the scaffold indicated 
some leakage was building up underneath the flap portion, but also that the seals around 
the edge of the flap were intact.  Leakage of the venous anastomosis was due to surgical 
inexperience.  This anastomosis was certainly the more challenging of the two because the 
vein was flimsy and not as amenable to handling and suturing.  
 The rabbit model proved to be more technically challenging, and would probably 
demand the use of microsurgical techniques in order to be done properly.  
 
6.2.5 Conclusions: 
 The porcine model proved to be feasible, but the rabbit model seemed as if it would 
present unnecessary complications due solely to its smaller anatomical features.  The 
difficulty of surgical procedures and stresses on animals will only become heightened with 
each successive study described below.  In view of this, we decided to move forward with 
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studies which used pigs as the recipients of scaffolds, and to abandon the idea of using a 
rabbit model.   
 
6.3 Group 1: Acute Implantation Testing:  
6.3.1 Methods:  
6.3.1.1 Modification of Myocardial Scaffold with Vascular Scaffolds for Anastomosis: 
 To facilitate attachment of the myocardial scaffold’s coronary arterial inlet and 
venous outlet to the pig vasculature, 6-10 cm lengths of DCELLed porcine carotid arteries, 
or vascular scaffolds, were anastomotically attached to both of those vessels.  This was 
necessary to ensure that the surgeon had enough length of conduit with which to work, as 
the graft’s own vessels may not have been long enough to reach the desired points of 
anastomosis on the aorta and pulmonary artery.    
 
6.3.1.1.1 Vascular Scaffold Preparation 
Fresh, 6–12 cm long, porcine carotid arteries with internal diameter tapering from 
about 8 mm to 3 mm were obtained from young animals via Animal Technologies (Tyler, 
TX).  The arteries were DCELLed in a bioprocessing system according to a recently 
published protocol developed in our lab.[9]  The system, shown below, used pressure 
vessels and a peristaltic pump to generate translumenal pressure (50-80 mmHg) in 
arteries mounted inside two custom-designed housings.  The combined action of several 
reagents and this pressure facilitated completely uniform DCELL of the arteries.  Filling 












Figure 6.6: Perfusion bioprocessor for decellularization of vascular scaffolds:  Porcine carotid arteries 
were mounted inside the clear housings, and a system of tubing and pressure heads was used to 
continuously pump a series of reagents though the vessels until the cells were removed from the tissue.  
6.3.1.1.2 Cleaning and Preparation 
Once received, arteries were kept on ice and cleaned of excess fat.  Luer lock 
fasteners were zip-tied to each end of the arteries for eventual mounting in the 
bioprocessing system.  To test for leaks, one luer lock was closed off with a luer cap 
while the luer on the opposite end was fastened onto a syringe filled with saline.  The 
arteries were pressurized and monitored for any leaks.  If a leak was observed, the hole 
was sutured shut using 3-0 Ethibond Excel braided polyester suture.  The arteries were 









6.3.1.1.3 Tissue Decellularization and Sterilization 
Samples were first treated overnight in 30 mM EDTA, 0.02% sodium azide 
(NaN3) (pH to ~7) on an orbital shaker at 3.5 rpm at 4C.  The following day, the arteries 
were removed from the EDTA solution and mounted in the bioprocessing system.  From 
this point on, the DCELL process continued inside of the bioprocessing system.  The 
steps for DCELL and sterilization are listed below. 
1. Mounted the arteries in the perfusion bioreactor. 
2. Filled the bioreactor with 30 mM EDTA, 0.02% NaN3 solution and left overnight. 
3. Rinsed bioreactor with ddH2O. 
4. Introduced 1% SDS solution into the reservoir and ran with pressure for 12 days; changed solution 
at 6 days. 
5. Rinsed with ddH2O overnight with pressure. 
6. Rinsed 3X with 1 L of 70% ethanol (EtOH).  
7. Rinsed with ddH2O for 30 min with pressure. 
8. Drained water, added 1400 mL of 0.1 M NaOH into system, incubated for 2 hr with pressure. 
9. After 2 hr, rinsed with ddH2O.  
10. Added 1400 mL PBS, circulated overnight with pressure. 
11. Treated scaffolds with DNAse/RNAse solution (720 mUnits/mL DNAse, 720 mUnits/mL RNAse, 
5 mM MgCl, in 1x PBS, pH=7.5 with 1% v/v antibiotic/antimycotic) for 96 hours at room 
temperature. 
12. Added 1400 mL PBS, circulated 1 hr with pressure. 
The system was moved into a sterile hood to ensure sterility 
13. Rinsed with ddH2O.  
14. Rinsed 2X with 1400 mL of sterile PBS; circulated the last 500 mL for 20 min with pressure. 
15. Placed in 1400 mL 0.1% w/v peracetic acid, circulated the last 500 mL for 2 hr with pressure at 
room temperature. 
 
Pigs (n=3) were used for testing and optimizing the surgical implantation of the 
myocardial scaffold in healthy hearts and observed for 30 min -1 h (non-survival surgery).  
Pigs were preanesthetized by an intramuscular injection of ketamine hydrochloride (20 
mg/kg) and xylazine hydrochloride (2 mg/kg).  The animals were positioned supine, and a 
22-gauge indwelling needle was inserted in the central vein of the auricle for continuous 
i.v. anesthetic injection.  The animals were intubated with an endotracheal cannula (6 
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French) and then connected to an artificial respirator with a stroke volume of 200–300 
cm3/stroke and frequency of 20/min. Propofol (6 mg/kg/h) and vecuronium bromide (0.05 
mg/kg/h) was continuously infused using a syringe pump.  Pigs were prepped for aseptic 
surgery using nolvasan scrub and sterile saline rinse in triplicate.  Surgery was performed 
using aseptic technique. 
The animals were fixed in a recumbent position so that the left thorax was exposed, 
and a left thoracotomy was performed as follows: the outer layer of skin and muscles 
between the third and fourth ribs were dissected. The distance between the third and fourth 
ribs was widened with a rib spreader to allow a direct view of the left auricle LAD coronary 
artery.  The pericardium was dissected along the LAD from the upper part of the left auricle 
(approximately 6 cm) to expose the myocardium.  The myocardial scaffold was attached 
to the descending aorta via its arterial vascular scaffold conduit and to the pulmonary aorta 
via its venous vascular scaffold conduit.  An area of about 10 cm2 was shaven off the lower 
left anterior ventricle and the scaffold glued onto the shaven area with fibrin glue, followed 
by placement of 6-8 sutures to secure the scaffold. The scaffold was allowed to stay in 
place for 1 hour to allow blood to clot around the implant and also test for blood leakage. 
After 1 hour, the pigs were humanely euthanized via intravenous injection of FatalPlus (1 
mL/10 lb; supplying 390 mg/mL sodium pentobarbital) followed by performance of a 
bilateral pneumothorax for euthanasia verification, and hearts and scaffolds were collected 






6.4 Group 2: Induction of Myocardial Infarct:  
Pigs (n=3) will undergo induction of MI by left anterior descending (LAD) 
coronary artery ligation and be allowed to survive for 4 weeks. Electrocardiography 
(EKG), echocardiography (ECG), blood chemistry and histology will ascertain induction 
of MI at 4 weeks (survival surgery).  EKG and ECG will be performed prior to surgery in 
order to establish baseline levels for these signals.  Pigs will be prepped for aseptic surgery 
using nolvasan scrub and sterile saline rinse in triplicate.  Surgery will be performed using 
aseptic technique.  Hearts will be exposed by left thoracotomy as described above. The 
pericardium will be dissected along the LAD from the upper part of the left auricle 
(approximately 6 cm) to expose the myocardium around the LAD. The LAD on the 
proximal side, below the left auricle from the myocardium, will be exfoliated for 
approximately 1 cm.  A lidocaine hydrochloride jelly will be applied to anesthetize the 
area. First, a complete ligation of the LAD will be made immediately distal to the second 
diagonal branch using a 2-0 suture.  Approximately 20 min later, an ameroid constrictor 
(3.5 mm internal diameter) will be fastened around the coronary artery just distal to the left 
circumflex artery branch using sutures.  The ameriod constrictor is designed to slowly 
(within 3-5 days) ligate the artery. To enhance the effect of the ameroid constrictor, 2 
additional suture strings will be loosely rounded at the site of the ameroid so that these 
strings will be located between (below) the ameroid constrictor and arterial wall.  This dual 
ligation approach has been shown to improve survivability of the procedure by reducing 
the likelihood of fatal arrhythmia and to produce a more pathologically relevant model with 
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respect to models generated using a single ligation point.  Following ligation, the fascia 
and intercostal space will be closed, buprenorphine (0.04 mg/kg) and prophylactic 
antibiotics (ceftiofur; 5.0 mg/kg) administered i.m., and pigs allowed to recover.  
Blood will be collected (described below) immediately before and after the surgical 
procedure and troponin (TN), lactate dehydrogenase (LDH), creatine phosphokinase 
(CPK) levels measured.  After 4 weeks, EKG and (ECG) will be performed under 
anesthesia. For ECG, pigs will be scanned in a parasternal short-axis view with 2D and M-
mode imaging and a broadband high-frequency (12-MHz) transducer. Left ventricular 
internal diastolic diameter (LVIDd), end diastolic volume (LVEDV), internal systolic 
diameter (LVIDs), and end systolic volume (LVESV) will be calculated and the left 
ventricle ejection fraction (LVEF) will be calculated. ST segment elevation and abnormal 
Q waves on EKG will be indicative of MI.  Pigs will be euthanized under anesthesia as 
described above. Hearts will be excised and analyzed for additional signs of infarction. 
 
6.5 Group 3: Short-term Implantation Testing:  
Pigs (n=3) will undergo induction of MI as previously described in Group 2 and be 
allowed to survive for 4 weeks before implantation of the myocardial scaffold; following 
scaffold implantation, pigs will be assessed for evidence of scaffold integration at 2 and 4 
weeks post implantation (multiple survival surgery).  At 4 weeks post-infarction, scaffolds 
will be implanted as described in Group 1, with the exception that the area to be cut away 
from the left ventricular wall will be the infarct scar.  After ensuring hemostasis, the fascia 
and intercostal space will be closed, buprenorphine (0.04 mg/kg) and prophylactic 
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antibiotics (ceftiofur; 5.0 mg/kg) administered i.m., and pigs allowed to recover.  At both 
2 and 4 weeks, EKG and ECG will be performed as previously described, and pigs will be 
euthanized after 4 weeks under anesthesia as described above.  Hearts will be excised and 
analyzed for evidence of scaffold integration. 
Subdermal adipose tissue (post-mortem) and blood (pre-op/ante mortem and post-
op) will be collected for isolation of ADSCs and circulating endothelial progenitor cells, 
respectively, which will be used for subsequent in vitro applications and future in vivo 
studies (blood collected will primarily be used for assays germane to results of the studies).  
Each collection procedure is described below. 
 
6.5.1 Blood collection:[10]  
While anesthetized, pigs will be laid laterally and the subcutaneous abdominal vein 
will be located.  The area will be swabbed with 70% ethanol to disinfect, and thumb 
pressure will be applied on the proximal end of the vessel to occlude blood flow. A 21 G 
or 19 G needle, depending on the animal size, will be introduced into the engorged vessel. 
Approximately 50 mL of blood will be collected, and hemostasis will be achieved by 
application of thumb pressure for about 5 min.  Blood collection will be carried out before 
and after the procedure described in Group 2, and also just prior to euthanasia in all groups 







6.5.2 Fat collection: 
Subcutaneous fat (10 g per pig) will be harvested from the dorsal abdominal and 
inguinal areas of the pigs immediately following euthanasia.  We will collect fat from these 
areas and compare stem cell counts.  After euthanasia, the subdermal adipose tissue is 
accessed through a 15 cm longitudinal incision in the abdominal or inguinal area.  After 
tissue identification, 10 ml of saline solution containing 1:1,000,000 dilution of 
epinephrine are added to minimize blood loss and after 3 minutes, a subdermal adipose 
tissue (5-10 cm diameter) is collected for isolation of ADSCs.   
 
6.5.3 Post-operative Recovery and Monitoring: 
Immediately post-op, the respiratory rate, reflexes, mucus membrane color, 
movement, and appetite of pigs will be monitored for 15-30 minutes, or until ambulatory.  
We will also be alert to redness, swelling or oozing at the surgical site; changes in appetite, 
attitude/activity, and temperature will be monitored every 6-12 hr for the first 48 hr, and 
daily thereafter. 
 Pigs will be housed singly during post-op recovery and may be housed in groups 
as determined by the attending veterinarian (AV).  If possible, single housing pen 
construction should allow for social interaction, as pigs are social animals.  
Other measures taken to monitor animal health include: 1) Appetite: documented 
daily. 2) Hydration: documented by skin test daily. 3) Weight: measured 2 times per week 
for the first 2 weeks, then weekly for 2 weeks. After 1 month every 2 weeks or at the 
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discretion of the AV. 4) Behavior will be assessed daily and considered together with other 
criteria over 3-4 days period. 5) Surgery site monitored daily for proper healing for first 
week, every other day thereafter. 
 
6.6 Results: 
6.6.1 Group 1: 
 To date, 1 pig from this group underwent a surgical procedure.  The anastomoses 
of vascular scaffolds to the coronary artery and cardiac vein were carried out on a back 
table in the operating room just prior to the surgery.  The integrity of the anastomoses was 
tested by inserting a syringe loaded with saline into the end of each vascular scaffold and 
injecting the liquid.  No leaks were observed (Figure 6.7A-C). 
 After opening the thoracic cavity of the animal and exposing the heart, the vascular 
scaffold connecting the venous circulation was successfully anastomosed to the pulmonary 
artery.  When blood was allowed to flow through this connection, no leakage was observed, 
and blood spread slowly through the venous circulation (Figure 6.7D and E).  This 
connection was clamped while the arterial anastomosis was made to an area of the 
descending aorta just inferior to the aortic arch (Figure 6.7H).  Blood was allowed to flow 
through this connection, and flowed at a much greater volume and velocity.  Leakage was 
observed from several arterial branches of the LAD CA that fed the septum, as these had 
been severed when the left ventricle was cut away from the rest of the heart.  These leaks 
were quickly closed with small metal clamps, and hemostasis was achieved shortly 
thereafter.   
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At the surgeon’s discretion, the procedure was halted at this point.  There were no 
complications which precipitated this decision – it was simply determined that the selected 
approach of a left thoracotomy did not provide the correct angle for sufficient access to the 
anterior left ventricle in order to proceed with resection and scaffold attachment.   
Following anastomosis, blood was allowed to flow freely through the scaffold.  
There was a clear change in its color, as it went from an opaque white to a reddish-pink 
(Figure 6.7G and I).  Blood was observed to perfuse the arteries and veins, even down to 
vessels of a size barely discernable to the naked eye (Figure 6.7J).  The scaffold was left 
in this state and observed for a period of about 30 minutes, during which time no purpleing 
of the blood was noticed.  Palpation of the vascular scaffolds and the LAD CA also 




 Figure 6.7: Acute 
implantation testing 
of myocardial 
scaffold in a porcine 
model:  A) A 
vascular scaffold is 
shown as it was 
anastomosed to the 
cardiac vein of the 
myocardial scaffold.  
B) Once the vascular 
scaffolds were 
attached, sterile saline 
was injected through 
them to test the 
integrity of the 
anastomoses.  C) 
Myocardial scaffold 
shown with vascular 
scaffolds 
anastomosed to the 
coronary artery and 
cardiac vein to allow 
for extensibility and 
surgical flexibility.  
D) Initial incision for 
left thoracotomy was 
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made and electrocautery equipment and retractor were used to cut down and open the thoracic cavity.  E) 
Anastomosis of the venous conduit to the pulmonary artery; shown clamped, but, when opened, low pressure 
and low velocity flow of blood into the scaffold was observed.  F) Myocardial scaffold shown as it would 
lay on the heart once fully implanted; in clinical application, scaffold would be trimmed down significantly 
from the size shown here.  H) After both conduits had been anastomosed to their respective vessels (arterial 
to the descending aorta (DA) and venous to the pulmonary artery (PA)), G) the scaffold’s vessels were clearly 
perfused with blood, especially when compared to an I) unimplanted scaffold.  J) Endocardial side of the 
myocardial scaffold, where perfusion of the scaffold’s microvasculature is visible. 
 
6.6.2 Histological Assessment of Scaffold Perfusion: 
 Histological sections obtained from both the arterial vascular scaffold conduit and 
the myocardial scaffold showed extensive perfusion of the entire construct with host blood 
(Figure 6.8).  Vessels of wide-ranging diameters were perfused, and inspection of high 
magnification micrographs revealed perfusion of vessels as small as 6-8 µm in diameter 
(Figure 6.8B, D and F).  A comparison of the blood within the vascular scaffold and that 
within the smaller vessels in the myocardial scaffold demonstrated differences in its 
structure.  The former showed clumps of loosely coagulated erythrocytes, while the latter 
appeared to be solid, compact fibrin with no identifiable erythrocytes (Figure 6.8G and 
H).  Additionally, erythrocytes and leukocytes (unclear if they were neutrophils or 
monocytes) were observed to attach to the vascular scaffold’s lumen (Figure 6.8C and E). 
 
Figure 6.8 (below): Histological evaluation of acute implantation of myocardial scaffold:  A, C, E, G) 
Micrographs of a circumferential section of the arterial vascular scaffold conduit, increasing in magnification 
downward. B, D, F, H) Micrographs of a section through the myocardial scaffold from a region about 1.5 
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cm distal to the scaffold LAD CA, increasing in magnification downward.  A) Vascular scaffold shown with 
erythrocytes in lumen. B, D) Myocardial scaffold showing extent of perfusion throughout a wide range of 
different-sized vessels.  C, E) Erythrocytes and leukocytes shown adhering to the lumenal wall.  F) High 
magnification micrograph of myocardial scaffold identifies perfusion of vessels on the scale of capillaries.  
G)  Magnification of erythrocytes in vascular scaffold lumen distinguishes individual cells, whereas 
magnification of blood in a more distal artery shows dense, fully formed thrombus.  A, B) 2.5X, bar=500µm; 











It was not clear to what extent or how rapidly coagulation set in, but judging from 
color alone, blood flow in the scaffold seemed to remain unobstructed for about 15-20 min.  
Instead of darkening slightly as thrombus does, the blood remained a scarlet red.  The lack 
of purple coloration (indicating deoxygenation) also suggested that the direction of its flow 
was from the arterial into the venous circulation.  In addition to having the proper 
directionality, this meant that blood must have flown through what remained of the 
capillary beds.  This confirmed the results of several in vitro methods we had previously 
used to demonstrate that the scaffold vasculature was patent and intact down to this level 
(see Chapter Three). 
Histological evaluation of the scaffolds agreed with these observations, as vessels 
of similar size to capillaries were perfused with blood.  As was expected, thrombus 
formation appeared to have begun first within smaller vessels and propagated proximally 
through larger vessels.[9]  This was supported by the observation that smaller vessels 
contained only solid, coagulated plasma, while the lumen of the much larger vascular 
scaffold contained identifiable erythrocytes that did not appear significantly coagulated. 
It was also noted that we did not observe any dispersion of erythrocytes outside of 
vessels and into the rest of the scaffold matrix, which would be indicative of leaks.  This 
suggested that all vessels within the scaffold retained their integrity post-DCELL.  This 
inference applies to capillaries as well, which is intriguing since a common question with 
the DCELL approach is whether the capillary conduits are left intact once endothelial cells 
are removed.  Had capillary conduits not remained intact, we would expect to see many 
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erythrocytes scattered throughout the scaffold because these cells would no longer be 
contained once they reached that level of the vasculature. 
Since this scaffold and its vascular channels consisted of bare collagen and other 
ECM components, it was our expectation that coagulation and eventual occlusion of the 
vasculature would occur.[11, 12]  We noted conditions that seemed to suggest arterial to 
venous blood flow for 15-20 min, implying patency of microvasculature during this time.  
While this was encouraging, future grafts implanted in this manner will require 
endothelialization, heparinization, or both to avoid the formation of significant 
thrombus.[11]   
To correct problems with accessibility to the ventricle, it was decided that future 
surgeries would proceed through a median sternotomy approach.  This approach involves 
cutting down the midline of the sternum by using a saw, and can be more traumatic than a 
left thoracotomy.  Despite this, it is important to use an approach that allows unencumbered 
access to the entire anterior surface of the heart so that an area of the ventricle can be 
resected and replaced with the scaffold in future experiments. 
Subsequent procedures should consider using longer lengths of vascular conduit so 
as to reach the right atrium and avoid crossing the conduits over one another as seen in 
Figure 6.7H.  The right atrium was specified above, rather than the pulmonary artery, 
because moving the point of venous anastomosis from the former to the latter would 
provide a more favorable pressure gradient for blood flow through the scaffold.  In contrast 
to pulmonary arterial pressures, which can range from 30-50 mmHg, right atrial pressures 
range from 5-12 mmHg.  This would provide a greater pressure differential between arterial 
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conduit inflow pressure (120 mmHg) and the retrograde resistance at the venous conduit, 
increasing flow velocity through arterioles and capillaries and avoiding potentially 
hypertensive conditions in these vessels.  Capillary pressure, which largely influences the 
extent of nutrient and waste exchange between blood and interstitial fluid, would be 
normalized by this change and it is therefore highly recommended in future surgical 
procedures.  
It was also apparent that open branches in the scaffold should be ligated or sealed 
prior to the surgical procedure.  This will be done by injecting a colored solution (e.g. 
sterile DMEM) through the vascular grafts and noting the position of any leaks before 
sealing them.  In doing so, hemostasis may be achieved more quickly. 
Overall, we noted there were no complications with the pig during surgery, and 
blood loss was limited to 250 mL or less.  By our estimates (70 mL blood/kg in a 37 kg 
pig), this volume was equal to about 10% of the circulating blood volume, well below the 
maximum allowable blood draw of 15% in a single procedure.[13] 
This was not the first instance of a successful procedure of this kind.  Other 
groups have attempted to employ this approach to solve the problem of providing a 
vascular supply to tissue-engineered grafts.[1, 14]  There is also precedent established for a 
few of the key implantation techniques we intend to use, including the resection of 
significant portions of the infarct scar to enable attachment of the device within the void 
created, and the anastomosis of the vessels supplying the graft to the patient’s 
vasculature.[14]  For the former, the reasoning is that attachment of the graft adjacent to 
any healthy, functional tissue will allow for greater electrical and vascular integration 
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with the host than would its attachment directly over nonfunctional, less vascularized 
infarct scar tissue (discussed in section 1.5.6).  Robinson et al. demonstrated the 
feasibility of scar resection prior to device implantation without compromising the 
ventricular wall’s integrity under systolic pressures.[15]  Ott et al. successfully 
anastomosed the aorta of a whole, DCELLed rat heart to the abdominal aorta of another 
rat, and showed that the acellular organ had an intact and patent vasculature that 
conducted the host’s blood adequately without bursting or leaking.[14] 
As discussed above, it will not be sufficient to merely connect grafts to the 
vasculature in the future.  Measures must be taken to prevent thrombus formation, 
otherwise the functionality of such grafts will be compromised.  Furthermore, vascular 
integration at the interface of host tissue and the graft may be necessary to ensure 
sufficient vascular supply, especially to peripheral portions of the graft. 
 
6.8 Conclusions: 
Given the functionality of the anastomoses and how well the surgery was 
tolerated by the animal, we considered this initial procedure a success.  We will continue 
with these studies as planned in order to establish the feasibility of future implantations of 
scaffolds seeded with cells.  To correct problems with accessibility to the ventricle, it was 
decided that future surgeries would proceed through a median sternotomy approach.  It 
may also be necessary to place pigs on heart-lung bypass in order to perform resection of 
the ventricle.  Moving the point of anastomosis of the venous conduit from the 
pulmonary artery to right atrium may prove more beneficial to the overall vascular flow 
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within the scaffold.  It was also apparent that open branches in the scaffold should be 
ligated or sealed prior to surgery in future procedures.   
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CHAPTER SEVEN: CONCLUSIONS AND RECOMMENDATIONS FOR 
FUTURE WORK 
 
7.1 Summary of Project Development: 
Based upon data furnished by the American Heart Association, an estimated 1.43 
million individuals are currently at risk of developing CHF as a result of tissue damage 
caused by MI.   Costs to treat CHF represent a significant burden to our society; 
currently, they stand at $44.6 billion but are predicted to double by 2030.  Patients with 
CHF perennially account for 6% of all Medicare beneficiaries, and are some of the most 
expensive to treat.  In fact, among the top 5% of patients in terms of overall expenditures, 
patients with CHF comprise a full third of the population.[1]  These facts and figures 
clearly outline why developing practical and effective therapies to treat these patients is a 
worthwhile cause.  
After gaining an understanding of the pathological link between MI and CHF and 
undertaking a critical evaluation of the current standards of care, limitations in our ability 
to treat this population of patients were identified.  These limitations represented an 
opportunity for innovation, so we set out to develop a novel, translational approach to 
treatment of the underlying causes of this condition.  We relied on a knowledge of the 
advantages offered by tissue engineering to inform our unique approach.  After studying 
some of the successes and failures by others in this application, we crafted an approach that 
demanded the development of a tissue-engineered graft that was thick, fully vascularized, 
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and functional (contained cells that mimicked the function of healthy myocardium) to 
replace infarct scar tissue and prevent or reverse development of CHF in affected patients.  
 
7.2 Progress toward Achievement of Specific Aims:  
To accomplish the overall objective of this project, we established 4 specific, yet 
interrelated aims and directed our efforts in toward achieving them.  These aims were 
described at length in Chapter Two but are presented in brief below: 
 
Aim 1 (Chapter 3): To develop and characterize a decellularized, vascularized scaffold 
for use in myocardial tissue engineering 
Hypothesis: Acellular left ventricular porcine myocardium will serve as an ideal 
supporting material for tissue engineered myocardial grafts due to its low immunogenicity, 
potential as an excellent “niche” for inducing differentiation of stem cells toward cardiac 
phenotypes, and its network of preserved, patent vascular channels. 
Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their 
in vivo degradation rate 
Hypothesis: Scaffolds which resist in vivo degradation for longer than 8 weeks will 
provide implanted cells sufficient stability and time to integrate with host tissue, improving 
functional outcomes. Treatment with a specialized cross-linking agent will mitigate the 
severity of the immune response to implanted scaffolds. 




Hypothesis: Exposure to conditions mimicking the physiological environment of the 
myocardium will induce stem cell differentiation and maturation of constructs into 
functional myocardial grafts 
Aim 4 (Chapter 6): To develop an animal model of infarction and demonstrate 
feasibility of surgical replacement of infarct scar with tissue-engineered constructs  
Hypothesis: A porcine model of infarction and surgical approach to construct 
implantation must be developed and optimized. 
  
Our progress toward completing these aims, as well as our conclusions in regards 
to their attendant hypotheses, have been discussed at length in each of the indicated 
corresponding chapters, but a summary of the major conclusions is as follows: 
 
7.2.1 .Aim 1 (Chapter 3): To Develop and characterize a decellularized, vascularized 
scaffold for use in myocardial tissue engineering: 
1) We evaluated both the myocardial and arterial matrix of our scaffolds, and 
found they are porous, retain collagen and elastin content and structure, exhibit 
excellent mechanical properties, and are cytocompatible.  Moreover, scaffolds 
retain laminin, fibronectin, and collagen IV.  We’ve also preserved the 
vasculature’s integrity and patency down to the capillary scale.   
2) Cytocompatibility and support of CM survival indicate that our scaffold is 
ideally suited for repopulation with relevant cardiac cell types as a tissue-
engineered construct for myocardial repair 
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3) Given its composition, intact vasculature tree, mechanical properties, and 
geometry, we believe constructs produced from this scaffold have the potential 
to functionally integrate with healthy host myocardium and to be nourished by 
direct anastomotic connection with the host’s own vasculature. 
4) Constructs resulting from recellularization of this scaffold may also be useful 
as physiologically accurate models for in vitro studies of cardiac physiology 
and pathology. 
 
7.2.2 Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their 
in vivo degradation rate: 
1) The host response in a xenogeneic implantation study was directed 
predominantly by cells commonly associated with immune functions (i.e. of 
leukocytic lineages).  The scaffold is “bioactive”, as opposed “inert”, with a 
heavy infiltration of host cells.  
2) Treatment of scaffolds with PGG can extend their lifetime up to, and possibly 
beyond, 12 weeks – presumably a sufficiently long period for delivered cells to 
integrate with host tissue in future implantations of recellularized scaffolds. 
3) The host response to scaffolds does involve some elements of the classical 
inflammatory response (FBGCs), but over time the environment becomes less 
pro-inflammatory as evidenced by the predominance of M2 macrophages. 
4) It was clear that this scaffold encouraged angiogenesis, which is a very desirable 
quality for our overall approach in generating functional, vascularized muscle. 
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5) We were unable to thoroughly describe the functionality, or “appropriateness”, 
of the tissue ultimately formed by host remodeling of the scaffold, as this is 
dependent upon the implantation site and the intended function of the implant.  
 
7.2.3 Aim 3 (Chapter 5): To condition cell-seeded myocardial constructs in vitro into 
functional grafts: 
1) Use of myocardial scaffolds as a substrate for hADSC growth precipitated 
expression of cardiac genes and proteins regardless of treatment with AZT. 
2) Evidence of increased CM marker expression in hADSC grown on scaffold vs. 
standard culture plastic was not abundant, but what little there was could be 
explained by an inductive role of the structure and composition of myocardial 
scaffolds in cardiomyogenic differentiation of hADSCs. 
3) The addition of variables such as electrical and mechanical stimuli may be 
necessary to achieve full differentiation of hADSCs into a CM phenotype. 
4) We successfully engineered a system capable of delivering mechanical and 
electrical stimuli in a coordinated manner to cell-seeded myocardial scaffolds. 
5) Early indications are that this system will serve as an efficient platform for 
testing the effects of these stimuli on the differentiation of hADSC into CM. 





7.2.4 Aim 4 (Chapter 6): To develop an animal model of infarction and demonstrate 
feasibility of surgical replacement of infarct scar with tissue-engineered constructs: 
1) The rabbit model seemed to present unnecessary complications due solely to its 
smaller anatomical features, and was abandoned. 
2) To correct problems with accessibility to the ventricle, it was decided that future 
surgeries would proceed through a median sternotomy approach. 
3) It was also apparent that open branches in the scaffold should be ligated or 
sealed prior to the surgical procedure.  This will be done by injecting sterile 
DMEM through the vascular grafts and noting the position of any leaks before 
sealing them.  This will ensure that hemostasis is achieved more quickly. 
4) The anastomoses were functional and hemostasis without significant blood loss.  
The surgery was tolerated well by the animal; we considered this initial 
procedure a success and surgeries will continue as planned. 
 
7.2.5 Perspectives on Progress Made and Comments on Potential Continued Research: 
The studies conducted and reported on here have fulfilled the objectives of Aim 1 
and made significant progress toward completion of the other aims.  Continued study of 
the host response may lead to better understanding of outcomes of future experiments 
wherein cells, autologous or otherwise, are delivered within scaffolds.  
Development of the Flexcell platform carried with it significant technical 
challenges, but as it is constituted now, the system should become a valuable tool in 
working toward the completion of Aim 3.  Along those lines, further experimentation with 
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the system may demonstrate that differentiation of hASDSs using only dynamic stimuli is 
a less effective or practical approach than using human IPSC, which are now being shown 
to be highly amenable to cardiomyogenic differentiation.[2-4]  In the context of our 
translational approach, it is still the opinion of the author that hADSCs represent the most 
practical option for reasons already delineated above.  However, it may be advisable to 
focus on using this platform as a tool to “condition” cells that already display a number of 
CM traits to become more functional, rather than using it to affect fully de novo 
differentiation.  
Initial progress toward Aim 4 is both promising and exciting, and significant 
thought and planning should be put into how future implantation studies are conducted, as 
their results have the potential to make or break the translational potential of this therapy. 
Regardless of future directions, it is expected that this research will have a positive 
impact upon efforts to treat a growing population of patients suffering from complications 
of MI. It will not only enable clinicians to prevent or reverse the progression towards 
CHF—saving lives and improving the quality of life for recipients of this therapy—but 
also contribute to the advancement of the cardiac tissue engineering field. 
 
7.3 Recommendations for Future Work: 
7.3.1 Aim 2: 
Moving forward, we will be able to use either PGG-treated or non-treated scaffolds 
in this translational approach, depending upon the desired degradation profile.  The 
response to scaffolds may also prove to be drastically different at the eventual target site, 
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the heart, and when there is an autologous cellular presence within the scaffolds, as would 
be the case with myocardial grafts.  It is advised that future implantation studies examine 
the response under these conditions.  
As for things that can still be studied in samples from both Biocompatibility 
Studies, a number of IHC and IF stainings can be done to look for certain factors of interest.  
Sections could be stained for peroxisome proliferator-activated receptors (PPAR), whose 
downregulation has been implicated in causing a phenotypic shift from M2 to M1, in order 
to provide further confirmation of polarization and gain insight into its possible 
mechanistic progression.[5] Stem cells that may be recruited to the vicinity of the implant 
can be identified by staining for CD34 or CD29, mesenchymal stem cell markers.[6] Their 
specific populations of origin may be determined by staining for the hematopoietic stem 
cell, adipose-derived mesenchymal stem cell, and bone marrow-derived mesenchymal 
stem cell markers CD144, CD146, and CD106, respectively.[6, 7] Other cell types such as 
fibroblasts and smooth muscle cells can be identified by staining against HSP47 and 
vimentin, and α-smooth muscle actin, respectively.  Lastly, one can look for evidence of 
newly secreted collagen within the scaffolds by staining for collagen type III and prolyl-4-
hydroxylase. 
 
7.3.2 Aim 3: 
  Cell seeding of scaffolds is absolutely critical.  The platform can function perfectly 
and provide excellent conditions for cell differentiation, but that is meaningless without the 
presence of cells on the scaffold.  Even with too few cells on the scaffolds their 
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differentiation may be adversely affected, and evaluation of the effects of the experiment 
may become too challenging because of a lack of cell density.  Pilot experiments should 
be conducted which directly compare the efficacy of different cell seeding methods.  
Future experiments could investigate the co-culture of cardiac fibroblast seeded 
along with hADSCs onto scaffolds and their effect when combined with the dynamic 
conditions provided by the platform.  The effects of changing the coordination of the 
mechanical and electrical stimuli could also be tested.  For example, the electrical impulse 
can be alternatively delivered at the peak of the pressure waveform, simulating an 
excitation followed by a compression of sorts (the relaxation of applied tensile force).  It 
might be determined that this method is more effective at producing differentiation and 
contractility in hADSC than delivering the stimulus just prior to the beginning of the 
pressure waveform. 
 The following is a suggested study once initial studies with the Flexcell system 
have been used to determine which specific stimuli are useful in cell differentiation.  This 
information can then be applied in concert with the use of a perfusion bioreactor described 
herein. 
 
7.3.2.1 In Vitro Conditioning of Cell-Seeded Constructs in a Bioreactor 
7.3.2.1.1 Bioreactor Design:  
The bioreactor will be designed using SolidWorks software, and machined by 
Clemson University Machining and Technical Services.  We have extensive experience in 
this area[8], and the process will be completed using formal methods of design.  Based upon 
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the results of the Flexcell studies, some of the design features described below may be 
changed or excluded, but the design we envision includes the capability to deliver all 
stimuli that will be tested in the Flexcell studies.  Design features and outputs are as follows 
(Figure 7.1): (1) a main housing with 6 chambers (one construct per chamber) which can 
be filled with chemically defined cell culture media, (2) silicone membranes to which each 
construct is fixed via suturing to extensions of lid that insert until nearly flush with bottom 
of each chamber.  The membranes will operate on the same principle as the Flexcell system, 
cyclically rising and falling in response to increased or decreased air pressure (driven by a 
compressed air source and controlled by LabView) in the chambers below them – this 
imparts cyclic tensile and compressive forces on the constructs (Figure 7.1 bottom); (3) 
insulated electrical leads extending from a LabView-controlled circuit which will be 
attached to electrodes as in the Flexcell system, providing paced electrical stimulation 
similar to the cardiac conduction system; the scale of the housing and chambers will be 
such that the entirety of constructs will lie between the electrodes, exposing all resident 
cells to the developed electrical field, (4) dynamic fluid circuit, digital peristaltic pumps, 
and pinch valves to control fluid pressure and simulate pulsatile blood flow using 
circulating culture media.  Computational fluid dynamics (CFD) analysis will be conducted 
on the pathway of fluid flow through the bioreactor.  CFD analysis software (SolidWorks) 
will provide measurements of wall shear stress at the coronary artery inlet.  These 
measurements will be informative regarding possible responses of endothelial cells seeded 
on the scaffold vascular lumen.  Additional design considerations will include sterility, 
238 
 
visibility, continuous monitoring of pressures, and ability to fit inside a standard cell culture 
incubator (Figure 7.1 bottom).  
 
Figure 7.1: Conceptual drawing of possible perfusion 
bioreactor:  At top, schematic of bioreactor components 
and their layout.  Components are as follows: (1) main 
housing with 6 chambers (2) compliance chamber/pressure 
head (3, 4) media reservoirs with attached micron-scale air 
filters (6) pinch valve for pulsatile flow (7, 8) media routing 
manifolds (9) data acquisition module and electrical 
stimulus generator (10) media outflow lines.  At bottom, 
CAD software-generated drawings (Solidworks ™) of the 
main housing and its features (isometric, lateral, and top 
views of the housing, respectively, from top to bottom).  
Blue arrows show path and action of air used to generate 
positive pressure and deflect silicone membrane (horizontal 
black line) upward.  Red arrows indicate the path of media 
flow in and out of the housing.  A seeded construct (SC) is 
shown occupying its designated position in one of the 
chambers with electrodes (E) located on both sides and just 
above it.  The flow of media in and out of the seeded 






7.3.2.1.2 Scaffold Preparation:  
DCELLed scaffolds (n=6) prepared as previously described will be trimmed to 3 
cm x 3 cm at the distal or apical portion of the left ventricular wall so that the intrinsic 
vasculature and afferent coronary artery are left attached; the resulting “flap” scaffolds will 
be sterilized, rinsed, and serum neutralized  
 
7.3.2.1.3 Cell seeding, incorporation of constructs into bioreactor, and conditioning:  
Results of the Flexcell studies will determine which, if any, cell types (e.g. 
fibroblasts) will be seeded in addition to hADSC.  We will begin the seeding process by 
injecting hADSC suspended in media at 5 x 106 cells/mL through the coronary vasculature 
of the scaffolds described above.  The intent of seeding cells in this manner is to 
reendothelialize the vasculature.  There is evidence that hADSC can differentiate into an 
endothelial cell phenotype under conditions of applied fluid shear stress, and we believe 
that once attached to the lumens of vasculature, they will be differentiated into an 
endothelial phenotype (hADSC-EC) by virtue of their exposure to the flow of media 
through the bioreactor and constructs.[9]  Prior to injection, the circumflex artery and the 
more proximal diagonal branches of the coronary artery will be ligated with sutures, and 
the edges of the scaffold, including the edge extending to the right ventricular wall and the 
ventricular septum, will be tightly clamped to prevent any initial leakage of the perfused 
cell suspension through severed vessels.  The seeded scaffolds will then be laid flat and 
cultured statically in a petri dish for 6 h to allow cells to attach securely to the vessel 
lumens.  At this point, the scaffolds will be turned over and laid on their opposite surface, 
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and the above cell suspension perfusion process will be repeated. The reasoning behind 
this is to ensure a more uniform coverage of the lumen, as cells will settle out of suspension 
during static culture, thus covering only up to ½ of the lumen surface in each perfusion 
step.  Following another 6 h of static culture, scaffolds will be placed within their respective 
housings in the bioreactor and the arterial and venous cannulas will be connected to inlets 
and outlets, respectively.  The scaffolds will be seeded with a combination hADSC (70%; 
to be differentiated into CM; hADSC-CM) and human CF (30%; should they be found in 
Phase 1 to be beneficial) cell suspension via injection at 15-20 points throughout the 
scaffolds’ interstitium and also on the epicardial surface by drop-wise pipetting.  At this 
point, the bioreactor will be sealed and will continuously circulate culture media (DMEM 
with 10% fetal bovine serum and 1% antibiotic/antimycotic) through the vasculature as 
well as throughout the chambers (immersion-perfusion).  We will adjust various stimuli 
and conditions within the bioreactor to approximate normal physiological conditions of the 
myocardium (fluid pressure = 120/80 mmHg, fluid shear = 12 dynes, fluid viscosity = 3-4 
cP (using dextran), electrical stimulus = 1.25 Hz, 2-4 V/cm, mechanical force = 2 N 
tension, 20% strain).  With these conditions set, the system will be placed inside an 
incubator at 37 °C and maintained in this state for 4 weeks to induce formation of inter-
CM and CM-fibroblast electrical connections, growth of a confluent endothelial layer on 
vessel lumens, development of global, synchronous contraction, and overall construct 





7.3.2.1.4 Cell Culture:  
Each of the cell types listed above will be cultured individually in cell-specific 
media and subcultured to attain sufficient numbers to seed the scaffolds (n=6) at about ¼ 
of the correct physiological cell density (5 x 107 cells/cm3)[10] of the native human 
myocardium (roughly 0.35 billion cells/scaffold).  We will use a cell culture scale-up 
apparatus, the CellSTACK® (Corning®), to produce sufficient numbers of cells for this 
study.  To account for differing proliferation rates among cell types, the proportions of each 
cell type seeded will be altered from their physiological levels (i.e. CF – 60% of total cell 
number in myocardium, CM – 25 %, and EC – 5%)[11, 12] to levels which we estimate will 
yield approximately correct ratios once conditioning and maturation is complete (i.e. CF – 
30% of total seeded cell number, hADSC-CM – 67.5%, hADSC-EC – 2.5%).  Should we 
find that treatment with AZT enhances differentiation of hADSC into CM in the Flexcell 
study, we will add AZT into the culture media in the bioreactor.  For hADSC targeted for 
EC differentiation, we will use endothelial cell growth supplement in cultures prior to 
seeding and treat them with AZT or another DNA-demethylating reagent shown to induce 
hADSC to EC differentiation, BIX-01294 (Sigma), just prior to harvest for seeding.[13]  
 
7.3.2.1.5 Characterization of conditioned constructs:  
After 4 weeks of culture within the bioreactor, we will evaluate constructs for cell 
density and distribution, maintenance of cell viability, and adoption of cell and tissue 
morphology, mechanical properties, and electrical stimulus propagation comparable to 
native myocardium.  Constructs will be cut into sections and processed for various methods 
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of evaluation: 1) fixation in 4% paraformaldehyde for histology and 
immunofluorescence/IHC; 2) extraction of protein and DNA via Trizol® reagent and 
homogenization for western blotting and RT-PCR, respectively; 3) preservation in cell 
culture media for tests of cell/tissue viability and functionality, including micro-electrode 
array (MEA) probing and patch clamping in both the presence and absence of agonists, 
calcium transient imaging using Fluo-4, and measurement of the force of any contraction 
produced by cells using a custom-designed force transducer.  We will also prepare samples 
of recellularized arteries for inspection via scanning electron microscopy to quantify 
confluency and study features of the newly differentiated endothelium.  These cells’ ability 
to take up oxidized LDL will also be evaluated as a test of their functionality.  We will 
evaluate the mechanical properties (modulus of elasticity and burst pressure, respectively) 
of both the arterial and myocardial portions of the tissue in the same manner as was done 
previously to evaluate DCELLed scaffolds.  
Histological sections will be stained via H&E and Masson’s trichrome methods to 
visualize cellular dimensions, number, and distribution.  Tissue morphology and 
maturation will be assessed with H&E, Movat’s pentachrome, Gomori’s trichrome, and 
Voerhoff van Geisen (VVG) stains (to facilitate semiquantitative measurement of cell 
types, elastin, and collagen content and structure).  IHC and IF will be used to stain for cell 
type-specific markers (CM: cardiac MHC, actin, α-sarcomeric actinin, troponin, and 
desmin; CF: vimentin and discoidin domain receptor 1 (DDR-1); EC: CD31, Von 
Willebrand factor, VE-cadherin).  Image analysis software (NIH) will be used to count 
nuclei in visual fields (taking into account that some CMs might be multinucleate), and the 
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principle of Delesse (area density=volume density) will be applied as described by 
Boyle[14] and Levkau[15] in order to determine cell density and proportions of specific cell 
types.  In addition, small samples (1 mm3) (n=6) of the constructs will be harvested, their 
masses will be recorded, and they will be subjected to a PicoGreen assay and gel 
electrophoresis to quantify DNA content as a measure of cell number.  Cell viability will 
be assessed by a colorimetric assay for cellular respiration (MTT/MTS) on small samples 
(n=6) of the constructs and by performing Live/Dead staining on small samples (n=6).  The 
induction of electrical integration will be evaluated via IF staining for connexin43 
(characteristic marker of gap junctions), and contractile force generation will be measured 
via a force transducer connected to a data acquisition module.  Additionally, the 
development of intercalated discs will be assessed semiquantitatively (using ImageJ) 
following staining with antibodies against N-cadherin.[16] 
 
7.3.2.1.6 Outcome Success Measures:  
Wherever possible, all measurements of construct characteristics will be compared 
with those of normal human myocardium, our control for these experiments.  We have an 
IRB protocol in place and collaborate with local cardiac surgeons who would provide 
samples for us. We also have a contract with NDRI for obtaining human tissues. Cell 
density of at least 75% of reported physiological cell density, or > 1.5 x 108 cells/cm3; 
percentages of specific cell types which fall within 15% of those values reported in the 
literature.[11]  Cell viability > 90% and tissue morphology reasonably similar to that of 
normal human myocardium.  Mechanical properties of constructs deviate from normal 
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myocardium by < 15%; generation of force > 0.5 N; calculated ratio of > 0.8 for number 
of intercalated discs:number of CMs; morphology that approximates that of native 
myocardium; positive staining for connexin43, actin, cardiac MHC, α-sarcomeric actinin, 
troponin T, and desmin; evidence of cells producing endogenous ECM, including collagen 
and basement membrane proteins. 
 
7.3.2.1.7 Challenges and Alternative Strategies:   
In the case of autologous stem cell therapies, hADSC are currently the population 
most readily translatable to clinical use.  Human IPSC may be a viable option in the future, 
as many groups have recently demonstrated these cells’ ability to differentiate into a CM 
phenotype.[17, 18]  Concerns remain, however, regarding the safety of using viral vectors 
and even small-molecule mediated methods to induce pluripotency, as well as the 
epigenetic stability of these cells following reprogramming.[19, 20]  The aversion of 
regulatory agencies towards these practices is a barrier that must be overcome before IPSC 
can be pursued fully as a stem cell source for translational regenerative medicine and tissue 
engineering approaches.  Should we encounter adverse outcomes with our planned studies 
involving low cell proliferation or differentiation, we will first attempt to alter our cell 
culture methods.  We will use 3D cell culture in the form of the hanging drop method to 
form spheroids of hADSC for subsequent seeding onto scaffolds.  Recent approaches for 
differentiating IPSC into CM have employed spheroid cultures as opposed to 2D 
monolayers, with the proposed benefit being that cells secrete endogenous ECM 
components and paracrine factors that contribute to more successful targeted 
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differentiation.[18]  With this approach, hADSC may be nearly differentiated or more 
primed for differentiation just prior to being seeded on the scaffolds.  
We will also address another frequent concern of regulatory agencies—the use of 
animal sera—in alternative strategies for cell culture.  We will explore the use of serum 
free media in culturing cells for seeding, which may not be as challenging as it sounds 
given that they proliferate very well in media formulations with low serum concentrations. 
Leakage and lack of cell engraftment or retention could be another challenge with seeding.  
In the event this becomes an issue, we will use fibrin glue to seal microvascular leaks and, 
as an alternative approach, lyophilize (freeze-dry) our scaffolds to encourage better 
infiltration of cells. If oxygen diffusion is limited within the scaffolds, we will improve this 
by adding oxygen carriers (perfluorocarbons) to the media.[21]  Access to sufficient human 
tissue to assemble data for control groups might be limited, although we do receive donated 
tissue periodically. This deficiency will be remedied by using figures and data published 
in the literature. In the event that constructs do not synchronously contract with a detectable 
force, we will analyze contractile force in individual CMs using a method described by 
Tasche et al.[22] 
 
7.2.4 Aim 4: 
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Figure 3.9: Continuous-flow, perfusion-immersion system for decellularization: A) (1) Inflow reservoir 
(2) Scaffold immersed in decellularization solution on multi-stirrer plate (3) Overflow and collection 







Figure 3.10: Continuous-flow, perfusion-immersion system for whole heart decellularization: A) (1) 
Inflow reservoir (2) Scaffold immersed in decellularization solution on multi-stirrer plate (3) Overflow and 
collection reservoir (4) Peristaltic pump.  B) Expanded view of a whole porcine heart being decellularized 
within a specially designed container.  C) Whole porcine heart shown securely attached to an aortic cannula 
with zip-ties.  All reagents flowed retrogradely across the aortic valve, into the left ventricle, and upward 
through the mitral valve into the left atrium.  Pressure was held in these chambers by suturing or plugging 
the pulmonary veins.  Reagents also flowed anteriogradely through the coronary circulation.  D) CAD 
rendering of the specially designed decellularization vessel shown in A and B.  The vessel and other parts in 
the assembly were designed using Solidworks software. 
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